Generated by All in One SEO Pro v5.0.0.1, this is an llms-full.txt file, used by LLMs to index the site. # Nocturnal Medical Device Development | Nocturnal Product Development | Durham, NC ## Posts ### [Medical device design considerations for the cash strapped startup](https://nocturnalpd.com/2025/07/30/medical-device-design-considerations-for-the-cash-strapped-startup/) **Published:** July 30, 2025 **Author:** Jen Rhoton **Content:** ![](https://nocturnalpd.com/wp-content/uploads/2023/06/market-scaled.jpeg "Businessman trading stocks market financial depressed – Crisis s") ##### The cold reality: Investment money is getting even harder to come by these days. When this article was initially published in 2023, things did not look great for medical device startups. Fast forward to 2025, and the picture looks eerily familiar. After a promising rebound in 2024, the [Q3 2025 J.P. Morgan MedTech report](https://www.jpmorgan.com/content/dam/jpmorgan/documents/cb/insights/outlook/jpm-medtech-deck-q3-2025.pdf)[![](data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==)](https://docs.google.com/viewer?url=https%3A%2F%2Fwww.jpmorgan.com%2Fcontent%2Fdam%2Fjpmorgan%2Fdocuments%2Fcb%2Finsights%2Foutlook%2Fjpm-medtech-deck-q3-2025.pdf&embedded=true&chrome=false&dov=1 "View this pdf file")[![](data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==)](https://docs.google.com/viewer?url=https%3A%2F%2Fwww.jpmorgan.com%2Fcontent%2Fdam%2Fjpmorgan%2Fdocuments%2Fcb%2Finsights%2Foutlook%2Fjpm-medtech-deck-q3-2025.pdf&embedded=true&chrome=false&dov=1 "View this pdf file")[](https://docs.google.com/viewer?url=https%3A%2F%2Fwww.jpmorgan.com%2Fcontent%2Fdam%2Fjpmorgan%2Fdocuments%2Fcb%2Finsights%2Foutlook%2Fjpm-medtech-deck-q2-2025-final-ada.pdf&embedded=true&chrome=false&dov=1 "View this pdf file") reveals a challenging funding environment for early-stage companies. While the total investment through Q3 seems to be on pace with the past two years, the total number of venture rounds YTD (259) is on pace for the lowest number on record in the last six years. ![](https://nocturnalpd.com/wp-content/uploads/2025/10/JPM-Q3-2005-Redone.png "JPM Q3 2005 Redone") The downturn is substantially more pronounced for early stage deals — only 93 seed and A rounds were completed so far this year, by far the lowest on record in recent history. ![](https://nocturnalpd.com/wp-content/uploads/2025/10/JPM-Q3-2025-Seed-A-Redone.png "JPM Q3 2025 Seed + A Redone") For medical device companies, this means a shorter runway to meet product milestones. It also means they have less room for errors and missteps, which could lead investors to pull out or force a significant down-round. First thing first: Understanding investor risk factors Investors these days are more cautious, and to be honest, they have good reasons to be. While economic uncertainty and rising interest rates play a role in the decline of investment across all sectors, medical device companies face some unique challenges that give many investors a longer pause when it comes to committing their capital. - Product development challenges: The lengthy product development cycles associated with medical device commercialization, combined with supply chain delays, create significant uncertainty about product cost and time-to-revenue. Prolonged product development cycles also bring greater risk of changing market conditions, which could adversely impact product viability, competitiveness, pricing, and profitability. - Regulatory challenges: Investors look for companies that have a well-defined reimbursement strategy and a solid plan for clearing regulatory hurdles – from obtaining the necessary documentation to conducting testing and completing clinical trials. - Manufacturing challenges: Scaling up production and manufacturing of medical devices can be complex and costly. Investors may be wary of startups that lack a clear plan and the right partners lined up to support scalable manufacturing. While none of these factors can be completely removed, there are several ways in which medical device entrepreneurs can mitigate these risks to ease investor apprehension. And here is the good news: Proactively addressing these concerns can also help startups stretch their raised capital to meet development milestones and reduce the risk of running out of runway. > Read more: [Why investors say No](https://nocturnalpd.com/2025/03/24/why-investors-say-no-to-medical-device-startups-and-how-to-get-them-to-say-yes/) ##### Manage to your goal: What you really need for a POC vs. v1 and v2 Running out of funds before reaching a market-ready product is a common pitfall for medical device companies. With that in mind, it's crucial to prioritize and focus on the essentials of what the company needs to prove at each stage in order to raise additional capital. To understand the difference in the development effort for a POC and a Version One of the product, it’s important to understand the different purposes they serve. The purpose of a POC is to demonstrate the feasibility of the concept to the investors, which typically doesn’t require the full functionality of the product. A POC version doesn’t need to be approved by a regulatory body, which means that there are no certification and documentation requirements imposed by regulators. The POC may also be designed and built using components that aren’t necessarily suitable for long-term use in a medical device, but are expedient for demonstration. Version One, by contrast, must be fully functional and ready for use in clinical trials. It must be suitable for submission for regulatory approval, which implies strict compliance and documentation requirements. This doesn’t mean, though, that Version One needs to have all the bells and whistles. The more efficient product development strategy is to treat v1 as a Minimum Viable Product (MVP) that can be used for clinical trials. While v1 may not be ready to be commercially marketed, its primary goal is to provide entrepreneurs with sufficient clinical data to validate the efficacy and safety of their medical device. These results can be leveraged to raise funds for further development to bring the desired product to market. Ideally, entrepreneurs should develop their v2 in parallel, to capitalize on the momentum gained from the v1 trials. This allows for a more efficient timeline, as v2 can be commercialized relatively quickly based on its similarity to v1 and the ability to leverage clinical data obtained with v1. When developing v2, entrepreneurs should focus on addressing the shortcomings or less desirable aspects of v1 that were not necessary for proving the technology's effectiveness in the clinical trials. This could involve improvements such as reducing form factor, increasing battery life, or enhancing usability. By refining the product based on user feedback and market demands, v2 and subsequent versions can become more attractive to potential customers and investors. ##### Cash is king: Accurately predicting development costs and timeline Entrepreneurs are an optimistic bunch. But that can sometimes come back and bite them. If they haven’t gone through the process before, entrepreneurs may also not have full appreciation of what goes into the product development process beyond the core technology. They are often unaware of what it takes to produce the proper documentation that is necessary to meet regulatory requirements. And they tend to grossly underestimate the time and effort required for verification and validation. To create a realistic product development plan with a predictable cost and timeline, you need someone on your team that has been through the entire process and appreciates all of the steps and details involved. Another way to ensure predictable development costs and timeline is by contracting a design partner to deliver the desired product milestones at a fixed cost and time. The reality is that most design and development contractors will not commit to fixed costs and times, since they are unwilling to assume the risk of overrunning the time and effort they estimated for the project. Only design firms with extensive experience in developing similar devices may be willing to commit to a fixed cost project and share the risk with you. ##### Stay on track: Controlling scope creep Scope creep can be highly detrimental to cash-strapped startups. To start with, it's important to have a clear understanding of your product's scope from the beginning and document it in a detailed project plan. When new ideas or feature requests arise, carefully consider what goals they support and where you are in the product development cycle. In most cases, you’d be better off putting these requests on the list of considerations for a future version rather than disrupting the timeline for the current version. Working with a partner on a fixed price for predetermined milestones can be helpful for controlling scope drift. It makes the entrepreneur clearly aware of the time and cost that out-of-scope feature requirements would add to the project. When these tradeoffs are clear, it is easier to make the right decision. > Read more: [How we manage fixed-cost projects](https://nocturnalpd.com/2023/10/31/the-secrets-to-navigating-fixed-cost-projects-in-medical-device-development/) ##### Plan for scale: Partnering with the right manufacturers When it comes to complex and novel medical device innovations, finding the right manufacturing partner is far from trivial. To start with, you’d be looking for manufacturers with experience with similar devices and a track record of delivering high-quality products within budget and timeline constraints. When bringing a new device to market, you need a partner who can accommodate your initial trial quantities, while offering the potential to scale up production as your business grows. This scalability is essential to avoid disruptions and higher costs associated with transitioning to a new manufacturing facility later on. ##### Last but not least: Keeping the team together Cutting costs and downsizing the team can be demoralizing and may lead to a loss of valuable talent. To mitigate these risks, be conservative with your hiring decisions, only bringing on board essential personnel that you know you’ll need for the long-run. Consider leveraging outsourcing strategically to provide flexibility and access to specialized skills while maintaining a predictable cash burn rate. Once your product has cleared regulatory hurdles and is ready for production at scale, you’ll be better prepared to hire additional resources and bring these skills inhouse. ##### Final words and takeaways While launching a medical device startup with limited funds presents many challenges, it's not an insurmountable task. By carefully considering design priorities to control costs and scope, you can navigate the cash-strapped startup journey more effectively. - Understand the differences in goals and requirements for a Proof of Concept (POC), v1, and v2 product design. - Consider a fixed cost development partner to help you accurately predict and manage product development costs and timeline. - Choose manufacturing partners with the ability to support small V&V and trial quantities and scale up production as the business grows. - Be conservative with hiring decisions, consider strategic outsourcing for specialized skills, and plan to expand the team once the product is ready for production at scale. > Read more: [Insights from a decade of milestone-based pricing projects](https://nocturnalpd.com/2023/09/19/celebrating-a-decade-of-milestone-based-pricing-projects-insights-and-lessons-learned/) ##### Get the ultimate guide to navigating funding cycles [![](https://nocturnalpd.com/wp-content/uploads/2025/07/Ebook-Linkedin-post-large-button-4.png)](https://nocturnalpd.com/ebook-navigating-medical-device-funding-cycles/) **Categories:** Funding, Milestone-based pricing, Startups --- ### [The Secrets to Navigating Fixed-Cost Projects in Medical Device Development](https://nocturnalpd.com/2023/10/31/the-secrets-to-navigating-fixed-cost-projects-in-medical-device-development/) **Published:** October 31, 2023 **Author:** Eran Livneh **Content:** ![](https://nocturnalpd.com/wp-content/uploads/2023/10/teamwork-design-515838341_1027x1027.jpeg "teamwork design") ##### These are exciting times for medical device innovation. At any given time, there are hundreds of medical device development projects underway, with thousands of people putting their creativity and skills to work and billions of dollars invested. They are in all areas of medical device development. Some are large, some are small. Some will be successful, and many will not. There is one thing common to almost all of these development efforts, with some notable exceptions. For the vast majority of these projects, the eventual cost of product development is unknown. While cost estimates exist, the track record shows that these forecasted development costs are far from being reliable. > There are good reasons that fixed-cost or milestone-based pricing is a rarity in this field. Medical device development—and especially for [Class II and Class III devices](https://nocturnalpd.com/class-ii-class-iii-devices/)—is a highly complex undertaking that can last years, not months. Going into it, there are many unknowns, and initial assumptions may prove inaccurate as the project unfolds. ##### So how does Nocturnal make fixed-cost projects work? We sat down with [Cinnamon Larson](https://nocturnalpd.com/leadership/), PhD, VP of Research and Development at Nocturnal, for a look behind the scenes at the formula that makes Nocturnal successful with its milestone-based pricing strategy. Over her twenty five years of experience, Larson has led numerous pivotal projects, notably in the development of [life-saving and implantable medical devices](https://nocturnalpd.com/lifesaving-implantable/). "I've always been kind of an artist but also very much interested in science and math. Growing up not too far from Cape Canaveral, I aspired to be an astronaut and was drawn to aerospace engineering, which allowed me to combine my passions for art and science.” The foundation in aerospace equipped Larson with a rigorous analytical mindset and meticulous attention to detail, virtues that proved indispensable as she transitioned to medical device development: “I am drawn to the intricacies of design, where every curve and material choice could potentially save a life,” says Larson. ##### Transparent communication: the bedrock of trust Working with clients, Larson views open communication as the lynchpin for successful fixed-cost projects. "Transparency is not just about keeping the clients in the loop. It’s about creating a shared vision that drives the project forward from start to finish." Ensuring that all stakeholders have a unified understanding of the project's scope, timeline, and deliverables is critical. It provides a solid foundation that minimizes the risk of misaligned expectations, scope creep, or budget overruns. “Working in a highly technical field, things can get confused. Terminology can mean one thing to one person and a different thing to another. We have to get really good at listening, asking questions, and hearing the client. And then it’s really important to play back to them what we understand from them and how we interpret it,” says Larson. ##### Detailed scoping: the blueprint of success That understanding of the client vision and goals then has to be translated into a project plan, and that can be a challenge when working with startups and innovators, as Larson has experienced firsthand. “Entrepreneurs tend to be dreamers, which is how they come up with great ideas. It’s up to us the engineers to put the details into the plan and do the reality check that it can be achieved given all the constraints we have—not just budget but also time, availability of material, regulatory requirements, and everything else that has to line up for that product to be successful.” It’s during this phase that the project's objectives, deliverables, and boundaries are meticulously defined. The more detailed the scoping, the smoother the project will run. “Clients are often in a rush to get started with the design work, and understandably so. It’s our role and responsibility to make sure we get the scoping done right first. We have to understand what requirements the design needs to meet, and we need to make sure these requirements are testable when it comes to verification and validation. We have seen it paying off time and again when it’s done right at the outset,” says Larson. ##### The best-laid plans of mice and men As rigorous as the planning can be, the best-laid plans can still go awry. Embracing an Agile approach allows Nocturnal to maintain a high degree of adaptability while staying within the project timeline and budget. The iterative nature of Agile facilitates regular feedback loops with clients, ensuring that the project remains aligned with the envisioned goals. "Agile allows us to be on the same page with the client at every stage of the project, making course corrections as a collaborative effort rather than a reactive adjustment," explains Larson. For Larson, this is when the strength of the team and the processes they’ve built at Nocturnal shine through. “When we face challenges in the design process, I view it as an opportunity. Each setback teaches us something valuable. As a team, we’ve learned to embrace the cycle of problem-solving, failing, and then succeeding—it's part of the process. We trust the system we’ve put in place to overcome challenges, and we use these experiences to improve the product we’re working on.” ##### Staying on track: a win-win proposition As Larson points out, it’s these challenging moments when managing a fixed-cost project gets tested. “If we were working on time and material, we could just say we need more time and we need more money and that would mean that the timeline for the device gets pushed out and the budget gets thrown out the window,” says Larson. “That’s not something that most startups can afford. So we have to be better at working through these challenges and course correcting while staying within the time and cost constraints and communicating these course corrections to the client.” Keeping the project aligned with the goals is an ongoing challenge even in the best times. Larson and the team often find themselves reminding clients that in most cases, “[less is more](https://nocturnalpd.com/2023/08/04/less-is-more-the-power-of-simplicity-in-implantable-medical-devices/)” when it comes to getting a medical device to the market. “Adding more features is not necessarily the right thing to do, especially when you are working on an implantable device that requires minimal form factor and power consumption,” says Larson. At Nocturnal, this collaborative approach has not only led to a track record of successful fixed-cost projects but has also nurtured enduring relationships with clients. "The success of a fixed-cost project is a testament to the synergy between us and our clients,” says Larson. “It’s about sharing the risk and moving beyond transactions to build relationships that thrive on mutual growth and success." > Is milestone-based pricing right for you? If you are interested in learning more about Nocturnal's unique approach, [drop us a note](https://nocturnalpd.com/get-a-quote/) and tell us about your project needs. ##### Learn more - [Lessons from a decade of milestone-based pricing project](https://nocturnalpd.com/2023/09/19/celebrating-a-decade-of-milestone-based-pricing-projects-insights-and-lessons-learned/) - [Nocturnal's fixed-cost pricing](https://nocturnalpd.com/fixed-cost-pricing/) **Categories:** Milestone-based pricing, Startups --- ### [The Next Wearables Frontier](https://nocturnalpd.com/2026/06/09/the-next-wearables-frontier/) **Published:** June 9, 2026 **Author:** Eran Livneh **Content:** ![wearables red ocean blue ocean](https://nocturnalpd.com/wp-content/uploads/2026/06/Red-ocean.png "Red ocean") ##### The wearable sensor red ocean The wellness wearables market has produced some remarkable companies. Oura, Whoop, Apple Watch, and other category leaders have shown what’s possible when continuous physiological data is paired with strong design, habit formation, consumer trust, and a clean user experience. If you can build the next Oura or Whoop, more power to you. For most medical device startups, though, the wearable market has become a red ocean. Investors — rightly so — have grown skeptical of “yet another monitoring device.” Nearly every physiological signal that mattered five years ago is now available through some combination of consumer devices, medical devices, and hybrid platforms. The incumbents already have distribution, brand recognition, user data, polished software, and massive product ecosystems. The next frontier for wearables isn’t collecting more signals. It’s using the right signals in combination to deliver meaningful clinical outcomes. ##### Beyond signals: delivering clinical outcomes The next-generation wearable medical device isn’t just a sensor. It’s part of a therapeutic system that requires a different proof point: Can the wearable safely deliver an intervention that improves a meaningful clinical outcome? Can it provide useful data to make that intervention more precise, timely, and personalized? The demands on a therapy program are different in kind from those placed on monitoring devices. From a design point of view, the burden of proof shifts in several ways: **Accuracy becomes a safety requirement.** A monitor can show a noisy reading and let a clinician decide. A therapy system has to make that decision itself, in real time. Signal-to-noise, motion-artifact handling, and the confidence threshold are now safety parameters, not just UX choices. **Reliability becomes uptime.** A monitor that drops out for even a minute leaves a gap in the data. A therapy device that drops out leaves a missed or an incorrect dose. Failure modes have to be deterministic, fail-safe, and gracefully recoverable. The engineering bar shifts from “mostly works” in the wellness world to “consistently works, and predictably recovers from potential failures.” **Power becomes a clinical variable.** Sensing draws power. On-device computing draws power. Delivering therapy — stimulation, actuation, dosing — draws more. A monitor that runs out of battery is an inconvenience; a therapy that runs out of battery is an interrupted treatment. Battery life sets the practical ceiling on how much therapy can actually be delivered, which means it has to be designed in from the architecture stage rather than retrofitted at the end. **Cybersecurity becomes patient protection.** A compromised monitor leaks data or generates false readings. A compromised therapy device can deliver a harmful intervention — or refuse to deliver a necessary one. The attack surface now includes the actuation path, not just the data path, and the consequence model shifts from data breach to bodily harm. Threat modeling, secure firmware updates, and authenticated command channels move from compliance line items to clinical safety controls. **The data has a new customer.** Monitoring data flows outward — to a dashboard, a clinician, a report. Therapy data flows back inward, into the device’s own decision-making. That changes how the signal has to be acquired, processed, and trusted from the moment it’s generated by the body. ##### The strongest moat: the therapy–data loop The shift in early-stage investor expectations does not mean startups need to do more upfront. In fact, misreading this data often leads teams in the wrong direction. **1. Don’t confuse higher expectations with more functionality** For wearable therapy systems, the real competitive advantage rarely lies in the sensor package or to the therapy mechanism alone. It’s most often the loop they close together. A well-designed therapy–data loop looks like this: - The system delivers a therapy. - The system captures the patient’s response. - The system analyzes the data to assess the effectiveness of the therapy. - The system refines therapy delivery parameters like scheduling, timing, intensity, or dependence on patient activities. - The product becomes more personalized and the benefits become more defensible over time. This is where signal quality matters more than signal quantity. Therapy-response data, captured well, becomes a proprietary asset that compounds with every patient. Captured poorly, it limits everything downstream. Placement, sampling rate, power management, motion-artifact handling, firmware logic, data compression — these aren’t just engineering choices. They determine whether the data collected can actually feed an algorithm, justify a clinical study, support a regulatory claim, or enable future product expansion. AI and analytics are only as strong as the data foundation they sit on, and AI-ready data acquisition has to be designed into the device — not patched on later. The right question for next-generation wearable systems isn’t whether the device can collect a signal. It’s whether the system can preserve the *clinical meaning* of that signal — from the body, to the algorithm, to the therapeutic decision. Biosignal acquisition, ultra-low-power architecture, embedded software, connected device infrastructure, and AI-ready data design all serve that single end. ![Therapy-Data Loop: circular workflow with Therapy, Response, Assessment, and Refinement stages in a clockwise loop.](https://nocturnalpd.com/wp-content/uploads/2026/06/Data-Therapy-Loop.png "Data-Therapy Loop") ##### Neuromodulation as a leading use case All of the above is particularly applicable to neuromodulation, where research focused on the nervous system as a treatment target is uncovering therapies that rival or outperform drugs for conditions that have resisted treatment for decades. Drugs tend to act systemically and often require multiple doses before they take effect. And while they may reach the target pathway, they also affect other parts of the body, sometimes producing broad side effects that discourage patient compliance. [Neuromodulation](https://nocturnalpd.com/neuromodulation/) offers a different value proposition: - more precise targeting of specific nerves, muscles, or anatomical regions, - adjustable stimulation parameters that can be personalized based on patient response, - therapy that can be turned on, turned down, or stopped, - potential reduction in systemic drug exposure, - compatibility with continuous real-time monitoring of efficacy and patient compliance, - and a path toward semi-closed-loop or closed-loop therapy. Two trends have converged to make neuromodulation more practical. First, researchers understand neural pathways better than ever — how specific circuits influence pain, inflammation, movement, sleep, mood, and organ function. Second, electronics technology has enabled more advanced devices: smaller electronics and electrodes, lower-power components, more capable firmware, improved batteries, and better wireless connectivity. Together, they create a strategic opening for replacing, reducing, or complementing drugs with more targeted, adjustable, data-driven therapy. It can be electrical, mechanical, thermal, acoustic, magnetic, or optical stimulation designed to influence specific nerves, muscles, or physiological pathways. A few opportunity areas where this is already taking shape: **Chronic pain.** Not just stimulation, but adaptive pain therapy informed by patient-specific data. Systemic pain medications have well-known limits — side effects, tolerance, adherence challenges, and the risk of life-threatening addiction. A wearable neuromodulation system can deliver targeted therapy while continuously monitoring function, activity, pain-related patterns, and response. **Migraine and headache disorders.** Wearable neuromodulation may offer an alternative or adjunct to drug therapy, especially where timing, early intervention, patient-specific triggers, and avoidance of systemic side effects all matter. **Neurorehabilitation and functional recovery.** Wearables can measure movement quality, guide therapy, improve adherence, and document progress outside the clinic. Some systems can also deliver functional electrical stimulation, biofeedback, or other interventions that help patients retrain movement rather than just track recovery. **Overactive bladder and pelvic health.** Targeted stimulation can modulate neural pathways involved in bladder control or pelvic floor function, while sensing and patient-reported data personalize therapy over time. **Neurologic disorders.** Wearables can deliver targeted stimulation directly to the brain or peripheral nervous system, using real-time sensing of movement patterns, neural signals, and other biomarkers to guide when and how that stimulation is applied. Applications range from tremor and movement disorders to epilepsy and cognitive rehabilitation. **Respiratory and sleep-related disorders.** Therapeutic wearables can use sensing to identify changes in breathing, sleep stage, position, or autonomic state — and deliver stimulation, feedback, or other interventions in response. ##### The New Wearables Playbook Knowing therapy is a key playing field for wearables is a great starting point. But how do you actually build a therapy-delivery wearable with finite capital and a long road to demonstrating clinical efficacy? In [our next post](https://nocturnalpd.com/2026/07/06/the-new-wearables-playbook/), we dive into the operating side of the problem and the five choices that impact time and risk for therapy-wearable development programs. **Categories:** Biosensors & Biosignal Acquisition, Neuromodulation, Startups, Wearable --- ### [The New Wearables Playbook](https://nocturnalpd.com/2026/07/06/the-new-wearables-playbook/) **Published:** July 6, 2026 **Author:** Eran Livneh **Content:** ![Conceptual depiction of a woman with glowing golden neural circuits around the head, representing brain–computer interfacing and a wearable device at the collarbone area.](https://nocturnalpd.com/wp-content/uploads/2026/07/Wearables-playbook.png "Wearables playbook") ##### A quick recap In our [previous blog post](https://nocturnalpd.com/2026/06/09/the-next-wearables-frontier/), we made the case that the wearable monitoring market has become a red ocean, that the next opportunity for medical device startups is in therapy-delivery wearables, and that the durable moat for those systems isn’t the sensor or the therapy mechanism alone — it’s the closed loop between therapy delivered and patient response captured. This part is about how to actually build a closed loop system, highlighting five operating choices that consistently compress time and risk. ##### Five choices that can compress time and risk Moving from therapy hypothesis to therapy-delivery wearable is a long road. The teams that make faster progress with lower risk tend to share a small set of operating habits. Five of them stand out. **1. Sequence the work to meet the next proof point** In a tighter capital environment, every funding round is expected to convert money into measurable risk reduction in order to justify the next round. Each major decision — what to design, what to defer, what to document, what to test — should serve a specific clinical, regulatory, or financing milestone, and not necessarily the eventual complete platform. New feature ideas will emerge constantly. Most belong on a future-version list and not in the iteration of the product for the next critical milestone. For a wearable therapy device, the first milestone isn’t a fully integrated wearable platform. It’s often a proof-of-concept study showing that the therapy mechanism actually works. Once the efficacy of therapy has been demonstrated, the wearable system can be designed around making that therapy more usable, targeted, adaptive, and scalable. - **POC** **validates feasibility:** The impact of therapy is real, the signals indicative of the need for therapy, and the effects of therapy exist. - **V1** **generates defensible clinical evidence:** The device performs reliably in target patients, with traceable data and documented controls. - **V2 optimizes for market scale:** Cost, manufacturability, usability. Designing for traceability from day one is part of this. Investors and regulators increasingly expect to see system architecture that can evolve without major rework, structured and traceable data, and a clear line from indications to claims to evidence. **2. Don’t reinvent the wheel (or the sensor)** A therapy-delivery wearable doesn’t have to own every biosignal. The strategic question for a new device startup is how to invest in signal acquisition in a manner that accelerates time-to-market without incurring unnecessary risk. **Look for proven reusable biosignal solutions.** The underlying biosignal acquisition stack rarely needs to be invented from scratch. Reference designs, validated biosensors, and proven low-power signal processing can be leveraged and reused for most solutions. Capital spent rebuilding what’s already been de-risked is capital not spent on your proprietary algorithm and therapy mechanism. **Integrate signals from existing devices if they meet your bar.** Pairing proprietary signals with data from a popular consumer or medical wearable can extend the system’s reach without expanding its scope. A consumer ring might supply recovery and autonomic context while the therapy device captures muscle activation near the treatment site. A smartwatch might contribute movement trends while the therapeutic wearable captures the local signals needed to titrate therapy. These external signals are only useful if they meet the accuracy and reliability requirements of your therapy. A consumer-grade reading that’s fine for fitness tracking may not be fine for a closed-loop intervention. Validating that bar before integrating is design work, not post-hoc QA. The same discipline applies across all device layers. The competitive advantage in a wearable therapy company is in the clinical insight, the unique algorithm, the therapy mechanism, and the evidence package — not in reinventing system architecture, embedded firmware, power management, or verification strategy that has already been proven a hundred times over. Capital spent re-building those layers is capital not spent on the parts of the system that actually create defensibility. Learn more here: [From biosignals to clinical insights – how to derisk and accelerate your path to market](https://nocturnalpd.com/2025/06/16/from-biosignals-to-clinical-insights-how-to-derisk-and-accelerate-your-path-to-market/) **3. Apply the proper level of design controls at each stage** Formal design controls, documentation, and traceability are non-negotiable for any medical device. But they aren’t always the right place to start. Sinking time and capital into exhaustive specifications before anything has been validated is a common way to miss the next milestone. The discipline is sequencing: lean and fast in early feasibility, then scaling compliance rigor as the device matures and the questions sharpen. A lighter-weight approach early on tends to look like this: - Capture user needs, key hazards, and product requirements informally. - Build quick prototypes that test the riskiest assumptions first. - Validate the therapy mechanism and signal logic before formalizing every requirement. The closer the program gets to verification, validation, and submission, the more those structures have to be in place. Learn more here: [How to build your device faster while staying compliant using smart design controls](https://nocturnalpd.com/2025/07/18/how-to-build-your-device-faster-while-staying-compliant-using-smart-design-controls/) **4. Treat power as a strategy issue, not just an engineering constraint** For therapy-delivery wearables, battery life and power management matter more than they do for monitoring devices. A therapy device that runs out of power is an interrupted treatment. Power constraints shape what can be sensed, processed, stored, transmitted, analyzed, and delivered as therapy. They also shape the user experience, adherence, safety architecture, and commercial viability of the product. There are many tradeoffs to consider, including: - Always-on sensing isn’t always clinically necessary or technically optimal. - Always-on therapy isn’t always safe, useful, or power-efficient. - Edge processing reduces data transfer but increases local compute demand. - Cloud processing enables richer analytics but introduces connectivity, latency, cybersecurity, privacy, and cost considerations. - Therapy delivery itself draws power, and that draw has to be balanced against sensing, connectivity, and patient usability. - Battery life can ultimately determine whether the device is worn consistently enough to generate meaningful therapeutic benefit and evidence, and an overly demanding charging schedule can reduce patient compliance. These engineering decisions have significant strategic implications. The right time to make them is early, while they’re still architectural choices, and before they become expensive redesign problems. Learn more : [Balancing signal data vs. power consumption in your implantable device](https://nocturnalpd.com/2024/04/22/balancing-signal-data-vs-power-consumption-in-your-implantable-device/) **5. Turn variable development cost into fixed-cost deliverables** In a market where funding takes longer and comes with greater security, capital efficiency and burn-rate predictability provide a hedge against running out of cash before the next funding round is secured. Two operating strategies can help mitigate the risk. The first is conservative hiring paired with strategic outsourcing. Early hiring should focus on proprietary expertise and disciplines specific to the core IP of the company. Everything else — biosignal acquisition, low-power design, embedded firmware, regulatory strategy, manufacturing engineering — is a candidate for a specialized partner. That keeps cash burn predictable, preserves the option to adjust the in-house/outsourced mix as the program matures, and avoids the risk of having to downsize later. The second is structuring engagements around fixed milestones rather than open-ended hourly projects. Fixed-cost, milestone-based work makes the cost of out-of-scope feature requests visible the moment they’re proposed, which makes scope discipline easier. It also aligns incentives: the partner succeeds when the milestone is reached, not when the clock runs longer. The net effect in both cases is the same — turning what would otherwise be variable, unbounded spend into a predictable cost tied to a specific proof point. That’s what preserves runway between rounds. Learn more : [Lessons learned from a decade of milestone-based fixed cost projects](https://nocturnalpd.com/2023/09/19/celebrating-a-decade-of-milestone-based-pricing-projects-insights-and-lessons-learned/) ##### The takeaways The next wearable opportunity is centered on therapy, not general-purpose sensing and monitoring. Neuromodulation and other targeted therapies represent a category that consumer wearables can’t follow into. For founders building toward that opportunity, the practical implications cluster into a few clear ideas: - **Lead with the therapy hypothesis:** The first proof point isn’t a finished platform — it’s evidence that the intervention works. - **Build the loop, not just the sensor:** The defensible asset is the closed loop between therapy delivered and patient response captured. - **Invest in what’s defensible, leverage what isn’t:** Generic context signals are commodity; unique therapy-site signals are moat. - **Make every dollar buy risk reduction:** Sequence your priorities around proof-point milestones, apply design controls just in time, treat power as a strategy decision, and keep spend predictable between rounds. The shift from monitoring to therapy changes what gets built, what gets measured, and what gets funded. The companies that internalize it early are the ones most likely to come ahead in the next wave of the wearable revolution. [See how we can help](https://nocturnalpd.com/wearable-medical-devices/). **Categories:** Biosensors & Biosignal Acquisition, Neuromodulation, Startups, Wearable --- ### [The Hidden Message in 2025 MedTech Investment Data](https://nocturnalpd.com/2026/02/04/the-hidden-message-in-2025-medtech-investment-data/) **Published:** February 4, 2026 **Author:** Eran Livneh **Content:** ![Milestone-based development roadmap reflecting 2025 MedTech funding and risk expectations](https://nocturnalpd.com/wp-content/uploads/2026/02/Feb-2026.png "Feb 2026") MedTech investment data coming out of 2025 sends a mixed signal. Despite the backdrop of growing regulatory turmoil and economic uncertainty, venture funding remained stable. IPO activity continued a slow but steady recovery, showing the market that capital is still available for the right companies. According to [J.P. Morgan’s MedTech Report](https://www.jpmorgan.com/content/dam/jpmorgan/documents/cb/insights/outlook/jpm-medtech-deck-q4-2025.pdf)[![](data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==)](https://docs.google.com/viewer?url=https%3A%2F%2Fwww.jpmorgan.com%2Fcontent%2Fdam%2Fjpmorgan%2Fdocuments%2Fcb%2Finsights%2Foutlook%2Fjpm-medtech-deck-q4-2025.pdf&embedded=true&chrome=false&dov=1 "View this pdf file")[![](data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==)](https://docs.google.com/viewer?url=https%3A%2F%2Fwww.jpmorgan.com%2Fcontent%2Fdam%2Fjpmorgan%2Fdocuments%2Fcb%2Finsights%2Foutlook%2Fjpm-medtech-deck-q4-2025.pdf&embedded=true&chrome=false&dov=1 "View this pdf file"), 2025 venture funding reached **$11.3B**. Overall dollar commitment was inline with the previous two years, suggesting continued investor engagement. While the overall level of investment held steady, the number of companies that secured ventured investment dollars continued to drop at a fast pace, reaching **a new 5-year low of only 323 rounds in 2025**. What the data show is that the **market didn’t pull back—it narrowed**. ![](https://nocturnalpd.com/wp-content/uploads/2026/02/2021-2025-MedTech-Investment-Trends.png "2021-2025 MedTech Investment Trends") Source: [J.P. Morgan 2025 MedTech Report](https://www.jpmorgan.com/content/dam/jpmorgan/documents/cb/insights/outlook/jpm-medtech-deck-q4-2025.pdf)[![](data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==)](https://docs.google.com/viewer?url=https%3A%2F%2Fwww.jpmorgan.com%2Fcontent%2Fdam%2Fjpmorgan%2Fdocuments%2Fcb%2Finsights%2Foutlook%2Fjpm-medtech-deck-q4-2025.pdf&embedded=true&chrome=false&dov=1 "View this pdf file")[![](data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==)](https://docs.google.com/viewer?url=https%3A%2F%2Fwww.jpmorgan.com%2Fcontent%2Fdam%2Fjpmorgan%2Fdocuments%2Fcb%2Finsights%2Foutlook%2Fjpm-medtech-deck-q4-2025.pdf&embedded=true&chrome=false&dov=1 "View this pdf file")[![](data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==)](https://docs.google.com/viewer?url=https%3A%2F%2Fwww.jpmorgan.com%2Fcontent%2Fdam%2Fjpmorgan%2Fdocuments%2Fcb%2Finsights%2Foutlook%2Fjpm-medtech-deck-q4-2025.pdf&embedded=true&chrome=false&dov=1 "View this pdf file") ##### Early rounds land fewer bets, higher commitment Nowhere is the narrowing of the market more evident than in early investment rounds. In 2025, Seed and Series A companies raised **$1.9B across 113 rounds**. Investment dollars in these early rounds were down twenty percent from 2024 levels, and the lowest registered in the past five years. The bigger story emerges when you look at deal count, which dropped significantly compared to prior years. This is a significant acceleration of a trend we have been observing over the past five years. At the same time, **average early-stage deal sizes increased**, reaching their highest levels of the past several years. Investors are making fewer bets, but committing more capital when they do. Taken together, these two trends show that early stage investment is no longer about proving an idea is interesting. It’s about proving it’s buildable, regulatable, and worth scaling. ![2021-2025 Seed and Series A MedTech funding Trends](https://nocturnalpd.com/wp-content/uploads/2026/02/Seed-and-Series-A-MedTech-funding-Trends.png "Seed and Series A MedTech funding Trends") Source: [J.P. Morgan 2025 MedTech Report](https://www.jpmorgan.com/content/dam/jpmorgan/documents/cb/insights/outlook/jpm-medtech-deck-q4-2025.pdf)[![](data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==)](https://docs.google.com/viewer?url=https%3A%2F%2Fwww.jpmorgan.com%2Fcontent%2Fdam%2Fjpmorgan%2Fdocuments%2Fcb%2Finsights%2Foutlook%2Fjpm-medtech-deck-q4-2025.pdf&embedded=true&chrome=false&dov=1 "View this pdf file")[![](data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==)](https://docs.google.com/viewer?url=https%3A%2F%2Fwww.jpmorgan.com%2Fcontent%2Fdam%2Fjpmorgan%2Fdocuments%2Fcb%2Finsights%2Foutlook%2Fjpm-medtech-deck-q4-2025.pdf&embedded=true&chrome=false&dov=1 "View this pdf file")[![](data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==)](https://docs.google.com/viewer?url=https%3A%2F%2Fwww.jpmorgan.com%2Fcontent%2Fdam%2Fjpmorgan%2Fdocuments%2Fcb%2Finsights%2Foutlook%2Fjpm-medtech-deck-q4-2025.pdf&embedded=true&chrome=false&dov=1 "View this pdf file")[![](data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==)](https://docs.google.com/viewer?url=https%3A%2F%2Fwww.jpmorgan.com%2Fcontent%2Fdam%2Fjpmorgan%2Fdocuments%2Fcb%2Finsights%2Foutlook%2Fjpm-medtech-deck-q4-2025.pdf&embedded=true&chrome=false&dov=1 "View this pdf file") ##### What investors are screening for earlier than before By 2026, early-stage diligence looks less like a pitch review and more like a risk audit. Here’s what many investors are effectively screening for—often before they say yes to a first meeting. **Regulatory credibility** - A realistic pathway and rationale - Early alignment between indications, claims, and evidence - No major unanswered regulatory questions parked for “later” **Technical readiness** - System architecture that can evolve without major rework - Clear tradeoffs across power, size, performance, and cost - Evidence the design can survive verification and validation **Manufacturability awareness** - Prototypes that can transition to pilot and low-volume builds - Early understanding of NRE, tooling, and supply chain risk - Clear visibility into scalability beyond early builds **Capital efficiency** - A plan that preserves runway while increasing certainty - Spend focused on proof points that increase valuation - Milestones tied to risk reduction, not calendar time **Data quality** - Data that is structured, traceable, and usable - Early signals that future clinical, AI, or commercial claims will hold up None of these are new concepts. What’s changed is how early investors expect these risks to be already understood and planned for at the Seed or Series A stage. ##### The takeaway for founders heading into 2026 The shift in early-stage investor expectations does not mean startups need to do more upfront. In fact, misreading this data often leads teams in the wrong direction. **1. Don’t confuse higher expectations with more functionality** A common reaction to tighter early-stage funding is to assume that investors want more: more features, more use cases, more integrations, more endpoints. That’s rarely what the data supports. What investors are really looking for is **focus**. Strong early-stage programs are increasingly defined by a clear, narrow objective—and disciplined execution against it. Teams that try to broaden scope too early often introduce unnecessary technical, regulatory, and manufacturing risk, exactly when the market is least forgiving. Less functionality—chosen intentionally and aligned to the immediate goal—often produces greater investor confidence. In practice, this means: - Defining a single, defensible use case - Designing only the functionality required to prove that use case - Resisting the temptation to future-proof the product with features that don’t serve the next inflection point **2. Manage the program to the goal, not the roadmap** Early-stage plans frequently fail because they optimize for activity instead of outcomes and risk reduction. Successful teams ensure that every engineering, regulatory, and clinical decision is mapped directly to the next value-creating milestone: a clearer regulatory path, stronger data, a manufacturable design, or a lower-risk clinical step. Programs that manage tightly to a defined goal: - Spend less capital to reach meaningful proof points - Avoid rework driven by late-stage surprises - Create cleaner narratives for the next raise **3. Treat data a critical asset from day one** Data is no longer just something you collect to support a future claim. It’s now a key criterion for investors to assess whether the system and the strategy are sound. Teams that treat data as an asset rather than a byproduct of development are better positioned to support regulatory scrutiny and future AI or analytics initiatives without rework. A strong early data strategy includes: - Designing data capture with regulatory, clinical, and commercial use in mind - Ensuring traceability from raw signals to claims - Avoiding one-off datasets that can’t be reused or extended **4. Build with manufacturing reality in mind—early** A working prototype is not the finish line. For many teams, it’s where the hardest problems begin—especially when manufacturing constraints surface late and force expensive redesigns. Early-stage investors are increasingly sensitive to this risk. Programs that integrate manufacturing considerations early tend to move faster and burn less capital over time. That includes: - Designing architecture and requirements with manufacturability in mind - Validating designs through low-volume builds for V&V, preclinical, or first-in-human use - Learning from real assembly and test processes, not just CAD models ##### Why milestone-based development matters more now In today’s market, milestones are the currency of confidence. As expectations move earlier, milestones are no longer just a way to organize work; they are how early-stage teams demonstrate discipline, focus, and credibility in a more selective market. A meaningful milestone isn’t a date on a timeline or a box to check on a roadmap. It is a moment where uncertainty is replaced with evidence and promises are replaced with progress. At the right milestones: > - Technical uncertainty drops because core architecture and performance tradeoffs are validated > > - Regulatory visibility improves because claims, indications, and evidence are aligned early > > - Manufacturability is designed in rather than deferred, reducing downstream risk > > - Capital efficiency improves because budgets are realistically scoped to completion > > - Investor risk perception changes because progress is tangible and predictable ##### Practical questions for your team If you’re planning a Seed, Series A, or extension round, here are some questions to ask yourself and your team: 1. What specific risks will we retire in the next 6–12 months and why do those risks matter most right now? 2. What concrete evidence will prove that each risk is meaningfully lower (data, test results, regulatory feedback, manufacturing learnings)? 3. Which investor objections does that evidence directly remove, and which new questions will it inevitably raise? Teams that can answer these questions crisply tend to control the fundraising narrative. They can explain not just what they’re building, but why each step matters, what uncertainty it resolves, and how it positions the company for the next round. Answer those questions clearly—and the 2026 funding environment becomes more navigable. Because the bar didn’t just move higher. It moved earlier. ##### Additional resources - [The Startup Guidebook: Navigating Medical Device Funding Cycles](https://nocturnalpd.com/ebook-navigating-medical-device-funding-cycles/) - [How we make fixed-cost pricing work](https://nocturnalpd.com/2023/10/31/the-secrets-to-navigating-fixed-cost-projects-in-medical-device-development/) - [Contact us](https://nocturnalpd.com/get-a-quote/) to see how milestone-based pricing can work for your project. **Categories:** Class II & Class III Devices, Funding, Milestone-based pricing, Startups --- ### [Celebrating A Decade of Milestone-Based Pricing Projects: Insights and Lessons Learned](https://nocturnalpd.com/2023/09/19/celebrating-a-decade-of-milestone-based-pricing-projects-insights-and-lessons-learned/) **Published:** September 19, 2023 **Author:** Eran Livneh **Content:** ![](https://nocturnalpd.com/wp-content/uploads/2024/01/bloghands.jpg "bloghands") This year marks a significant landmark for Nocturnal as we celebrate a decade of delivering projects through our milestone-based pricing model. Over the years, we've had the privilege of partnering with numerous medical device startups. Our unique approach to pricing has been instrumental in ensuring their success, as Joe Passman, Sr. Principal R&D Engineer for NXT Biomedical noted: > “Nocturnal understands the pressures and realities of operating an early-stage medical device company. Their technical capabilities, collaborative process, and startup-friendly business model made working with them a true pleasure." ##### Why milestone-based pricing? Medical device development is complex, and projects often take unexpected turns. It’s no surprise that the concept of fixed-cost, milestone-based pricing was met with some skepticism. But that’s where Nocturnal's founder and president [KC Armstrong](https://nocturnalpd.com/leadership/) saw an opportunity for a more collaborative and transparent approach: “Our business model is designed so that our success is intrinsically tied to our client's success. Unlike traditional hourly billing systems, where there's a risk of projects going off track, leading to increased costs and delays, our fixed-cost pricing model creates a mutual incentive for both parties to stay focused and reach milestones efficiently. This alignment ensures that we are all working towards the same goal of completing the project successfully and on time.” ##### Why now? The current funding environment brings the need for better cash flow control into greater focus. Nocturnal’s VP of Business Development [Eyal Dayan](https://nocturnalpd.com/leadership/) hears these concerns in his conversations with clients: “The one constant that early stage companies tell us these days is that funding takes longer. Entrepreneurs typically want to do as much as possible in the first go round. This project structure requires them to [be more disciplined](https://nocturnalpd.com/2023/08/04/less-is-more-the-power-of-simplicity-in-implantable-medical-devices/) and strategic about their spending.” That’s where milestone-based pricing offers clients an added layer of transparency and control : “When they want to add new features or make changes to the project, our pricing structure allows them to make immediate, informed decisions. They can quickly assess the impact of these changes on both the budget and timeline, without worrying about unexpected costs. This clarity enables them to decide whether the additional investment is truly worth it, giving them [more control](https://nocturnalpd.com/2023/06/12/medical-device-design-considerations-for-the-cash-strapped-startup/) over the project's outcome." ##### What makes fixed cost projects work Sticking to a predictable timeline and cost over the course of a years’ long development project is a challenge that requires both rigor and discipline. We asked [Cinnamon Larson, PhD](https://nocturnalpd.com/leadership/), Nocturnal's VP of Research and Development, what’s the secret that makes it work for Nocturnal and its clients. According to Larson, “efficiency and consistency are critical to the success of fixed-cost projects. That's why we've invested in internal tools and team training to streamline our processes. Whether it's setting requirements, conducting hazard analyses, or any other aspect of development, we aim for a unified approach. By maintaining high standards internally, we're better equipped to deliver on our fixed-cost promises, keeping projects on schedule and within budget. This isn't just about saving time; it's about ensuring the quality of our work to meet and exceed client expectations." In milestone-based projects, effective communication is a necessity. Larson likens it to 'marital therapy for business.' “Both parties—Nocturnal and the client—need to be adept at clearly articulating their perspectives, requirements, and expectations. This level of communication acts as the glue that holds the project together, ensuring it stays on track from start to finish.” ##### A rewarding approach As we celebrate a decade of milestone-based pricing, the lessons learned are invaluable for both Nocturnal and the broader industry. As KC Armstrong notes, the focus on aligned goals, effective communication, and comprehensive documentation has proven to be a successful formula for medical device development projects: "One of the most rewarding aspects of our fixed-cost model is the trust it builds with our clients. They are often pleasantly surprised when we deliver exactly what we promised without any additional fees or price changes. This not only establishes a strong foundation of trust but also proves that we're as committed to the success of their project as they are. It's a win-win situation that fosters long-term relationships." This sentiment is echoed by Dr. Bruce Ferguson, Perfusio’s founder and Chief Medical Officer: > “Nocturnal exceeded the milestones that were specified. Using off-the-shelf computational hardware has kept this developing product costs competitive. Perhaps most importantly, these achievements were integrated within the scalable software platform developed by Nocturnal, demonstrating the platform's capabilities for supporting our expanded product roadmap.” ##### Is milestone-based pricing right for you? If you are interested in learning more about Nocturnal's unique approach, [drop us a note](https://nocturnalpd.com/get-a-quote/) and tell us about your project needs. **Categories:** Milestone-based pricing, Startups --- ### [Why Investors Say No to Medical Device Startups (and how to get them to say yes)](https://nocturnalpd.com/2025/03/24/why-investors-say-no-to-medical-device-startups-and-how-to-get-them-to-say-yes/) **Published:** March 24, 2025 **Author:** Eran Livneh **Content:** ![](https://nocturnalpd.com/wp-content/uploads/2025/03/Say-Yes.jpg "Say Yes") Raising money for a medical device startup is difficult. Our friends at [Avio MedTech Consulting](https://www.aviomedtech.com/) shed a unique light on these challenges, based on interviews with over 100 venture capitalists (VCs). Their blog post, [Why Investors Say No to Medical Device Startups](https://www.aviomedtech.com/post/why-investors-say-no-to-medical-device-startups-key-considerations-for-funding), identifies 12 key factors that often deter investors. While all 12 points have their merits, we take a deeper dive into four critical areas that frequently impact early-stage medical device companies in our experience. ##### Insufficient Team Experience A proven track record is crucial. Investors prioritize experienced teams that can effectively execute their vision. **Nocturnal’s Deep Dive** Many startups assume they must build an entire team in-house before they are ready for investment. This often leads to delays, increased costs, and gaps in expertise. Instead, startups should embrace a networked approach—leveraging expert advisors, contract development partners, and even crowdsourced problem-solving to efficiently fill skill gaps. Showing investors that you know how to build the right expertise around your product—even if not all of it is internal—can make a significant difference in their confidence in your team’s ability to execute. Crowdsourcing technical expertise, regulatory strategy, or market research can help startups demonstrate agility and resourcefulness—two qualities investors value highly. Being able to access expertise without the overhead of a large team can also make a company more financially sustainable in the early stages. For more on how startups can leverage external expertise to accelerate growth, check out this blog: ["Crowdsourcing: A Startup’s Secret Weapon for Accelerating Innovation and Growth"](https://nocturnalpd.com/2024/10/30/crowdsourcing-a-startups-secret-weapon-for-accelerating-innovation-and-growth/). ##### High Regulatory Hurdles Successful medical device startups prioritize regulatory strategy from the very beginning of the design phase. Understanding the device's regulatory classification, testing requirements, and reimbursement landscape is crucial, as it shapes product development and business models to align with investor expectations. Startups that can confidently articulate their regulatory plan, including timelines and risks, significantly increase their chances of securing funding. Engaging regulatory bodies can be helpful in smoothing the path to approval, but it can also create challenges if not done right. For example, the FDA Q-submission process can provide valuable feedback through Pre-Submissions and Informational Meetings, which can help guide the product’s regulatory strategy and development path. With the proper guidance and preparation, this FDA feedback can be extremely valuable for complex products such as implantable devices. At the same time, premature exposure without a solid plan for what is being proposed and what feedback is desired can be counterproductive and risky. Last but not least, startups should look beyond the standard PMA and 510(k) regulatory pathways. While these are the most well-known FDA programs, there may be other, less common options that are more suitable, including programs designed to expedite device approval. For more insights on these programs and how to avoid regulatory pitfalls, read this blog: ["Five Costly Mistakes That Can Sink Your Device Startup – Part I"](https://nocturnalpd.com/2024/05/28/five-costly-mistakes-that-can-sink-your-device-startup-part-i/). ##### Insufficient Financial Projections Financial projections demonstrate the resources needed to create value. Assumptions and analysis are more important than the specific numbers. Investors want to know how your business will make money and what it will cost to get there. **Nocturnal’s Deep Dive** A common financial mistake startups make is failing to plan for the true cost of development and commercialization. Early financial models often underestimate product development costs, leaving companies short on funding at critical milestones. Rather than projecting an optimistic timeline with vague cost estimates, successful startups take a [milestone-based budgeting approach](https://nocturnalpd.com/2023/09/19/celebrating-a-decade-of-milestone-based-pricing-projects-insights-and-lessons-learned/). The ideal milestone acts like a golden ticket, providing enough evidence of progress to secure the next round of funding. But it also needs to be achievable within the startup's limited resources. Partnering with a design and development company that provides milestone-based fixed cost pricing can mitigate the risk of exceeding product budgets. For more details on financial planning pitfalls, read this blog: ["Five Costly Mistakes That Can Sink Your Device Startup – Part II"](https://nocturnalpd.com/2024/06/11/five-costly-mistakes-that-can-sink-your-device-startup-part-ii/). > *“This was my first experience with milestone-based pricing, and I will never go back to hourly billing. Nocturnal’s process ensures all parties are fully aligned and incentivized for success, and the results speak for themselves."* > > *Alex Cooper, CEO, Relief Cardiovascular* ##### Lack of Investor Confidence Investors need to believe in both the startup’s potential and the team’s ability to deliver. A lack of confidence can stem from poor execution, unclear messaging, or a failure to address major risks. **Nocturnal’s Deep Dive** Medical device startups often believe their challenges are entirely unique, leading them to try to create everything from the ground up. However, there's a difference between true innovation and simply 'reinventing the wheel.' Leveraging proven product designs, manufacturing processes, regulatory strategies, and clinical trial plans can provide a strong foundation and save valuable time and resources. Often overlooked is the fact that much of the necessary know-how is transferable between different devices and medical fields. For example, power management, signal acquisition, energy delivery, and data communication are common challenges in [cardiac](https://nocturnalpd.com/cardiac-rhythm-management/) and [neuromodulation](https://nocturnalpd.com/neuromodulation/) devices as well as wearables. While these components require specialized features and can't be bought off-the-shelf, they often rely on technologies already tested and proven in other devices. Identifying where these existing technologies and expertise can be used and adapted can significantly lower the cost, time, and risk involved in product development. > *“The scalable software platform developed by Nocturnal demonstrated its capabilities for supporting our expanded product roadmap, and using off-the-shelf computational hardware has kept product costs competitive.”* > > *Bruce Ferguson, MD, Chief Medical Officer & Co-Founder, Perfusio* ##### Final Thoughts Raising capital as a medical device startup is challenging. Investors are looking for more than just an exciting idea—they want your startup to demonstrate you are prepared for the realities of medical device development: - **Assemble the right expertise**—whether in-house or through external networks. - **Develop a regulatory strategy early** to avoid costly delays. - **Create financial models based on realistic, milestone-driven projections**. - **Clearly articulate your path to market and risk management strategies**. By addressing these critical factors early, startups can not only increase their chances of securing funding but also set themselves up for long-term success. ##### Additional Resources - [12 Reasons Investors Say No to Medical Device Startups (Avio MedTech post](https://www.aviomedtech.com/post/why-investors-say-no-to-medical-device-startups-key-considerations-for-funding)[)](https://nocturnalpd.com/ebook-navigating-medical-device-funding-cycles/) - [The Startup Guidebook: Navigating Medical Device Funding Cycles](https://nocturnalpd.com/ebook-navigating-medical-device-funding-cycles/) - [Medical device design considerations for the cash strapped startup](https://nocturnalpd.com/2023/06/12/medical-device-design-considerations-for-the-cash-strapped-startup/) **Categories:** Funding, Milestone-based pricing, Startups --- ### [Milestones That Matter: A Conversation with KC Armstrong on Reaching “First in Human”](https://nocturnalpd.com/2025/10/29/reaching-first-in-human/) **Published:** October 29, 2025 **Author:** Eran Livneh **Content:** ![](https://nocturnalpd.com/wp-content/uploads/2025/10/KC-QA.jpg "KC QA") ##### KC Armstrong, MSEE, is Nocturnal's Founder & President. ##### A design engineer with over 25 years of experience, KC specializes in developing Class II and Class III medical, automotive safety, and Class 4 industrial safety devices. ##### He has implemented circuitry, systems, and algorithms for multiple implantable devices and other complex, high-reliability, safety-critical products, and has filed 14 US patents and patent applications. **Q: Three of Nocturnal’s clients have active implants in humans this year. What does that represent for you and your team?** **KC:** Anyone in the medical device field knows that’s no small thing. Actual clinical use is when ideas and engineering stop being theoretical and finally meet patients. It’s a huge achievement. And reaching that point safely and efficiently is never “luck” — it’s the product of focus, persistence, and trust. It’s when all of the late nights, debugging, and documentation start to mean something tangible. **Q: Are these the kind of outcomes you imagined when you started Nocturnal?** **KC:** When I started Nocturnal 14 years ago, my goal wasn’t to be yet another design services company. I’d spent years inside the medical device world and in design services. I knew how hard it was for startups to navigate the path from proof-of-concept to human studies, especially under the pressures of funding, milestones, and regulatory demands. I know that what they needed wasn’t just engineering horsepower; they needed a partner who understood the whole lifecycle and could adapt to where they were along their development path. **Q: What makes Nocturnal uniquely positioned to help clients achieve these milestones?** **KC:** We’re not just hardware designers or firmware developers — we all think about the system and the patient. Our team includes engineers, regulatory experts, and product strategists who understand how every decision at the bench ripples through verification, validation, and ultimately, clinical use. We work on a range of devices — from implantables and wearables to ultra-low-power devices and cloud-connected systems that turn biosignals into clinical insights. But what truly makes this team special isn’t just the depth of experience we bring to projects — it’s our mindset. **Q: You often describe Nocturnal as a “trusted partner.” What does that mean to you?** **KC:** It’s not just a tagline, and it’s not about complying with a contract. It’s about being in the room when the hard decisions get made — when a team has to pivot, simplify, or take a calculated risk to stay alive. It’s about asking the uncomfortable questions that save months later and never saying, “that’s not our problem.” For me, trust is earned through action — by showing up, solving problems, and doing whatever it takes to keep the project moving forward. We approach every project as if it were our own company. Our milestone-pricing model reinforces a mindset that is cost-aware, schedule-aware, and focused on the milestones that really matter. We don’t overbuild for the sake of process, but we don’t cut corners either. It’s all about balance — defining what’s critical now, what can wait, and making sure our clients are ready when success comes faster than they expect. **Q: Milestone-based pricing model is not common in this industry. Why take that approach?** **KC:** Because it reflects how we view our relationships with clients — built on transparency, accountability, and shared goals. Through my many years in design services prior to Nocturnal, I was never comfortable with exchanging money for time. Startups don’t just need our time - they need a solution. Most firms still bill by the hour, but startups need predictability. They deserve to know what they’ll get, when they’ll get it, and what it will cost. Pricing by milestones puts the focus on outcomes, not effort. We shoulder the uncertainty so our partners can focus on building value. It’s the exception in medical device development, but for us, it’s the only way that makes sense. **Q: What’s next for Nocturnal and your clients?** **KC:** For the startups that have reached human studies, this is where the real impact begins. It means they’ve built a solid foundation of technical capability and risk management. Now comes the learning, the data, and the refinement that lead to improved clinical experiences and, eventually, to commercialization. For our team, it’s about continuing to be the partner that makes those leaps possible — combining technical rigor, relentless collaboration, and the belief that true innovation doesn’t happen in isolation. It’s also a reminder of what makes us different: a commitment to shared accountability, to building lasting partnerships, and to bringing breakthrough technologies safely and swiftly into the hands of clinicians and patients who need them most. ##### ##### **Additional resources** - [Webinar recording](https://nocturnalpd.com/webinar-on-demand-from-biosignals-to-clinical-insights/): From biosignals to clinical insights – how to derisk and accelerate your path to market - [Mastering the MedTech Data Explosion](https://nocturnalpd.com/mastering-the-medical-device-data-explosion/): Your guide to product design best practices for the age of mega data – from biosensors to data platforms and everything in between - [Linxens Healthcare website](https://healthcare.linxens.com/) #### [Lessons from a Decade of Milestone-based Pricing Projects](https://nocturnalpd.com/2023/09/19/celebrating-a-decade-of-milestone-based-pricing-projects-insights-and-lessons-learned/) [![](https://nocturnalpd.com/wp-content/uploads/2024/01/bloghands-square.png)](https://nocturnalpd.com/2023/09/19/celebrating-a-decade-of-milestone-based-pricing-projects-insights-and-lessons-learned/) #### ## [The Secrets to Navigating Fixed-Cost Development Projects](https://nocturnalpd.com/2023/10/31/the-secrets-to-navigating-fixed-cost-projects-in-medical-device-development/) [![](https://nocturnalpd.com/wp-content/uploads/2023/10/teamwork-design-515838341_594x594.jpeg)](https://nocturnalpd.com/2023/10/31/the-secrets-to-navigating-fixed-cost-projects-in-medical-device-development/) #### ## [Your Guide to Navigating Medical Device Funding](https://nocturnalpd.com/ebook-navigating-medical-device-funding-cycles/) [![](https://nocturnalpd.com/wp-content/uploads/2025/02/Feb-2025-eBook-no-intro.png)](https://nocturnalpd.com/ebook-navigating-medical-device-funding-cycles/) **Categories:** Class II & Class III Devices, Lifesaving & Implantable, Milestone-based pricing, Startups --- ### [Linxens and Nocturnal partner to accelerate medical device innovation](https://nocturnalpd.com/2024/07/08/linxens-and-nocturnal-partner-to-accelerate-medical-device-innovation/) **Published:** July 8, 2024 **Author:** Eran Livneh **Content:** ![](https://nocturnalpd.com/wp-content/uploads/2024/06/Linxens-Nocturnal-Logos-2.png "Linxens + Nocturnal Logos 2") Paris, France and Durham, North Carolina – [Linxens](https://healthcare.linxens.com/), a global expert in the design and manufacture of electronic components, and Nocturnal, specialized in the design and development of wearable and implantable medical devices, announce their partnership to accelerate time to market of advanced medical devices. ##### A Promising Partnership for Ultra-low Power Wearables and Implantables The challenge within the MedTech industry today lies in offering patient-friendly solutions that seamlessly integrate electronic skin patches, biosensors, and connectivity into a single life-enhancing device. Linxens has more than 40 years of experience, covering the entire industrial process, from R&D and prototyping to mass production. Nocturnal brings over two decades of expertise in medical device engineering, specializing in ultra-low power hardware and software development. By combining Linxens’ and Nocturnal’s respective competences, the entire development process can be accelerated, giving patients faster access to solutions that improve their daily lives. > "Through our partnership with Nocturnal, we offer a complete and integrated solution, from concept design to final packaging, to accelerate the commercialization of innovative and transformative medical devices for patients. We are proud of our expertise in developing high-quality solutions and are committed to supporting our customers every step of the way,” said Minh Lê, Vice President at Linxens Healthcare. ##### Accelerating Market Access with High Standards of Safety Both Nocturnal and Linxens have a proven track record of maintaining the highest quality and safety standards. Linxens' smartpatches are manufactured at its facility in Sweden, which is ISO 13485:2016 certified, while Nocturnal’s office and development labs hold the same certification for the provision of electrical, mechanical, and software design and development services to manufacturers of medical devices. This commitment to quality ensures that any product developed through this partnership will not only reach the market faster, but will do so without compromising safety or efficacy. > "Our collaboration is designed to fast-track the introduction of groundbreaking medical devices that can transform patient care," stated KC Armstrong, Founder and President of Nocturnal. "Incorporating Linxens’ advanced medical-grade biosensors and skin electronic adhesion technologies into our product designs will provide device innovators with the latest advances in bio-sensor technology while reducing the risk associated with new product introduction." ##### About Linxens For over 40 years, [Linxens](https://healthcare.linxens.com/) has been a world leader in the electronics industry, providing innovative, customized component-based solutions to meet the most demanding technical specifications in terms of connectivity, traceability and authentication. Linxens has 7 R&D centers and 8 factories worldwide, and employs over 3,500 people. Linxens has a unique infrastructure to meet the specific needs of its customers, from prototyping to mass production, supported by roll-to-roll manufacturing capabilities. To offer its solutions and expertise to MedTech, the Group is deploying a dedicated offering under the Linxens Healthcare brand, which includes solutions in electronic skin patches / wearables, biosensor manufacturing and connected solutions. The Group has delivered over 500 million electrochemical sensors and more than 15 million electronic skin patches to the healthcare market until today. ##### About Nocturnal Nocturnal helps medical device innovators accelerate the path to commercialization. Led by experts with over 25 years of experience in [Class II and Class III](https://nocturnalpd.com/class-ii-class-iii-devices/) [lifesaving and implantable devices](https://nocturnalpd.com/lifesaving-implantable/), The company specializes in areas that include [cardiac rhythm management](https://nocturnalpd.com/cardiac-rhythm-management/), [neuromodulation](https://nocturnalpd.com/neuromodulation/), [biosignal acquisition](https://nocturnalpd.com/biosignal-acquisition/), and [ultra-low power hardware and software design](https://nocturnalpd.com/ultra-low-power-software-hardware/). By offering a unique [milestone-based pricing model](https://nocturnalpd.com/why-nocturnal/), Nocturnal helps medical device companies focus on achieving critical product milestones with greater predictability and transparency throughout the development process. [Contact us](https://nocturnalpd.com/get-a-quote/) to find out how this partnership can help accelerate your device commercialization. **Categories:** Biosensors & Biosignal Acquisition, Lifesaving & Implantable, Wearable --- ### [How to Build Your Device Faster While Staying Compliant Using Smart Design Controls](https://nocturnalpd.com/2025/07/18/how-to-build-your-device-faster-while-staying-compliant-using-smart-design-controls/) **Published:** July 18, 2025 **Author:** Eran Livneh **Content:** ![](https://nocturnalpd.com/wp-content/uploads/2025/07/Design-Controls.jpg "Design Controls") > The difference between a stumbling block and a stepping stone is in how you approach it. For MedTech startups, speed is everything. Investors expect traction. Founders want to see their ideas come to life. And patients—ultimately—can’t wait. And amid the rush to develop and deliver, design controls can feel like an obstacle: a set of regulatory hoops to jump through on the way to FDA clearance. This perception is not only outdated—it’s risky. When approached strategically, design controls can actually help you build safer, better products faster. In this post, we’ll explore how startups can integrate compliance into their development process without slowing down innovation—and why doing so gives you a long-term advantage. ##### What Are Design Controls and Why Do They Matter? Design controls are a regulatory requirement—but they’re also much more than that. At their core, design controls are a structured approach to product development. They are an often-iterative series of steps that ensure medical devices are safe, effective, and meet the needs of end users. For startups trying to move fast and break new ground, understanding these controls can be the difference between costly delays and confident progress. **A Quick Primer on FDA Design Control Requirements (21 CFR 820.30)** The FDA’s Quality System Regulation (QSR) includes a section—[21 CFR 820.30](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-820/subpart-C/section-820.30)—that outlines the expectations for design controls in medical device development. These rules apply to nearly all Class II and III devices, and even some Class I products with software or specific risk profiles. And while the FDA recently announced its intention to harmonize these with [ISO 13485](https://www.iso.org/standard/59752.html), the fundamental concepts of design controls will remain unchanged. The goal of these regulations is to ensure that devices: - Perform as intended, - Address real user and patient needs, and - Meet applicable safety and regulatory requirements. The regulation mandates a systematic approach to managing the design and development process, including documentation, reviews, and traceability. **Key Components of Design Controls** Here’s a breakdown of the core elements within 21 CFR 820.30: - **Design and Development Planning** The bedrock of the development effort, the D&D plan outlines the goals of the project, delineates responsibilities, and identifies the major tasks, deliverables, milestones, and timelines. It also specifies what documentation will be generated and who is responsible for reviewing it. - **Design Inputs The product’s starting point: design inputs specify what the device must do. These are derived from user needs, intended use, regulatory requirements, and applicable standards. These inputs form the foundation for development tasks as well as subsequent verification and validation activities. - **Design Outputs The tangible results of the design effort—specifications, drawings, software code, manufacturing instructions—that must align with the inputs. - **Design Verification Confirmation that outputs meet the inputs. This answers the question: ***Did we build the device right?*** - **Design Validation Ensures the device meets user needs in the real world, addressing the question: ***Did we build the right device?*** - **Design Reviews Formal checkpoints during development where multidisciplinary teams evaluate progress, identify issues, and document decisions. - **Design Transfer The transition from development to production—ensuring the device can be manufactured consistently according to the design. - **Design Changes A controlled process for evaluating and documenting changes during or after development to avoid unintended consequences. - **Design History File (DHF) / Design and Development File A complete record showing how the design evolved and how it meets its final requirements. This is a key deliverable during audits or FDA submissions, serving as a central source of information for the post-market device. - **Risk Management (per [ISO 14971](https://www.iso.org/standard/72704.html)) While not explicitly listed in 21 CFR 820.30, modern quality systems integrate risk management throughout the design process to ensure hazards are identified, evaluated, and mitigated. > **Nocturnal’s Approach to De-Risking Product Development** > > At Nocturnal, we believe early design control documentation is most valuable when accompanied by an architectural component that serves as a conceptual plan for how we would implement the product to meet the design input requirements. > > It is by no means a finished design—but a strategic effort to de-risk development and identify whether any requirements could pose high technical or cost risk before we embark on a detailed design. > > Our **Product Architecture Documentation** may include: > > \- Block diagrams > > \- Key component lists > > \- High-level bills of materials and cost estimates > > \- 3D concept models > > \- PCBA space studies > > \- Power budgets ##### Why Startups Can’t Afford to Overlook Design Controls—But Timing Matters For many MedTech startups, the instinct is to postpone formal design controls. And that instinct isn’t wrong—at least not entirely. That doesn’t mean design controls aren’t important—it means they’re most effective when introduced at the right moment. In the earliest phases, teams need to move fast—testing ideas, demonstrating core functionality, and gathering user input. Applying rigid documentation requirements too soon can lead to wasted effort and unnecessary revisions as the concept evolves. By focusing on architectural planning and risk awareness, startups can maintain speed without losing sight of quality. Once the concept works and key requirements are validated, formal design controls become a powerful accelerator. That’s when structured documentation and traceability help teams: - **Ensure Safety and Efficacy Mistakes in design can have life-threatening consequences. Formal controls reduce the risk of design flaws going undetected. - **Enable Lifecycle Traceability Clear links between risks, requirements, design features, and testing outcomes are critical. You must be able to show that a risk was identified, mitigated with a design feature, and verified as effective. - **Avoid Regulatory Delays Whether it’s an FDA submission or ISO 13485 certification, auditors will ask to see a well-structured design history. And you can’t build that overnight. - **Accelerate Development Done well, design controls streamline—not slow—your path to market. When teams align on requirements, risks, and test plans early, they reduce rework, avoid surprises, and move faster. The key isn’t doing everything up front—**it’s doing the right things at the right time**. > **Nocturnal’s “Right-Time” Approach to Design Controls** > > In early-stage development, speed and feasibility are the top priorities. For many companies, this means that we can delay formalizing design control documentation until after the first meaningful product demonstration. > > Instead, we utilize **lightweight documentation**, concentrating on essential user needs, potential hazards, and core functional requirements. We develop an initial product version that meets the first set of critical technical milestones with a medical-grade design implementation, including just enough documentation to ensure that full design controls can be applied later with negligible impact on the design. > > Once feasibility is confirmed, we activate our ISO 13485-compliant design control process—ensuring full traceability, structured documentation, and a QMS-backed framework aligned with FDA expectations. ##### Turning Compliance into Acceleration The truth is, design controls aren’t just about compliance—they are rooted in sound project management principles. When baked into the development process from the outset, they help product teams: - **Catch issues earlier:** Design reviews surface risks before they become expensive problems. - **Stay aligned:** Clear inputs and outputs ensure your team stays focused on solving the right problems. - **Reduce iteration cycles:** Verification and validation prevent endless prototyping and guesswork. Done right, compliance doesn't slow you down—it keeps you moving in the right direction. > **Nocturnal’s Lean, Phase-Based Validation** > > At Nocturnal, we run documented **phase reviews** aligned with design control checkpoints (such as input, detailed design, and verification). These lightweight validations confirm deliverables are complete and ready for the next phase—without overburdening teams. > > These phase reviews are designed to be efficient and focused, targeting the essential elements required to ensure quality and compliance without introducing unnecessary delays or overhead. > > By anchoring these reviews to the design control process, we establish a traceable and transparent framework that fosters accountability and alignment with the client team. ##### Tools and Tactics for Streamlining Design Controls Startups today have a major advantage: modern tools built specifically for them. Solutions like [QuickVault by Veeva](https://quickvault.veeva.com/) offer out-of-the-box eQMS functionality tailored to the needs of growing MedTech companies. Here are some of the key benefits they provide: - **Pre-built templates** for design control documentation - **Automated traceability** between inputs, outputs, risks, and testing - **Collaborative workflows** for design reviews, training, and quality events - **Regulatory readiness** with built-in audit trails and change control Instead of wrangling spreadsheets and scattered folders, your team can work in a unified system that supports both innovation and compliance. > **Built-In Design Control Documentation from Day One** > > Working with Nocturnal, you get a **complete set of design control documentation** that’s audit-ready and built for transfer. > > All deliverables—design and development plans, risk analyses, architecture docs, test protocols, firmware files, and more—are managed within an ISO 13485 certified QMS environment structured to meet FDA regulations. > > That means when you’re ready to scale, raise funds, or transition to your own QMS, everything is already organized, traceable, and exportable. ##### **Lessons from the Field: Compliance as a Catalyst** At Nocturnal, we’ve worked with dozens of early-stage companies. They often come to us focused on prototyping, but are not always prepared for the documentation and regulatory rigor required to scale. The most successful teams build quality into their process from the beginning. They treat design controls not as a burden, but as a way to clarify thinking, reduce risk, and increase their startup’s valuation. Design controls aren’t in the way—they *are* the way. When implemented thoughtfully, they can help startups avoid common pitfalls and accelerate time to market. ##### **Additional Resources** [![](https://nocturnalpd.com/wp-content/uploads/2025/07/On-demand-square-banner-1.png)](https://nocturnalpd.com/scaling-from-prototype-to-commercial-success-a-lean-approach-for-medical-startups/) **Categories:** Funding, QMS, Startups --- ### [From biosignals to clinical insights – how to derisk and accelerate your path to market](https://nocturnalpd.com/2025/06/16/from-biosignals-to-clinical-insights-how-to-derisk-and-accelerate-your-path-to-market/) **Published:** June 16, 2025 **Author:** Eran Livneh **Content:** ![](https://nocturnalpd.com/wp-content/uploads/2025/06/Blog-featured2.png "Blog featured2") If you're building a medical device that relies on biosignals, the hardest part may be collecting the right data to prove it works, and doing so quickly enough to meet milestones and keep funding flowing. In our recent webinar, “[Derisk Device Development—From Biosignals to Clinical Insights](https://nocturnalpd.com/webinar-on-demand-from-biosignals-to-clinical-insights/),” we were joined by our partner [Linxens Healthcare](https://healthcare.linxens.com/) to offer some proven strategies for accelerating time to data—without compromising quality. Here are the key takeaways from the conversation between Alix Joseph, Healthcare Marketing Director at Linxens, and KC Armstrong, Nocturnal’s Founder and President. ##### ##### **Data is your product—and your bottleneck** The value of most biosensor-enabled devices lies in the data they generate. Whether wearable or implanted, these devices are essentially conduits for collecting, transmitting, and analyzing physiological signals. The challenge? You often need large amounts of high-quality, clinically relevant data to validate your solution, but you can't collect that data until the device is built. That’s where modular, scalable platforms become game-changing. They allow early-stage teams to start capturing data in a clinically relevant form—sometimes before a full product even exists—helping prove value, attract funding, and build regulatory confidence. ##### ##### Case in point: Accelerating data collection for Future Cardia Device startup [Future Cardia](https://www.futurecardia.com/) needed to collect a large amount of cardiac data for FDA submission, but doing it with their implantable device would have required an infeasibly large and expensive study, possibly delaying their time-to-market by years. Instead, Linxens and Nocturnal helped Future Cardia transform the core device technology into a wearable patch that could collect comparable data for FDA approval. With Linxens’ pre-approved patch and Nocturnal’s data processing design, what would have been a year-long costly development project was successfully accomplished in record time and at substantially reduced cost. In just a few months, Future Cardia started collecting high-quality data that met FDA standards—saving the company substantial amounts of time and money. ##### ##### **Biosensor and clinical data explosion: Demand-driven, technology-enabled** The rise of remote diagnostics and monitoring isn’t just about convenience—it’s a structural shift driven by aging populations, increased awareness of chronic and infectious diseases, and persistent shortage in healthcare workers. At the same time, the maturing of technologies like AI, connectivity, miniaturization, and low-power design enables accurate and continuous biosignal monitoring. The post-COVID acceleration of at-home care has only strengthened this trend, creating the perfect moment for biosensor-based innovation. Examples of such innovations can be found across a variety of use cases. Here are just a few examples: - Cardiac monitoring is a mature application with well-established demand, reimbursement pathways, and clinical expectations. Long-wear ECG patches can capture high-fidelity signals for up to 14 days, enabling detection of intermittent arrhythmias that traditional monitors may miss. - Sweat analysis is another emerging application, with growing interest in non-invasive detection of biomarkers like sodium, lactate, and even inflammation indicators such as CRP. While technically more complex, the ability to combine clinically-proven biosensors with flexible patches makes it possible to explore this frontier without starting from scratch. - Temperature sensing, often overlooked, has high-impact applications in pediatrics, fertility, and infection monitoring. Success hinges on careful material selection, patch design, and accurate thermal contact—all of which must be tailored to body location, wear duration, and user profile. ##### ##### **The partnership advantage: Lower risk, faster path to approval** For early-stage medical device companies, it's a constant race to meet critical product and regulatory milestones before funds run out. Speed and predictability aren’t just helpful—they’re critical. That’s where the partnership between Linxens and Nocturnal offers a strategic edge. On the biosensor side, there are decades of experience in medical-grade patch manufacturing and sensor integration that Linxens brings. With over 100 million clinical-grade sensors delivered, their platforms use materials and processes that are already validated for human use. This gives startups a powerful advantage when preparing for regulatory submissions—offering clear precedent, built-in documentation, and less friction with FDA or CE reviewers. Nocturnal adds specialized capabilities in ultra-low-power electronics and embedded software, developed specifically for wearable and implantable devices. But it’s not just the technology that matters to startups. Nocturnal’s [fixed-cost, milestone-driven model](https://nocturnalpd.com/why-nocturnal/) is designed for startups navigating tight timelines and investor-backed funding. By working with predictable timelines and known components, teams can reduce technical unknowns, control costs, and avoid delays that often derail early-stage companies. Together, [Linxens and Nocturnal](https://nocturnalpd.com/2024/07/08/linxens-and-nocturnal-partner-to-accelerate-medical-device-innovation/) offer medical device startups a faster, safer, and more regulator-friendly path to collecting clinical data. Instead of spending valuable time designing a new patch or vetting components for biocompatibility, startups can tap into a proven ecosystem—with the confidence that every element has been purposely built, thoroughly tested, and audited for medical use. > This isn’t just about moving fast. It’s about moving forward with less risk, less rework, and a clearer path to regulatory approval. ##### ##### **Final thoughts: Time-to-data is your risk reduction strategy** Startups don’t usually fail because their technology doesn't work. They fail because they run out of money or time before they can prove that it works in a commercializable format. If you can shorten the time it takes to validate your idea, you reduce your risk. That’s why smart founders take advantage of what’s already been solved, and double down on the differentiators that will set them apart in the market—their algorithm, their novel data correlation, their predictive model. Biosensor-enabled solutions from Nocturnal and Linxens are designed to give innovators a faster, safer, and more cost-effective path to the data they need. That’s what the Linxens and Nocturnal partnership is all about. ##### ##### **Additional resources** - [Webinar recording](https://nocturnalpd.com/webinar-on-demand-from-biosignals-to-clinical-insights/): From biosignals to clinical insights – how to derisk and accelerate your path to market - [Mastering the MedTech Data Explosion](https://nocturnalpd.com/mastering-the-medical-device-data-explosion/): Your guide to product design best practices for the age of mega data – from biosensors to data platforms and everything in between - [Linxens Healthcare website](https://healthcare.linxens.com/) Webinar Recording [![](https://nocturnalpd.com/wp-content/uploads/2025/06/Linxens-webinar-on-demand.png)](https://nocturnalpd.com/webinar-on-demand-from-biosignals-to-clinical-insights/) #### Guide [![](https://nocturnalpd.com/wp-content/uploads/2025/04/Data-Guide-Cover.png)](https://nocturnalpd.com/mastering-the-medical-device-data-explosion/) #### Press Announcement [![](https://nocturnalpd.com/wp-content/uploads/2024/06/Linxens-Nocturnal-Logos-2.png)](https://nocturnalpd.com/2024/07/08/linxens-and-nocturnal-partner-to-accelerate-medical-device-innovation/) **Categories:** Biosensors & Biosignal Acquisition, Lifesaving & Implantable, Startups, Ultra-low Power Software Hardware, Wearable --- ### [5 Things Startups Get Wrong about Software-Enabled Medical Devices](https://nocturnalpd.com/2025/05/09/5-things-startups-get-wrong-about-software-enabled-medical-devices/) **Published:** May 9, 2025 **Author:** Eran Livneh **Content:** ![](https://nocturnalpd.com/wp-content/uploads/2025/05/Software-enabled-Medical-Device.jpg "Software-enabled Medical Device") Developing a software-enabled medical device isn’t just a technical challenge—it’s a strategic one. Startups and growth-stage companies often enter the space with a compelling idea, only to find themselves buried in documentation, bogged down by power constraints, or tripped up by regulatory surprises. But it doesn’t have to be that way. In a [recent expert panel on medical device development and FDA clearance](https://nocturnalpd.com/medtech-leading-voice-webinar-software-enabled-medical-device/), five standout strategies were shared—hard-earned insights that can help development teams stay focused, move faster, and avoid costly missteps. Whether you’re building an implantable device, a connected wearable, or software as a medical device (SaMD), these takeaways offer a smarter path forward. ##### 1. You don’t need to start with a mountain of documentation—you need to prove it works > “Contrary to formal teaching, it does not always make sense to follow the full formal medical product development process right away.” [https://nocturnalpd.com/wp-content/uploads/2025/05/Slide\_01.mp4](https://nocturnalpd.com/wp-content/uploads/2025/05/Slide_01.mp4) Formal design controls are and documentation important—but they’re not always the right starting point. In the early days, your priority should be proving the product works and that there’s a real market need. In the early stages, the most urgent goal is demonstrating **technical feasibility and functional value**. Why? Because that’s often the key unlocks your next round of funding. Investors don’t fund documentation. They fund momentum—proof that your product solves a real problem and can be built in the real world. Rather than sinking time and money into detailed specifications before anything is validated, consider a lighter-weight approach: - Capture user needs, key hazards, and product requirements informally - Build quick prototypes - Test the concept - Validate key assumptions Yes, you will absolutely need to formalize design inputs, traceability, and risk management at some point. But leading with lean, fast-moving development gives you the traction you need to secure additional funding—and then scale your compliance process with additional time and resources. ##### 2. Version one should not be feature-complete > “Everybody tries to put the kitchen sink in their product… You’ll run out of money before you get what really matters to the market.” [https://nocturnalpd.com/wp-content/uploads/2025/05/Slide\_02.mp4](https://nocturnalpd.com/wp-content/uploads/2025/05/Slide_02.mp4) Feature creep is one of the most common—and most dangerous—startup traps. Founders often feel pressure to chase every competitor feature or customer wishlist item—but in medical device development, that’s a slippery slope toward a prolonged timeline and an overblown budget. The better approach is to ruthlessly prioritize what makes your product unique and **defer everything else** to later releases. Put simply: don’t overbuild. Design a clean, lean version one that solves a real clinical or user problem—then build from there. Fewer features mean: - Simpler testing - Easier documentation - Faster time to market - Less risk during FDA review Focus is not just a design principle—it’s a survival strategy. Solve one problem exceptionally well. ##### 3. Keep the smart stuff away from the patient > “The closer a device is to a patient, the harder it is to get approved and the harder it is to update later.” [https://nocturnalpd.com/wp-content/uploads/2025/05/Slide\_03.mp4](https://nocturnalpd.com/wp-content/uploads/2025/05/Slide_03.mp4) In today’s connected ecosystems, devices often include multiple layers: implants or wearables, mobile apps, and cloud platforms. Where you place functionality across this stack matters. **Implantables and wearables should focus on stability, data capture, and safety**—collecting data and delivering therapy as needed, but doing minimal “thinking.” The device connected to the patient should perform only the tasks that it is uniquely qualified to perform. Unless they’re strictly required to enable the patient device to do its job, sophisticated logic, analytics, and adaptive algorithms should live in the app or cloud—where updates and regulatory approvals are faster and easier. Why it matters: - Firmware updates to implantables are difficult and potentially high-risk to the patient - Regulatory scrutiny increases with proximity to the patient - Moving logic to the cloud enables more flexibility and easier iteration This kind of architectural decision can dramatically reduce technical risk and regulatory overhead. It also has profound implications on power consumption, which is our next point. ##### 4. Low-power design starts on day one > “Everything you do, especially with software, you need to be thinking low power… It’s an art as much as it’s a science. And datasheets lie.” [https://nocturnalpd.com/wp-content/uploads/2025/05/Slide\_04.mp4](https://nocturnalpd.com/wp-content/uploads/2025/05/Slide_04.mp4) In medical devices—especially wearables and implantables—battery life isn’t just a spec, **it’s a constraint that should shape your entire design approach**. How you write your software is a key driver of device power consumption. Too often, we see teams prototype algorithms on a PC or use code that’s not optimized for embedded systems. Then they try to port it, only to discover the power draw is far too high for a wearable or implantable form factor. But you can’t sprinkle in low-power optimizations at the end. Ultra-low power performance has to be baked into every design decision from day one: - Structure software to minimize processor clock cycles. Every single one counts. - Test on real hardware early - Iterate for power optimization as you add functionality **Ultra-low power is an art as much as it is a science.** Datasheets may tell you the theoretical power draw of a microcontroller—but real-world behavior is often different. That’s why at Nocturnal we emphasize early hardware prototyping and iterative measurement, not just analysis on paper. > “For one of Nocturnal’s implantable clients, we were able to take the customer’s existing algorithm, rethink the implementation for embedded hardware, and reduce power consumption by 20x.” ##### 5. Your architecture should match your roadmap > “You have to architect from day one for what you want to do in V3.” Smart teams start with the bigger picture in mind, aligning engineering with the business strategy. Short-sighted decisions about system architecture and component selection can create long-term barriers to product evolution, clinical expansion, or market scaling. This advice doesn’t contradict the point we made earlier (#2). It doesn’t mean you need to implement every feature upfront—but it does mean **making foundational choices** that will prevent a total rebuild when you want to expand functionality, enter a new market, or pursue a different reimbursement path. From a regulatory standpoint, this also helps mitigate major rework. Architectural changes later on are harder to justify than the addition of new functions, and can trigger new validation cycles or resubmissions. Designing for flexibility early on keeps you agile without adding risk. ##### Final thoughts: What sets high-performing teams apart There are no shortcuts to building a safe, effective, and FDA-cleared medical device. But there are proven strategies that experienced teams get right: - Prioritize proving real-world function over producing documentation early on - Keep version one laser-focused - Push logic away from the patient as much as possible - Design for ultra-low power from day one - Align technical architecture with business goals For startups and innovators in the space, these aren’t just nice ideas—they’re difference-makers. Implementing these principles can reduce cost, accelerate timelines, and improve your odds of successful funding and long-term success. ##### Additional Resources - [Less Is More: The Power of Simplicity in Implantable Medical Devices](https://nocturnalpd.com/2023/08/04/less-is-more-the-power-of-simplicity-in-implantable-medical-devices/) (5 min read) - [The Startup Guidebook: Navigating Medical Device Funding Cycles](https://nocturnalpd.com/ebook-navigating-medical-device-funding-cycles/) - [View the webinar recording](https://nocturnalpd.com/medtech-leading-voice-webinar-software-enabled-medical-device/) for additional insights on product development, cybersecurity, and FDA clearance for software-enabled medical devices **Categories:** Embedded Software, Funding, Startups, Ultra-low Power Software Hardware --- ### [Transforming Biosignals into Clinical Insights: Putting the Pieces Together](https://nocturnalpd.com/2024/11/19/transforming-biosignals-into-clinical-insights-putting-the-pieces-together/) **Published:** November 19, 2024 **Author:** Eran Livneh **Content:** ![](https://nocturnalpd.com/wp-content/uploads/2024/11/Biosensor2.jpg "Biosensor2") *This blog post was created in collaboration with our partner [Linxens Healthcare](https://healthcare.linxens.com/), a leading provider of electronic skin patches, biosensors, and connected solutions.* In the rapidly advancing world of healthcare technology, the transformation of biosignals into actionable clinical data is key to enhancing patient care and improving outcomes. With a growing demand for real-time monitoring, diagnostics, and data-driven therapy delivery, the ability to seamlessly capture, interpret, and transmit these signals is more critical than ever. Linxens and Nocturnal have come together to offer integrated services that facilitate this process. This partnership leverages their combined expertise to simplify the path from biosignal acquisition to clinical data analysis, while accelerating device development timelines and minimizing the risks of delays and setbacks in the development process. ##### It All Starts with Quality Signal Acquisition Biosignals, the measurable physiological signals produced by the body, offer a wealth of information about our health and well-being. Advances in sensor technology have enabled the capture of a diverse range of biosignals, opening new avenues for continuous health monitoring and personalized medicine. Electrical signals, such as those generated by the heart, brain, and muscles, are among the most commonly captured biosignals. Electrocardiograms (ECGs) measure heart activity, providing insights into cardiac health and rhythm. Electroencephalograms (EEGs) record brainwave patterns, helping to diagnose neurological disorders and monitor brain function. Electromyograms (EMGs) assess muscle activity, aiding in the diagnosis of muscle diseases and the development of rehabilitation therapies. Chemical signals, often measured through biosensors, offer valuable information about metabolic processes and overall health. Continuous glucose monitoring (CGM) systems, for example, track glucose levels in real-time, empowering individuals with diabetes to manage their condition effectively. Lactate monitoring can provide insights into muscle fatigue and exercise performance, while cortisol monitoring can help assess stress levels and overall well-being. In addition to electrical and chemical signals, physical signals, such as body temperature and movement data, can also be captured by integrated sensors. Body temperature monitoring is essential for detecting fever and other health issues, while acceleration and posture data can be used for activity tracking, fall detection, and sleep monitoring. By combining these various biosignals, it is possible to gain a comprehensive understanding of an individual's health status and lifestyle patterns. ![](https://nocturnalpd.com/wp-content/uploads/2024/11/Linxens-Patch-plateform.png "Linxens Patch plateform") Image courtesy of Linxens High Resolution, Low Noise, and Better AI Data Once the raw data has been collected, the transformation from raw biosignals to clinical data relies on both hardware and software capabilities to ensure the delivery of accurate, meaningful, and actionable insights. A major challenge in biosignal processing is noise—unwanted interference that can distort the signals being collected. Sources of noise may include electromagnetic interference, motion artifacts, or physiological processes that obscure the targeted signals. To ensure data accuracy, noise reduction techniques are applied during signal acquisition and processing. Sophisticated algorithms, filtering methods, and active noise-canceling technologies help eliminate these interferences while preserving the integrity of the core data. By minimizing noise, medical devices can deliver cleaner, higher-resolution signals, making the analysis more reliable, particularly in devices where the distinction between a normal and abnormal signal is subtle, such as in cardiac monitoring or neurological assessments. As AI becomes an integral part of nearly every medical device, the need for clean, high-quality data is more critical than ever. AI-driven diagnostic tools rely heavily on the accuracy of the input data to deliver reliable, actionable insights. Any noise or distortion in the biosignal data can lead to false interpretations or missed diagnoses. Therefore, ensuring low-noise, high-resolution data is essential for maximizing the potential of AI in medical diagnostics, enabling more precise decision-making and improving patient outcomes across a range of applications. ##### Power Efficiency in Signal Processing and Transmission Power efficiency is a critical factor in the design of biosignal acquisition devices, especially wearable and implantable devices that rely on continuous, long-term monitoring. Not only must these devices acquire and process biosignals like ECG or chemical markers efficiently, but they must also transmit this data to external devices or healthcare systems without draining the battery quickly. The integration of [ultra-low-power](https://nocturnalpd.com/ultra-low-power-software-hardware/) components and intelligent signal processing algorithms is key to ensuring these devices operate for extended periods without frequent recharging or battery replacements. Hardware-based noise reduction, such as active noise-canceling circuits, plays a dual role in this process. It reduces signal distortion to enhance data quality while operating with minimal power consumption. In combination with optimized signal processing algorithms, these systems allow for the continuous monitoring of vital signs, such as heart rhythms or glucose levels, without compromising on battery life. In addition to efficient signal acquisition, low-power data transmission is essential for preserving energy. Wireless communication protocols such as Bluetooth Low Energy (BLE) are commonly used in medical wearables to transmit data to external devices. These protocols are designed to use minimal power while maintaining reliable, real-time communication between the wearable device and the healthcare provider’s monitoring system. For example, in ECG monitoring, once the data is acquired and filtered, the use of a low-power transmission method ensures that the patient’s vital signs are continuously sent to the healthcare provider without excessive battery drain. Balancing power-efficient data transmission with the needs of real-time monitoring allows for longer operational cycles, which is essential for devices that are meant to be worn for days, weeks, or even months at a time. This balance between effective biosignal acquisition, noise reduction, and low-power data transmission ensures that the device remains functional and reliable over extended periods, enabling continuous, accurate data collection and improving overall patient outcomes. ##### End-to-End Safety and Compliance Ensuring patient safety is a top priority in medical device design. Devices must not only be accurate but also comply with stringent regulatory standards. The end-to-end safety of a medical device involves robust testing, risk management, and quality assurance procedures. In addition to safety features, regulatory documentation plays a crucial role in securing market approval for medical devices. Detailed records of the design process, testing protocols, and risk management strategies must be compiled and submitted to regulatory bodies to demonstrate that the device meets the required safety standards. Streamlining this documentation process helps accelerate time to market while ensuring compliance with all necessary regulations. ##### Documentation for Regulatory Approval For any medical device, gaining regulatory approval is a pivotal milestone. Regulatory bodies like the FDA or EMA require detailed documentation that proves the safety, efficacy, and quality of the device before it can be brought to market. This process can be daunting, but thorough and accurate documentation can significantly streamline the approval timeline and reduce potential delays. Documentation for regulatory approval includes extensive records of the device’s development lifecycle. This begins with the design and risk assessments, followed by testing data, quality assurance protocols, and clinical trial results. Each step must be clearly documented to demonstrate that the device and development process comply with medical industry standards, such as ISO 13485 for quality management systems and ISO 62304 for software development . Additionally, the integration of biosensors, data processing algorithms, and communication protocols must be outlined, ensuring that the device not only meets functional requirements but also adheres to stringent safety regulations. For example, implantable devices must pass rigorous tests to confirm they do not cause adverse effects within the body, while wearables must prove that they can function accurately and safely in dynamic, real-world external environments. Regulatory documentation also extends beyond the product launch. Post-market surveillance, ongoing risk management, and device updates must be documented to maintain compliance and ensure patient safety throughout the product’s lifecycle. By building a comprehensive documentation framework from the beginning, companies can navigate the regulatory landscape more efficiently, ensuring that their innovations reach patients faster. ##### Some Exciting Use Cases **Sweat Monitoring via Stick-to-Skin Patches** Linxens Healthcare possesses strong expertise in designing and manufacturing stick-to-skin patches and chemical biosensors. In combination with Nocturnal's advanced [ultra-low-power hardware and software](https://nocturnalpd.com/ultra-low-power-software-hardware/), Linxens’ technology enables innovative solutions for continuous health monitoring. By capturing and analyzing sweat biomarkers like sodium, potassium, lactate, and cortisol, patches can provide real-time insights into hydration status, electrolyte balance, muscle fatigue, and stress levels. This technology empowers individuals to optimize their performance, manage chronic conditions, and improve overall well-being through extended monitoring with minimal battery consumption. **Monitoring Cardiac Activity with ECG Stick-to-Skin Patches** Linxens’ industrial capabilities in design, functional printing, and assembly of stick-to-skin patches make it possible to reliably capture electrical signals from the heart in ambulatory applications. Combining these patches with ultra-low power hardware and software designed by Nocturnal to condition and analyze biosignals enables [accurate detection of cardiac rhythms](https://nocturnalpd.com/cardiac-rhythm-management/) over extended monitoring periods using readily available batteries. **Temperature Monitoring in Clinical and Remote Settings** Linxens can incorporate vital sign sensors into their patches through the use of both functional printing and traditional circuit assembly. These capabilities allow small, inexpensive stick-to-skin patches to reliably detect changes in skin temperature, offering valuable information for health monitoring. By combining these features with Nocturnal-designed ultra-low-power hardware and software, continuous extended temperature monitoring is practical even in remote or clinical settings. ##### The Future of Biosignal Integration The Linxens Healthcare - Nocturnal collaboration provides a comprehensive end-to-end design and manufacturing service for wearable health device development, streamlining the process from sensor integration to data analytics and regulatory compliance. The combination of these innovative technologies enable the capture of low-noise, high-resolution biosignals using minimal power, allowing for better signal quality over longer periods. By ensuring the accuracy of data, extending the operational life of devices, and streamlining regulatory approval, these key elements form the foundation for effective biosignal monitoring and analysis. To learn more about how this collaboration is driving innovation in healthcare, visit [Linxens](https://healthcare.linxens.com/) and [Nocturnal](https://nocturnalpd.com/biosignal-acquisition/). ##### Additional Resources [![](https://nocturnalpd.com/wp-content/uploads/2025/04/Data-ebook-Linkedin-image.png)](https://nocturnalpd.com/mastering-the-medical-device-data-explosion/) **Categories:** Biosensors & Biosignal Acquisition, Lifesaving & Implantable, Neuromodulation, Startups, Ultra-low Power Software Hardware, Wearable --- ### [2024 Medical Device Investment Data: A Brighter Exit Path, A Challenging Funding Road](https://nocturnalpd.com/2025/02/21/2024-medical-device-investment-data-a-brighter-exit-path-a-challenging-funding-road/) **Published:** February 21, 2025 **Author:** Eran Livneh **Content:** ![](https://nocturnalpd.com/wp-content/uploads/2025/02/Feb2025.jpg "Feb2025") A look back at the investment trends for medical device companies in 2024 presents a picture of renewed vigor at the bookends of the path to commercialization, with challenging times for companies in the middle of the road. While early-stage funding and merger and acquisition (M&A) activity showed considerable gains compared to the previous year, late-stage investments grew at a much slower rate and often with depressed valuations. To successfully cross the late-stage funding chasm, startups must make every dollar count by focusing on meeting investor expectations and hitting key product milestones with their limited early-stage capital. Prioritizing critical development goals and adopting milestone-based pricing can help maximize resources, maintain investor confidence, and increase valuations for late-stage rounds. Exit activity: A resurgence in M&A, and are IPOs back? Following a slow M&A activity in the first half of the year, medical device companies saw a strong rebound in Q3, ending 2024 with 14 major acquisitions, a 56% year-over-year (YoY) increase. The surge was led by 5 cardiovascular deals with a median upfront value of $500M and 2 orthopedic deals with a median upfront value of $415M. While the median valuation for M&A deals was down from its high of 2023, it showed an upward trend compared to the previous 5 years. In Q4 we saw the first medical device IPO of the year, when Ceribell raised $180 million in proceeds. The IPO reflected a pre-money step-up from its last private round, and its stock has since nearly doubled in post-money value. Whether this was an exception or a signal of renewed IPO interest remains to be seen. ![](https://nocturnalpd.com/wp-content/uploads/2025/02/MA-Deals.png "M&A Deals") Source: [HSBC 2024 Annual Venture Healthcare Report ](https://www.business.us.hsbc.com/-/media/media/us/pdfs/campaigns/2024-annual-venture-healthcare-report.pdf) ##### Venture financing grows with broad investor interest In 2024, **total medical device venture investment reached $7.5 billion across 421 deals, a 15% increase** from the $6.5 billion raised in 2023 across 430 deals. Despite this overall growth, the market showed clear signs of concentration of capital in established, commercial-ready players, with the top 10% of deals representing 60% of all investment dollars. Late-stage medical device deals attracted the most varied funding mix in over a decade, signaling renewed interest from strategic investors in the medical device sector, including traditional venture capital, private equity, growth investors, and crossover funds. Corporates from pharma, diagnostics, and medtech also re-entered the investment space, helping fund both large and small transactions. ##### Early-stage rebounds, late-stage gets greater scrutiny Early-stage investment in medical devices showed considerable growth in 2024, with **total first-financing investment reaching $971 million across 106 deals, a 34% increase** from $726 million across 105 deals in 2023. **Late-stage rounds (Series B or later) grew at a much slower rate in 2024**, with a smaller number of deals compared to 2023—315 deals raising $6.5B in 2024 compared to 325 deals raising $5.8B in 2023. Series C and later rounds saw the slowest growth. **They also experienced considerable pressure on valuations, with two thirds securing flat or down rounds**. These trends show that investors are seeking to lower financial risks and scrutinizing late-stage investments for stronger proof of viability, making it critical for companies to demonstrate clinical progress, regulatory traction, and a clear commercial strategy early in their development. ##### Investors reward innovation, but path to exit gets longer In 2024, M&A values for PMA (Pre-Market Approval) devices reached record highs, with median up-front payments hitting $550M and total deal values reaching $810M—both significantly higher than historical averages. For 510(k) devices, 2024 showed a return to higher deal volume with 10 transactions (up from just 3 in 2023), but with more moderate valuations—median up-front payments of $254M and total deal values of $293M, down from the 2023 peaks or both metrics. 2024 saw longer exit timelines for both pathways. PMA deals averaged 13.8 years, while 510(k) deals reached 11.1 years, suggesting companies needed more time to achieve exit-worthy milestones compared to previous years. Notably, all 510(k) acquisitions over the past three years were for FDA-cleared, revenue-generating products, emphasizing the importance of commercial readiness. ![](https://nocturnalpd.com/wp-content/uploads/2025/02/MA-Deals-by-Submission-Type.png "M&A Deals by Submission Type") Source: [HSBC 2024 Annual Venture Healthcare Report ](https://www.business.us.hsbc.com/-/media/media/us/pdfs/campaigns/2024-annual-venture-healthcare-report.pdf) ##### Neurology leads the pack for new investments Neurology remained the leading area for medical device investment in 2024, attracting $1.2 billion across 48 deals, slightly down from $1.3 billion in 2023. Funding was driven by strong interest in brain-computer interface (BCI) and neurostimulation technologies. Non-invasive monitoring (NIM) surpassed $1 billion in funding, a significant jump from $640 million in 2023, reflecting growing investor interest in cardiovascular and metabolic monitoring technologies. Other high-growth areas included orthopedic and vascular devices. Orthopedic investment surged to $868 million across 54 deals, up from $635 million in 2023, with strong backing for implant technologies (19 deals) and surgical robotics (7 deals). Vascular investment more than doubled, reaching $759 million across 26 deals. Cardiovascular investment remained stable at $542 million, but funding was 15-20% lower than pre-2022 levels, reflecting a more selective investment approach. In contrast, imaging investments declined sharply to $543 million (from $847 million in 2023), as the market became increasingly competitive with fewer acquirers. ![](https://nocturnalpd.com/wp-content/uploads/2025/02/Funding-by-Indication.png "Funding by Indication") Source: [HSBC 2024 Annual Venture Healthcare Report ](https://www.business.us.hsbc.com/-/media/media/us/pdfs/campaigns/2024-annual-venture-healthcare-report.pdf) ##### What this means for medical device startups **Opportunities at the bookends** The surge in M&A activity presents strong exit opportunities for later-stage startups, particularly those with regulatory approvals and market-ready products. Investors are showing enthusiasm for robotics, AI-driven diagnostics, and cardiac monitoring devices, making these key areas of innovation and growth. Early-stage funding is strong, meaning that new ideas get more opportunities to prove their worth. **Challenges on the long road** The slow growth and high number of flat or down rounds in late-stage funding means that securing subsequent investment beyond the early stages is more difficult than in previous years. Investors are demanding clear milestones, such as clinical validation, regulatory approvals, and reimbursement strategies, before committing capital. To put it in plain words, investors are saying “we’ll give you the money to develop your idea, but you better show us you can make it before we give you more money.” **Strategies for success** For startups that can prove their worth and push past these challenges, the long-term outlook remains promising, with M&A exits offering a viable path forward. The takeaways for startups are: **1. Define and prioritize milestones** Prioritizing critical milestones can help startups manage their cash flow and maintain investor confidence. Clearly define achievable goals for each stage of development, from proof of concept (POC) to clinical trials and eventual market entry. Fixed-cost pricing for predefined milestones helps eliminate unexpected expenses, giving startups better control over their cash outlay and reducing financial risk. > “Working with Nocturnal has dramatically accelerated our time-to-market. In just one year, Nocturnal took our implantable cardiac monitor from a concept to a fully functional device with a mobile application and secure cloud connectivity.” > \- Jaeson Bang, Founder and CEO, Future Cardia **2. Implement a strong Quality Management System (QMS) early on** Prioritizing quality from the outset minimizes regulatory risks, protects brand reputation, and accelerates market adoption. A well-documented Quality Management System (QMS) is essential for regulatory approval and long-term success. Regulatory bodies like the FDA require a structured QMS to ensure product safety and effectiveness throughout its lifecycle. Beyond compliance, a strong QMS enhances operational efficiency, ensuring consistency, reducing errors, and freeing up resources for innovation. **3. Establish predictable costs for predefined milestones** With guaranteed product development costs for predefined deliverables, startups gain cash flow predictability while reducing financial strain and optimizing resource allocation. Adopting a milestone-based pricing model fosters transparency and trust between startups and development partners, ensuring that both parties are aligned in their goals and keeping projects on track and within budget. > “This was my first experience with milestone-based pricing, and I will never go back to hourly billing. Nocturnal’s process ensures all parties are fully aligned and incentivized for success, and the results speak for themselves." > \- Medical Device Stealth Startup CEO ##### Additional resources - [The Startup Guidebook: Navigating Medical Device Funding Cycles](https://nocturnalpd.com/ebook-navigating-medical-device-funding-cycles/) - [How we make fixed-cost pricing work](https://nocturnalpd.com/2023/10/31/the-secrets-to-navigating-fixed-cost-projects-in-medical-device-development/) - [Contact us](https://nocturnalpd.com/get-a-quote/) to see how milestone-based pricing can work for your project. **Categories:** Funding, Milestone-based pricing, PMA, Startups --- ### [Five costly mistakes that can sink your device startup - Part I](https://nocturnalpd.com/2024/05/28/five-costly-mistakes-that-can-sink-your-device-startup-part-i/) **Published:** May 28, 2024 **Author:** Eran Livneh **Content:** ![](https://nocturnalpd.com/wp-content/uploads/2024/05/Startup-Sinking.webp "Startup Sinking") ##### Five Costly Mistakes that Can Sink Your Device Startup - Part I Translating a groundbreaking concept into a commercially viable medical device requires navigating a complex web of challenges, from securing funding to overcoming stringent regulatory hurdles. Here are five common mistakes that can derail your medical device startup on the path to commercialization, along with actionable strategies to overcome them. ##### Mistake #1: Not Optimizing your Regulatory Path Imagine this: You've poured your heart and soul into developing a revolutionary medical device. It has the potential to change countless lives. But then you hit a brick wall—the regulatory maze. Deadlines loom, costs balloon, and worst of all, your device gets delayed. The key to avoiding these pitfalls is having a comprehensive regulatory strategy from the get-go. When considering regulatory pathways, there is more to it than PMA and 510(K). While device entrepreneurs are typically aware of the most common FDA programs, they may miss out on opportunities for more suitable options that are less commonly used, such as: 1. De Novo: For novel, low-to-moderate risk devices without a predicate 2. Humanitarian Device Exemption (HDE): For devices treating rare conditions 3. Custom Device Exemption (CDE): For devices tailored to specific patients 4. Expanded Access Program (EAP): For investigational devices used in serious conditions 5. Product Development Protocol (PDP): For well-established technologies, allowing early agreements on safety and effectiveness​ You can find additional information about each of these pathways in this [Greenlight Guru](https://www.greenlight.guru/blog/fda-pathways-medical-device-to-market) article.​​ Additionally, in recent years the FDA has introduced several programs to expedite device approval, including: - [**Breakthrough Devices Program**](https://www.fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program): For devices treating life-threatening conditions, offering prioritized review and frequent FDA interactions.​ - [**Safer Technologies Program (STeP)**](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safer-technologies-program-medical-devices): For devices improving safety compared to current treatments, providing interactive communications and early data development engagement.​ ​​ - [**Early Feasibility Study (EFS) Program**](https://www.fda.gov/medical-devices/investigational-device-exemption-ide/early-feasibility-studies-efs-program): Allows early clinical evaluations to gather preliminary safety and effectiveness data, facilitating early testing and iterative development. One of the grave mistakes startups make is delaying engagement with regulatory authorities. Early interaction can help identify potential regulatory hurdles and provide guidance on the necessary studies and documentation. Q-Submissions, including Informational Meetings and Pre-submissions, allow sponsors to obtain FDA feedback on specific questions, which is particularly useful for complex products like implantable devices or innovative testing strategies. At the same time, there is never a second chance for a first impression, so make sure you are well-prepared for any interactions with the regulators. Last but not least, it is important to recognize that no matter which path you choose, regulatory considerations such as adherence to standards like ISO 14971 and IEC 62340 will significantly impact product development timelines, presenting specific requirements for risk management and documentation throughout the process. ##### Mistake #2: Trying to Do Too Much Too Soon One of the most common pitfalls for medical device startups is the temptation to cram as much functionality as possible into the initial version of their implantable device. In reality, more is not always better, and trying to compete with mature, state-of-the art products on standard features is a distraction from proving the benefits of a novel and differentiating technology. Getting a medical device to market is a journey riddled with regulatory hurdles and the constant pressure to prove market viability. Startups, forever resource-constrained, typically have just enough capital to reach the next critical milestone. This makes defining these milestones with laser focus absolutely essential. To start with, minimizing regulatory burden at the early stages of the device lifecycle is crucial. Complex devices with multiple components and extensive functionality require increased testing and documentation to satisfy regulatory requirements for approval. By concentrating on the core functionalities that prove the device’s efficacy and safety, startups can navigate regulatory hurdles more efficiently. No less important is building trust with both regulators and end-users. By eliminating superfluous complexities in the initial release, developers can create a reliable device that consistently fulfills its intended purpose, fostering confidence with regulators and patients. This initial success establishes a solid foundation for subsequent iterations where additional functionality can be safely introduced. Last but not least, overly complex designs can easily lead to cost overruns and project delays, jeopardizing crucial milestones. Conversely, a simpler design translates to streamlined manufacturing processes, reduced testing expenditures, and a more predictable development timeline. To reduce risk and safely meet their funding milestones, medical device startups must [resist the urge to overcomplicate their initial designs](https://nocturnalpd.com/2023/08/04/less-is-more-the-power-of-simplicity-in-implantable-medical-devices/). Seeking the advice of product development experts with experience in developing similar devices can provide a well-balanced outside perspective to help you prioritize the essential functionality at each development stage based on a startup’s most crucial resources: money and time. ##### Mistake #3: Failing to Take Advantage of Existing Know-how Medical device entrepreneurs take pride in being innovators. But there is a fine line between innovation and the tendency to “reinvent the wheel”. The medical device industry has a rich history of innovation, with countless lessons learned from both successes and failures. Ignoring this history means you might waste valuable time and resources solving problems that have already been addressed. Proven product blueprints, established manufacturing processes, successful regulatory pathways, and tested clinical trial designs can provide a solid foundation upon which to build, rather than starting from scratch. Device startups often get caught up in the notion that their challenge is unique enough to warrant inventing every aspect of the product from scratch. They grapple with the challenge of distinguishing their product's unique features while navigating the multifaceted layers of medical device development. The key to success lies in a nuanced understanding of the different technological components that make up the product architecture and their associated risks. By distinguishing these elements, startups can focus their innovation efforts where it counts, while utilizing existing assets and expertise to mitigate risks and streamline their path to market. When it comes to implantable devices, off-the-shelf components are rarely suitable beyond the proof of concept stage. Depending on specific market requirements, it may be possible to reduce development cost and time by using off-the-shelf or “catalog” components for a first-generation device in places where development can be extremely expensive, such as leads, batteries, or hermetic feedthroughs. What is more applicable yet commonly overlooked is existing know-how that can be transferable across devices and clinical domains. This know-how applies to device components that require specific medical and implantable device expertise but are not unique to your specific application. For instance, power management, signal acquisition, energy delivery, and data communications are common challenges for both [cardiac](https://nocturnalpd.com/cardiac-rhythm-management/) and [neuromodulation](https://nocturnalpd.com/neuromodulation/) devices, as well as wearables. These building blocks require specialized features and cannot be sourced off-the-shelf. Yet they rely on technologies that are often already utilized, tested, and proven in other devices. Understanding where existing technologies and expertise can be leveraged and repurposed in your device can significantly reduce the cost, time, and risk associated with your product development. > “The Nocturnal team greatly contributed to the development of our ground-breaking implantable device combining CCM® therapy and defibrillation functionality. They provided expertise that helped us to overcome several design challenges and played an important role in turning our vision into a clinically-viable product.” > > David Prutchi, Ph.D., CTO and Executive VP, Impulse Dynamics ##### Continue reading in [Part II](https://nocturnalpd.com/2024/06/11/five-costly-mistakes-that-can-sink-your-device-startup-part-ii/) of this post **Categories:** Class II & Class III Devices, Funding, Milestone-based pricing, PMA, QMS, Startups --- ### [Crowdsourcing: A Startup’s Secret Weapon for Accelerating Innovation and Growth](https://nocturnalpd.com/2024/10/30/crowdsourcing-a-startups-secret-weapon-for-accelerating-innovation-and-growth/) **Published:** October 30, 2024 **Author:** Eran Livneh **Content:** ![](https://nocturnalpd.com/wp-content/uploads/2024/10/Crowdsourcing.png "Crowdsourcing") *This blog post was created in collaboration with [RedCrow](https://redcrow.com), an equity crowdfunding platform specializing in advancing healthcare innovation through the power of the crowd.* Successful entrepreneurs master the art of doing more with less, finding innovative ways to tackle big challenges with limited resources. For medical device startups navigating the early stages of growth, crowdsourcing has emerged as a powerful strategy for accelerating innovation while minimizing costs. By tapping into the collective expertise of diverse contributors, startups can move quickly, adapt effectively, and gain valuable insights. Let’s look at the key benefits of crowdsourcing and how they translate into meaningful opportunities for early-stage companies. ##### Accelerating Innovation Cycles Crowdsourcing enables startups to quickly gather insights and solutions, allowing for rapid iteration and refinement. With this steady flow of external input, startups can move more swiftly from concept to market-ready product, maintaining a competitive edge by staying agile and responsive to market demands. This acceleration in the innovation cycle empowers startups to continually improve and adapt, pushing out updates and new features at a faster pace. ##### Saving Time and Reducing Costs By leveraging the collective skills and resources of a global community, crowdsourcing helps startups accomplish tasks more efficiently and cost-effectively. Whether it’s gathering feedback, conducting tests, or developing new features, relying on a crowdsourced approach minimizes the need for extensive in-house teams or lengthy development timelines. For startups working within budget constraints, this resourcefulness is essential, enabling them to achieve growth while keeping overhead low. ##### A New and Fresh Perspective Working on a project day in and day out can lead to tunnel vision. Crowdsourcing introduces a valuable influx of fresh perspectives, with contributors bringing diverse backgrounds, experiences, and insights to the table. This external input can help startups identify blind spots, challenge assumptions, and develop solutions that are both innovative and inclusive. By harnessing the collective intelligence of the crowd, startups can refine their ideas and deliver offerings that resonate more deeply with their target audience. ##### Building a Supportive Community Crowdsourcing isn’t just about resources; it’s also about fostering a community around a startup's mission. Engaging with the crowd allows startups to form early connections with potential customers, investors, and advocates who are invested in the company's journey. Over time, these early supporters build a loyal audience, amplifying the brand’s presence and creating a foundation of trust. This community can evolve into a dedicated network that enhances the startup's visibility and solidifies its standing in the market. ##### Crowdsourcing in Action Examples **Refining Ideas Through Crowdsourced Feedback** Early feedback from crowdsourced communities can be a quick and inexpensive way to gain critical insights, spot potential issues, and even challenge their initial assumptions. As highlighted in the RedCrow article [Perfect Your Business Idea with Crowdsourced Feedback](https://www.redcrow.com/blog/perfect-your-business-idea-with-crowdsourced-feedback/), this kind of feedback enables early-stage companies to make iterative improvements before committing significant resources, ultimately honing their products to better align with market needs.It’s a fast and cost-effective way to validate ideas and adjust them based on real-world input. **Early Stage Capital** Crowdfunding through platforms like RedCrow is emerging as a powerful alternative to traditional venture capital, reshaping the funding landscape for startups. Crowdfunding democratizes access to capital by enabling a wider audience of investors to contribute to innovative ideas. This model provides early-stage companies with more than just funding; it helps them build a community of dedicated supporters who believe in their vision. By raising capital directly from the crowd, startups gain early visibility and traction, strengthening their brand while diversifying their sources of support. **Complex Problem-Solving** Complex challenges often benefit from diverse solutions, which is where crowdsourced problem-solving shines. Platforms such as [Wazoku](https://www.wazoku.com/) allow companies to pose open-ended questions to a global community of problem-solvers, drawing on a broader knowledge pool to speed up innovation cycles and uncover unique solutions that in-house teams might overlook. **AI and Machine Learning Development** In the AI/ML space, crowdsourcing has become a major driver of innovation. Platforms like [Kaggle](https://www.kaggle.com/) host competitions that attract data scientists from around the world to solve complex machine-learning challenges. For startups with limited AI resources inhouse, participating in such crowdsourced competitions can accelerate the development of sophisticated algorithms and advanced predictive capabilities. **Software Testing** For startups developing digital products, software testing can be a bottleneck. Platforms like [Testlio](https://testlio.com/) offer crowdsourced testing, connecting startups with a global network of QA professionals. This not only speeds up the testing process but also ensures that products are tested across a variety of devices, environments, and user scenarios. By catching bugs and improving user experience early, startups can launch more reliable software with confidence. ##### Balancing Crowdsourcing with Expertise By leveraging the wisdom of the crowd, startups can innovate faster, reduce costs, and optimize product development. But while crowdsourcing offers significant advantages, it’s important to recognize its limitations. For example, the development of [implantable devices](https://nocturnalpd.com/lifesaving-implantable/) demands multiple proficiencies that go beyond clinical expertise, including deep understanding of regulatory standards, biological compatibility considerations, and [ultra-low power hardware and software](https://nocturnalpd.com/ultra-low-power-software-hardware/) design — a combination of skills and experience that is not easy to find. The key to success lies in knowing when to augment crowdsourced insights with expert knowledge, particularly in specialized fields where the number of people who can effectively contribute may be significantly limited. **Categories:** Funding, Startups --- ### [2024 H1 MedTech Funding: Insights and Takeaways](https://nocturnalpd.com/2024/08/06/2004-h1-medtech-funding-insights-and-takeaways/) **Published:** August 6, 2024 **Author:** Eran Livneh **Content:** ![MedTech Funding Trends](https://nocturnalpd.com/wp-content/uploads/2024/08/MedTech-Funding-Blog.png "MedTech Funding Blog") ##### New MedTech Funding: A Light at the End of the Tunnel? The first half of 2024 paints a hopeful picture for MedTech startups. Three recent reports published by [J.P. Morgan](https://www.jpmorgan.com/content/dam/jpmorgan/documents/cb/insights/outlook/jpm-medtech-deck-q2-2024-final-ada.pdf)[![](data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==)](https://docs.google.com/viewer?url=https%3A%2F%2Fwww.jpmorgan.com%2Fcontent%2Fdam%2Fjpmorgan%2Fdocuments%2Fcb%2Finsights%2Foutlook%2Fjpm-medtech-deck-q2-2024-final-ada.pdf&embedded=true&chrome=false&dov=1 "View this pdf file")[![](data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==)](https://docs.google.com/viewer?url=https%3A%2F%2Fwww.jpmorgan.com%2Fcontent%2Fdam%2Fjpmorgan%2Fdocuments%2Fcb%2Finsights%2Foutlook%2Fjpm-medtech-deck-q2-2024-final-ada.pdf&embedded=true&chrome=false&dov=1 "View this pdf file"), [Rock Health](https://rockhealth.com/insights/h1-2024-digital-health-funding-resilience-leads-to-brilliance/), and [Galen Growth](https://www.galengrowth.com/digital-health-funding-h1-2024/) present slightly different views of the market, but all show encouraging funding growth trends. According to the J.P. Morgan report, US MedTech startups raised $9.7 billion in venture funding across 353 rounds in the first six months of 2024. This upward trend is promising. If this momentum continues, we can expect over 20 percent growth in total MedTech funding for the year.[![](https://nocturnalpd.com/wp-content/uploads/2024/08/MedTech-H1-2024-800x513.png)](https://nocturnalpd.com/wp-content/uploads/2024/08/H1-Trends.tif) Data Source: J.P. Morgan **Early Stage Surge** In contrast to previous years, early-stage funding rounds stood out as a bright spot in the MedTech funding landscape. With $2.4 billion in 188 rounds completed in H1 2024, seed and A round investments are on track to beat the previous two years and come close to the pandemic-fueled record of 2021. This surge in early-stage funding indicates that investors are increasingly prioritizing innovation and showing a greater willingness to embrace risk. It also helps that new startups don’t have the same inflated valuations that some previously-funded companies carry from the pandemic bubble years. ![](https://nocturnalpd.com/wp-content/uploads/2024/08/Early-Stage-H1-2024-800x434.png) Data Source: J.P. Morgan **Decline in Unlabeled Rounds** Unlabeled rounds—investments that do not clearly specify the stage of funding—often increase during transitional periods in market conditions, when startups require capital but haven't yet achieved the necessary benchmarks for their next funding round. While the number of these unlabeled rounds is still significant, it is clearly declining from its peak. This trend suggests a return to more traditional and transparent funding patterns, where both investors and startups are aligning expectations more closely. Investors are becoming more discerning, focusing on startups with clear value propositions and strategic objectives. ![](https://nocturnalpd.com/wp-content/uploads/2024/08/Share-of-Unlabled-Rounds-400x346.png) Data Source: Rock Health **AI Is the Locomotive** AI continues to be a driving force in MedTech funding, attracting significant investor interest in the first half of 2024. According to the Galen Growth report, AI-focused ventures accounted for 57% of total digital health funding globally, underscoring the technology’s pivotal role in shaping the future of healthcare. ##### But Don’t Get Blinded by the Light: How Do You Make Your Funding Dollars Go the Extra Mile? Despite the resurgence in MedTech funding, startups still face a highly demanding investment environment. They must make the best use of early rounds funds to achieve critical milestones, gain investor confidence, and secure subsequent financing. **Simplify for Success** Innovators often fall into the trap of overloading their initial product versions with an abundance of features. However, simplicity can often be the key to unlocking a device's true potential. By focusing on novel features and critical functionality, eliminating superfluous features, and relegating extensive data analysis to external systems, we can create a device that excels in its intended purpose while optimizing development effort. Simplified designs are not only easier to develop but can also enhance reliability, streamline regulatory approval, improve energy efficiency, and reduce costs: - Enhanced reliability: Fewer components and simpler functions reduce the likelihood of malfunctions, ensuring a more consistent performance. - Streamlined approvals: By minimizing non-critical features, startups can reduce extensive testing and documentation requirements and minimize delays in regulatory approvals. - Energy efficiency: Simpler designs can help minimize power consumption—reducing the frequency of surgical replacements or recharging procedures for patients. - Cost-effectiveness: Simplification often leads to lower material and assembly costs, making the device more affordable. > Read more: [The Power of Simplicity in Implantable Medical Devices ](https://nocturnalpd.com/2023/08/04/less-is-more-the-power-of-simplicity-in-implantable-medical-devices/) **Manage Development Priorities** Prioritizing critical milestones can help startups manage their cash flow and maintain investor confidence. This involves defining clear, achievable goals for each stage of product development, from proof of concept (POC) to fully functional versions ready for clinical trials and market entry. - Proof of Concept (POC): The primary goal at this stage is to demonstrate technological feasibility without the need for full functionality or regulatory approval. - Version One (V1): This version must be fully functional and ready for clinical trials, meeting strict compliance and documentation requirements while avoiding non-essential functions. - Version Two (V2): A fully commercialized version incorporating user feedback and refinements, V2 can be developed in parallel to V1. **Leverage Proven Technologies** By focusing innovation on unique aspects of the device and leveraging transferable technologies, startups can significantly cut down development time and costs. Utilizing proven technologies for non-unique aspects of the device can also reduce development risks, enhance reliability, and shorten approval timelines. > Read more:[ Leverage Existing Know-how to Accelerate Device Commercialization ](https://nocturnalpd.com/2024/01/22/accelerating-neuromodulations-path-to-commercialization/) **Apply Efficient Data Strategies** With AI representing a key driver of investor interest, formulating a clear data acquisition strategy that accounts for clinical and operational tradeoffs becomes critical for any device venture. Implantable devices operating in an ultra-low power setting require a careful balance between data collection parameters and power consumption. While more detailed data may provide deeper insights, it comes with the added cost of increased storage space, extended wireless transmission times, and more powerful on-board processing requirements. Greater power consumption means more frequent battery charging or replacements, resulting in added cost, risk, and patient discomfort. > Read more: [Balancing Signal Data vs. Power Consumption in Your Device](https://nocturnalpd.com/2024/04/22/balancing-signal-data-vs-power-consumption-in-your-implantable-device/) **Establish Predictable Product Development Costs** Fixed-cost pricing for predefined milestones eliminates concerns over unexpected expenses, providing startups with better control over their cash outlay. Milestone-based pricing models create a symbiotic relationship between device innovators and their development partners, fostering transparency, trust, and mutual success. This approach aligns the incentives of both parties, ensuring that projects stay on track and within budget. > Read more: [Celebrating A Decade of Milestone-Based Pricing Projects ](https://nocturnalpd.com/2023/09/19/celebrating-a-decade-of-milestone-based-pricing-projects-insights-and-lessons-learned/) ##### Seize the Moment, Make it Last The recent rise in MedTech investment is a moment to celebrate and capitalize on the opportunities it presents. At the same time, it remains to be seen whether this surge marks the start of a lasting trend or merely a temporary uptick. Startups should seize the moment by leveraging new funding to accelerate innovation, while keeping an eye on the prize and optimizing product development strategies to make whatever funds they can raise go as far as they can. > [Contact us to explore how we can help](https://nocturnalpd.com/get-a-quote/). **Categories:** Class II & Class III Devices, Funding, Milestone-based pricing, Startups --- ### [How to avoid five costly mistakes that can sink your device startup - Part II](https://nocturnalpd.com/2024/06/11/five-costly-mistakes-that-can-sink-your-device-startup-part-ii/) **Published:** June 11, 2024 **Author:** Eran Livneh **Content:** ![](https://nocturnalpd.com/wp-content/uploads/2024/06/Five-Mistakes-Part-II.png "Five Mistakes Part II") ##### Five Costly Mistakes that Can Sink Your Device Startup - Part II Translating a groundbreaking concept into a commercially viable medical device requires navigating a complex web of challenges, from securing funding to overcoming stringent regulatory hurdles. In this two-part post, we review five common mistakes that can derail your medical device startup on the path to commercialization, along with actionable strategies to overcome them. This is part II of this post. [You can find Part I here](https://nocturnalpd.com/2024/05/28/five-costly-mistakes-that-can-sink-your-device-startup-part-i/). ##### Mistake #4: Underestimating QMS and Documentation Requirements In the fast-paced world of medical device startups, the focus often leans towards rapid development and getting a groundbreaking product to market first. However, neglecting a crucial element – a robust Quality Management System (QMS) and its associated documentation – can prove to be a costly misstep. Regulatory bodies like the FDA demand a documented QMS that ensures consistent quality throughout the entire product lifecycle. Think of it as a detailed roadmap demonstrating your unwavering commitment to patient safety and product effectiveness. It allows auditors and regulators to trace every step of your product's development, fostering trust and confidence in your product, while a weak QMS with sparse documentation can result in costly delays and roadblocks. A well-defined QMS with clear procedures and documented processes isn't just about regulatory compliance. It goes a long way towards building trust and transparency, the cornerstones of market confidence. This transparency unlocks doors to partnerships, attracts investors, and ultimately translates to wider market adoption. Well-documented quality management procedures also translate to increased operational efficiency. They ensure consistency, minimize errors, and free up valuable resources for innovation. A robust QMS fosters a culture of quality, allowing proactive identification and mitigation of potential issues before they snowball into costly product recalls and reputational damage. It protects your brand, your investment, and your intellectual property. While a robust QMS and comprehensive documentation require time and attention, they can also provide a strategic differentiator. Prioritizing these efforts from the outset will ensure a smoother regulatory approval, minimize risk, and ultimately, shorten the path to commercial success. The good news? Establishing a QMS doesn't have to be an overwhelming task, even for startups. Here are some practical tips to keep in mind: - **Invest in Expert Guidance:** Seek assistance from consultants and regulatory professionals who can help you navigate QMS implementation effectively. - **Harness Technology:** Explore QMS software solutions specifically designed for medical devices to streamline documentation and process management. - **Leverage Partners:** You don’t necessarily need to have your own QMS from day one. Instead, find a design partner that integrates QMS into their services. Mistake #5: Failing to Manage Development Milestones and Cost Medical device startups are in a constant race to secure the next round of funding to stay afloat. To raise the next round, they must hit performance milestones, which are typically tied to product development, clinical studies, and regulatory approvals. The ideal milestone acts like a golden ticket, providing enough evidence of progress to secure the next round of funding. But it also needs to be achievable within the startup's limited resources. Startups that hire people to develop their product commit themselves to substantial recurring costs month after month. This can be a risky proposition, since most medical device entrepreneurs tend to underestimate the development effort required to bring their product to market or even to the next milestone. > Pre-market medical device companies misjudge commercialization timelines by an average of 53%. > Source: [Greenlight Guru 2023 MedTech Industry Benchmark Report](https://www.greenlight.guru/state-of-medical-device) As development timelines stretch beyond initial expectations, the company continues to bleed cash. Given this common scenario, it is little wonder that running out of funds before reaching a market-ready product is a recurring pitfall for device startups, often requiring the company to let go of key people they worked hard to recruit. Cutting costs and downsizing the team can be demoralizing and may lead to a loss of valuable talent. To mitigate these risks, be conservative with your hiring decisions, only bringing on board essential personnel that you know you’ll need for the long-run. Consider leveraging outsourcing strategically to provide flexibility and access to specialized skills while maintaining a predictable cash burn rate. Once your product has cleared regulatory hurdles and is ready for production at scale, you’ll be better prepared to hire additional resources and bring these skills inhouse. Partnering with a design and development company that provides milestone-based pricing can mitigate the risk of exceeding product budgets. Working with a partner on a fixed price for predetermined milestones is also helpful for controlling scope drift. It makes startup leaders clearly aware of the time and cost that out-of-scope feature development would add to the project. When these tradeoffs are clear, it is easier to make the right decision. > “Our pricing structure allows clients to make informed decisions. They can quickly assess the impact of any change request on both the budget and timeline, without worrying about unexpected costs." > [Eyal Dayan, VP of Business Development, Nocturnal](https://nocturnalpd.com/leadership/) Most design and development contractors will not commit to fixed costs and times, since they are unwilling to assume the risk of overrunning the time and effort they estimated for the project. Only firms with extensive experience in developing similar devices may be willing to commit to a fixed cost project and share the risk with you. > “This was my first experience with milestone-based pricing, and I will never go back to hourly billing. Nocturnal’s process ensures all parties are fully aligned and incentivized for success, and the results speak for themselves." > Alex Cooper, CEO, Stealth Medical Device Company ##### Final Thoughts: How Can You Avoid These Mistakes? The road to success for medical device startups is riddled with challenges. However, by understanding and addressing these common pitfalls, you can significantly increase your probability of success. - **Chart a Clear Regulatory Path:** Plan early, explore alternative pathways, and seek guidance from experts. - **Prioritize Simplicity:** Focus on core functionalities for a smooth regulatory journey and build reliability for patient trust. - **Leverage Existing Knowledge:** Learn from past successes, utilize proven designs, and identify transferable know-how to save time and resources. - **Build a Robust QMS:** Invest in a documented Quality Management System for trust, efficiency, and smoother regulatory hurdles. - **Manage Milestones and Costs:** Hire strategically, consider outsourcing and partnering with a development company offering fixed-cost, milestone-based pricing. By proactively addressing these challenges, you can navigate the complexities of medical device development and bring your life-saving innovation to market faster. > [Contact us to find out how we can help](https://nocturnalpd.com/get-a-quote/). **Categories:** Class II & Class III Devices, Funding, Milestone-based pricing, PMA, QMS, Startups --- ### [Balancing Signal Data vs. Power Consumption in Your Implantable Device](https://nocturnalpd.com/2024/04/22/balancing-signal-data-vs-power-consumption-in-your-implantable-device/) **Published:** April 22, 2024 **Author:** Eran Livneh **Content:** ![](https://nocturnalpd.com/wp-content/uploads/2024/04/Balancing-data-and-power.webp "Balancing data and power") ##### Hungry for Data Whether your implantable device is designed for monitoring or therapy delivery, data acquisition and analysis play a critical role in optimizing patient outcomes. Ongoing data collection from implantable devices allows early detection of trends and potential issues, and can be used for automated or patient-initiated regulation of therapeutic devices​. In addition, both biosignal data and device operational metrics provide useful input related to device functionality, which can be helpful for improving future design iterations. At the same time, data acquisition and analysis strategies for implanted devices must be balanced with the limitations of these devices in terms of storage, memory, and [ultra-low power consumption](https://nocturnalpd.com/ultra-low-power-software-hardware/). > “Future Cardia will obtain the most comprehensive, long-term cardiac data to date as biomarkers for cardiology. This will allow us to venture into predictions for cardiac events, and human longevity study.” > > Source: [Future Cardia Start Engine Prospectus](https://www.startengine.com/offering/futurecardia/updates) ##### Commonly Collected Data Types **Physiological parameters:** Implantable devices gather a range of physiological measurements, depending on their diagnostic or therapeutic goals. These can include [electrical signals](https://nocturnalpd.com/biosignal-acquisition/) like EGM, EEG, or EMG, as well metrics like heart rate, respiration rate, body temperature, and patient activity level. Some implants may collect specialized data like blood pressure, bioimpedance, or some other proprietary measurements specific to their purpose. **Therapy-specific data:** Implants that deliver therapy monitor physiological parameters connected with the specific condition they treat. They gather therapy-specific metrics before, during, and after therapy delivery to enable assessment of efficacy and improvement of therapy protocols. This data often includes measurements of how quickly therapy takes its intended effect, how much therapy was required to obtain that effect, and the device settings and configuration at the time therapy was delivered. **Device performance data:** Device parameters such as battery life, signal integrity, and sensor accuracy are critical to ensuring the device functions as intended. These types of data are important for assessing device functionality, longevity, and reliability. **Fault detection:** Implantable devices must regularly verify the integrity of their memory, internal timing sources, and programmable parameters and undertake other self-testing to ensure that they operate reliably. Therapy devices may also verify their electrical connections to the patient. **External data:** Devices that are part of the overall implantable system, such as chargers, programmers, or patient home monitors may collect data as well. The temperature of a charger, for example, can be critical to patient safety, and environmental parameters like ambient temperature, pressure, or humidity may be important to system performance and reliability. ##### Questions to Ask **Who is the user of the data?** Is it the health provider, the patient, the device manufacturer, or a combination of the above? Healthcare providers and device manufacturers might need detailed data for diagnosis and treatment planning, whereas patients might need simpler, actionable insights to manage their condition or adjust device settings. **How will the data be used?** Delving deeper into the application of the collected data can influence the optimal data collection strategy. Will the data be used for real-time monitoring, long-term health trend analysis, emergency notifications, or a combination of these? For instance, real-time monitoring requires robust and reliable wireless transmission capabilities, while trend analysis might demand more substantial data storage and sophisticated data analytics tools. **With what systems does the data need to integrate?** Integration with existing healthcare IT systems, such as Electronic Health Records (EHRs), patient management systems, and remote monitoring platforms is critical for seamless use of the data. Understanding these systems' requirements early on can significantly influence device development – ensuring compatibility and facilitating easier adoption by healthcare providers and patients. Consider the data formats, transmission protocols, and security standards these systems use and how your device will comply with them. > “Remote patient monitoring (RPM) led to a 50% reduction in 30-day hospital readmissions for patients with heart conditions.” > > Source: [Medical Economics](https://www.medicaleconomics.com/view/rpm-cuts-hospital-readmissions-by-50-for-heart-patients-study-finds) ##### Top Trade-offs to Consider Operating in the ultra-low power setting of an implanted device requires a balance between data collection parameters and power consumption. More detailed data may provide deeper insights, but at the cost of increased storage space, wireless transmission times, and on-board processing power. Greater power consumption means more frequent battery replacements, resulting in added cost, risk, and patient discomfort. However, insufficient data quality or quantity can lead to reduced efficacy of therapy, lower quality of patient care, and lower-quality input for future product evolution. A careful consideration of the tradeoffs is necessary to optimize implant performance for a specific application. **Sampling resolution:** Sample rate and resolution should be optimized to provide the precision necessary for the implantable system to perform its primary functions – both in the current product revision and in future product evolutions. For example, basic rate-based cardiac sensing can be accomplished with as little as 8 bits and 128 samples per second, while advanced morphological or frequency-domain analysis may require 24 bits and a 1kSPS rate. In this example, the more robust data sampling requires 24x as much power to acquire, store, and transmit – so such high resolution should not be chosen casually. It is generally wise to err on the side of a little too much data, but being too conservative can easily lead to an order-of-magnitude increase in the power burden for managing data within the implant. **Storage frequency:** As with data resolution, the regularity with which data is collected, stored, and transmitted should also be matched carefully to the application. Most implantable devices require some manner of real-time data acquisition and monitoring – either to assess the need for therapy delivery, or to trigger a detailed recording of biosignals or other patient metrics. But much of the detailed data used for these decision-making processes need not necessarily be stored and transmitted. The choice for how and when to store data for later transmission out of the implant and subsequent analysis depends on the nature of the data and its intended use. In therapy applications, the state of patient parameters prior to therapy delivery can be extremely useful in assessing both patient health and device performance. In monitoring applications, a sufficient recording duration of key metrics and signals is necessary to properly diagnose a patient’s condition. The growing role of AI and machine learning in healthcare is pressing implantable systems to provide as much data as possible. But in every application it’s important to ensure that data truly adds value for the patient, to balance the increased complexity and risk associated with regular battery charging or device replacement. **Noise and signal quality:** Noise is a key concern with every signal acquisition application, and the small scale of biosignals elevates that concern when you’re monitoring electrical activity in the human body. Understanding what components of your biosignals of interest are important and how much noise your algorithm can tolerate are critical to optimizing power in your signal acquisition process. Lower noise and broader bandwidth in a biosignal amplifier chain generally lead to higher power consumption and require additional circuit board space. While the use of custom silicon provides significant advantages for minimizing noise, power, and space for a given set of amplifier parameters, the same tradeoffs apply though on a different scale. With an understanding of which biosignal features are truly critical to an application, it is possible to optimize amplifier gain and passband to achieve suitable signal quality while limiting power consumption to the minimum necessary. > “We all want to collect more data. Understanding the implications of data acquisition on power and storage requirements is critical for optimizing device design for maximum performance and usability.” > > [KC Armstrong](https://nocturnalpd.com/leadership/), Nocturnal ##### It’s Never Too Early to Start Thinking about Data vs. Power For medical device entrepreneurs, the journey from concept to implementation is filled with challenges and trade-offs. Optimizing data acquisition is an important consideration that can impact the efficacy, adoption, and longevity of your implantable medical device. The earlier these considerations are incorporated into the design of your device, the easier it is to avoid roadblocks and complications that can elongate product development cycles. Interested in diving deeper into the optimal data acquisition strategies for your device? [Contact us](https://nocturnalpd.com/get-a-quote/)[ ](req)to schedule a consultation. **Categories:** Biosensors & Biosignal Acquisition, Lifesaving & Implantable, Ultra-low Power Software Hardware --- ### [Leverage Existing Know-how to Accelerate Device Path to Commercialization](https://nocturnalpd.com/2024/01/22/accelerating-neuromodulations-path-to-commercialization/) **Published:** January 22, 2024 **Author:** Eran Livneh **Content:** ![](https://nocturnalpd.com/wp-content/uploads/2024/01/neuro.jpg "neuro") ##### What breakthroughs are made of One of the greatest achievements in medical ingenuity in recent memory is the rapid development of the COVID-19 vaccine. Pivotal in combating the pandemic, the vaccine was designed using pre-existing mRNA technology, which was originally developed for research purposes. There is a lesson here for medical device entrepreneurs. Bringing a medical device from concept to market is a complex journey that requires a delicate balance of innovation, risk management, and efficient resource management. This becomes even more intricate when dealing with implantable devices, where the stakes are exceptionally high due to the long development cycles and the direct impact on patient health. For neuromodulation devices, the challenge may be further compounded by the limited ability to conduct animal testing. The result is a long device development cycle with high risk of failure. ##### A 3-tier approach to innovation Device startups often get caught up in the notion that their challenge is unique enough to warrant inventing every aspect of the product from scratch. They grapple with the challenge of distinguishing their product's unique features while navigating the multifaceted layers of medical device development. The key to success lies in a nuanced understanding of the different technological components that make up the product architecture and their associated risks. By categorizing these elements into three distinct tiers, startups can focus their innovation efforts where it counts, while utilizing existing assets and expertise to mitigate risks and streamline their path to market. > Reusing existing technologies and know-how doesn’t take away from the uniqueness of your device. It just allows you to focus on it. ##### Tier 1: Off-the-shelf components The first level of technology in any medical device development encompasses common, easily sourced components. Where possible, utilizing these components offers several advantages in cost-effectiveness, speed to market, and reduced risk. > “The re-architecture of the software imaging processing and analysis algorithms has produced immediate real-time analytics at 15 frames per second, and using off-the-shelf computational hardware kept the product cost competitive.” - Dr. Bruce Ferguson, Founder and Chief Medical Officer, Perfusio The reality is that off-the-shelf components are rarely suitable for implantable devices beyond the proof of concept stage. Depending on the specific market requirements for an implant, it may be possible to reduce development cost and time by using off-the-shelf circuit board components to minimize the need for ASIC development for a first-generation device. Beyond this, there may also be some available implantable components like batteries or hermetic feedthroughs that will be suitable for getting a device to market for the first time. The key when it comes to off-the-shelf components is to quickly understand whether any can be suitable for the device beyond the proof of concept stage. > “With Nocturnal’s help, we went from a rough concept made of off-the-shelf components to a fully integrated design that can be controlled using a smartphone in four months.” – Alex Cooper, CEO, Stealth Medical Device Company And in the rare cases when off-the-shelf components are suitable, efficiently sourcing these components while ensuring they meet the required quality and regulatory requirements can yield substantial benefits for a medical device startup. ##### Tier 2: Transferable implantable device technology and know-how The second tier involves components that require specific medical and implantable device expertise but are not unique to your specific application. For instance, aspects such as power management, biocompatibility, and miniaturization are common challenges in both cardiac and neuromodulation devices. This means that certain elements of your medical device, while complex in nature, may benefit from the knowledge and experience accumulated in the design of other implantable devices. These elements may include: - Ultra-low power firmware design - Ultra-low-power hardware blocks for signal acquisition and power management - High density interconnect (HDI) PCB substrate architectures These building blocks require specialized features and cannot be sourced off-the-shelf. Yet they rely on technologies that are often already utilized, tested, and proven in other implanted devices. Understanding where existing technologies and expertise can be leveraged and repurposed in your device can significantly reduce the cost, time, and risk associated with your product development. > There is a significant body of knowledge from other implantable devices that can be applied to neuromodulation devices. ##### Tier 3: Your unique technology (The “Secret Sauce”) While neuromodulation devices are used in a wide range of clinical therapies, the foundational functional needs are largely similar across different types of neuromodulation devices. They typically relate to the ability to monitor and stimulate different areas and nerve systems as well as the ability to operate the device in a constrained placement. The real differences can be found in one or more of the these areas: - Implant location within the body - The specific areas targeted for stimulation; - The unique pulse shapes used; - What data is collected; and - How the data is used to adjust the therapy. This is where the true innovation of your device lies. It requires a deep understanding of the specific physiology your device targets and the unique features of the therapy it delivers. This is where you want to focus the time and attention of your subject matter experts, while leveraging other resources to address areas that are not necessarily proprietary and unique to your device. ##### Balancing value creation through risk analysis The ability to strategically navigate the layers of product innovation and their associated risk is critical to the success of product development in complex areas such as implantable medical devices. Embracing a tiered approach to innovation empowers neuromodulation device startups to effectively allocate their resources, leveraging existing solutions where possible while applying groundbreaking innovation where it matters most. > Reusing proven knowledge and technologies is not just a shortcut. It is also a safer path to device commercialization. Using this approach can deliver significant benefits: - Shorter time to market: Repurpose established designs and technologies in areas such as power management, signal acquisition, and device miniaturization, adapting them to the needs of neuromodulation. - Enhanced design: Apply insights from other implantable device engineering to optimize the design and functionality of your neuromodulation device. - Reduced risk: Repurpose proven technologies and know-how from other implantable devices to reduce technology and operational risk. - Greater predictability: [Consider fixed priced projects](https://nocturnalpd.com/2023/10/31/the-secrets-to-navigating-fixed-cost-projects-in-medical-device-development/) for the development of proven components and technologies that can be repurposed for your device. - Resources and budget efficiency: Utilize outside expertise to free up your most valuable resources to focus where they can make the greatest impact. ##### Not sure how to apply this 3-tier approach to your device development project? [Contact us](https://nocturnalpd.com/get-a-quote/) to schedule a consultation. **Categories:** Lifesaving & Implantable, Neuromodulation --- ### [Less is More: The Power of Simplicity in Implantable Medical Devices](https://nocturnalpd.com/2023/08/04/less-is-more-the-power-of-simplicity-in-implantable-medical-devices/) **Published:** August 4, 2023 **Author:** Eran Livneh **Content:** ![](https://nocturnalpd.com/wp-content/uploads/2023/08/IPGSketch_blog-e1691186869909.png "IPGSketch_blog") ##### The “more with less” era From our private lives to our business endeavors, the desire to achieve more with less is a constant driving force. In every corner of our modern world, technological innovations have enabled us to accomplish extraordinary feats in increasingly compact and efficient ways. Examples are all around us: - The smartphones in our pockets boast processing powers exponentially greater than the computers that sent astronauts to the moon. - LED lighting offers the same level of illumination while consuming just a fraction of the electricity of incandescent light bulbs. - Nano drones can fit in the palm of your hand and weigh just a few grams, yet they can still carry superb cameras and cover a useful range. Maybe nowhere is the trend more evident and consequential than in medical device innovation, and particularly in implantable devices. Here are just a few examples: - The latest generation of pacemakers are less than 1/10th the size of traditional devices, providing the same life-saving functionalities without the need for leads or surgical pockets. - Micro-implants for drug delivery are now the size of a grain of rice and can be implanted using minimally invasive techniques, with only a small incision needed. - Modern neurostimulation pulse generators are the size of a small matchbox, allowing for more discreet placement while still providing life-changing therapy. ##### The “more is better” trap While technology allows us to do more with less, more is not always better. According to Nocturnal's president KC Armstrong, one of the most common distractions for medical device startups is the desire to pack as much functionality as possible into the initial version of their implantable device. “Many entrepreneurs believe that their first device must compare favorably on specifications they share with other mature products on the market. They focus on competing on size, longevity, or other common features rather than highlighting their novel technology that provides a benefit to the patient that isn’t offered by any other product,” shares KC. There are several drawbacks to this approach. In KC’s experience, “the main challenge is that it can lead to an overly complex initial version of the implant. By trying to incorporate too many features into the device, they risk making the development and approval process much longer and more expensive. There is also a delicate tradeoff between functionality and use of device resources that can detract from the core technology in favor of less critical features. We find ourselves helping entrepreneurs define their products in a way that optimizes their unique functionality and true competitive advantage, and then keeping them on that track during development.” The shift to “less is more” mindset With over two decades of extensive experience developing implantable medical devices, Armstrong often finds himself walking entrepreneurs through the merits of "less is more" as a guiding principle in creating efficient and effective devices. Here are some of the key benefits of this approach according to KC: Minimizing regulatory burden: Complex devices with multiple components and extensive functionality require increased testing and documentation to satisfy regulatory requirements for approval. Novel devices often already face unique regulatory challenges in order to demonstrate their safety and effectiveness, so it is important to minimize the burden associated with non-critical features. Enhanced reliability: A simpler design with fewer components and fewer complex functions inherently reduces the likelihood of malfunctions and device-related adverse events. By eliminating unnecessary complexities, we can create more reliable devices that perform their intended functions consistently. Energy efficiency: The volume of an electronic implant is typically dominated by its battery. By prioritizing simplicity, engineers can design devices that minimize power consumption – reducing battery size and extending battery life and reducing the frequency of surgical replacements or recharging procedures for patients. Cost-effectiveness: Simplicity can contribute to cost-effectiveness throughout the device's lifecycle. Simpler designs require fewer materials, reduced assembly labor, and less time to configure and test during implant. ##### Okay, but how do we make it work? Keeping the design simple doesn’t mean that we sacrifice the desire to make the device smarter and more effective. “One key is to focus on driving logic up the stack,” says KC. “Instead of burdening the implant with extensive analysis, we design the device to gather essential data efficiently and provide a seamless interface with the patient. The device itself should perform only the analysis necessary to acquire time-sensitive data or provide therapy or timely notifications directly to the patient. More in-depth analysis should be performed externally wherever possible.” Cloud technology plays a vital role in achieving device simplicity coupled with increased capabilities. By leveraging the cloud for data analysis and processing, and by pushing data to an EHR system, we can empower healthcare providers with comprehensive insights without overburdening the implant with extensive processing, power, and memory requirements. Future-proofing is critical for implantable medical devices with long lifecycles. “Replacing an implantable medical device, or even upgrading its software functionality after implant, is very costly. It also introduces potential risks to the patient,” says KC. “By keeping the implant's core functionality simple - focusing on data gathering and therapy delivery and managing business logic outside of the implant - we create a device that remains adaptable to future innovations. When we want to introduce new diagnostics, the implant can continue to collect relevant data and transmit it for analysis without requiring significant revisions. It's easier to refine algorithms or introduce new features in the cloud than it is within the confines of an implanted device.” ##### The power to hold back Embracing simplicity is a reminder that innovation doesn't have to be convoluted. Just because we have the ability to make a device do more doesn't mean that we have to pack non-essential functionality into it. In fact, simplicity can often be the key to unlocking a device's true potential. By focusing on novel features and critical functionality, eliminating superfluous features, and leaving extensive analysis to external systems, we can create devices that excel in their intended purpose while optimizing development effort as well as device cost, reliability, and longevity. **Categories:** Lifesaving & Implantable --- ## Pages ### [Home](https://nocturnalpd.com/) **Published:** August 15, 2019 **Author:** Jen Rhoton **Content:** ##### # Startup-friendly Medical Device Development We stay awake so you can sleep well [](https://nocturnalpd.com/implantable-wearable-expertise/?h)![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27100%27%20height%3D%27100%27%20viewBox%3D%270%200%20100%20100%27%3E%3Crect%20width%3D%27100%27%20height%3D%27100%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "heart") Implantables & Wearables [](https://nocturnalpd.com/fixed-cost-pricing/?h)![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27100%27%20height%3D%27100%27%20viewBox%3D%270%200%20100%20100%27%3E%3Crect%20width%3D%27100%27%20height%3D%27100%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "dolad") Fixed-cost Pricing ![icon_owl](https://nocturnalpd.com/wp-content/uploads/2023/03/icon_owl.png "icon_owl") > ##### “Nocturnal greatly contributed to the development of our ground-breaking implantable device.” > > ###### David Prutchi, Ph.D., CTO & Executive VP, Impulse Dynamics > ##### “In just one year, Nocturnal took our implantable cardiac monitor from a concept to a fully functional device.” > > ###### Jaeson Bang, Founder & CEO, Future Cardia > ##### “Working with Nocturnal was my first experience with milestone-based pricing, and I will never go back to hourly billing.” > > ###### Alex Cooper, CEO, Relief Cardiovascular > ##### “Nocturnal has once again exceeded the milestones specified.” > > ###### Bruce Ferguson, MD, Chief Medical Officer & Co-Founder, Perfusio > ##### “Nocturnal understands the pressures and realities of operating an early stage medical device company.” > > ###### Joe Passman, Sr. Principal R&D Engineer, NXT Biomedical > ##### “Nocturnal’s expertise helped us overcome design challenges and turn our vision into a clinically-viable product.” > > ###### David Prutchi, Ph.D., CTO & Executive VP, Impulse Dynamics > ##### “With Nocturnal’s help, we went from a rough concept to a fully integrated design in just four months.” > > ###### Alex Cooper, CEO, Relief Cardiovascular > ##### “Working with Nocturnal has dramatically accelerated our time-to-market.” > > ###### Jaeson Bang, Founder & CEO, Future Cardia > ##### “The scalable software platform developed by Nocturnal demonstrated its capabilities for supporting our expanded product roadmap, and using off-the-shelf computational hardware has kept product costs competitive.” > > ###### Bruce Ferguson, MD, Chief Medical Officer & Co-Founder, Perfusio > ##### “Nocturnal’s technical capabilities, collaborative process, and startup-friendly business model accelerated our ability to demonstrate our novel implantable technology in a preclinical setting.” > > ###### Joe Passman, Sr. Principal R&D Engineer, NXT Biomedical [](#)[](#)[](#)[](#)[](#)[](#)[](#)[](#)[](#)[](#) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27161%27%20height%3D%2760%27%20viewBox%3D%270%200%20161%2060%27%3E%3Crect%20width%3D%27161%27%20height%3D%2760%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27149%27%20height%3D%2760%27%20viewBox%3D%270%200%20149%2060%27%3E%3Crect%20width%3D%27149%27%20height%3D%2760%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27127%27%20height%3D%2746%27%20viewBox%3D%270%200%20127%2046%27%3E%3Crect%20width%3D%27127%27%20height%3D%2746%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ![](https://nocturnalpd.com/wp-content/uploads/2026/03/NeuroTronik.png) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27161%27%20height%3D%2754%27%20viewBox%3D%270%200%20161%2054%27%3E%3Crect%20width%3D%27161%27%20height%3D%2754%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27173%27%20height%3D%2760%27%20viewBox%3D%270%200%20173%2060%27%3E%3Crect%20width%3D%27173%27%20height%3D%2760%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27173%27%20height%3D%2748%27%20viewBox%3D%270%200%20173%2048%27%3E%3Crect%20width%3D%27173%27%20height%3D%2748%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ![](https://nocturnalpd.com/wp-content/uploads/2026/03/Gradient.png) ![](https://nocturnalpd.com/wp-content/uploads/2026/03/futura.png) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27144%27%20height%3D%2732%27%20viewBox%3D%270%200%20144%2032%27%3E%3Crect%20width%3D%27144%27%20height%3D%2732%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27149%27%20height%3D%2747%27%20viewBox%3D%270%200%20149%2047%27%3E%3Crect%20width%3D%27149%27%20height%3D%2747%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ![](https://nocturnalpd.com/wp-content/uploads/2026/03/EPF.png) ### ## CLASS II & CLASS III DEVICE EXPERTISE #### [ ACTIVE IMPLANTABLES ](https://nocturnalpd.com/lifesaving-implantable/) #### [ WEARABLES ](https://nocturnalpd.com/wearable-medical-devices/) #### [ CARDIAC ](https://nocturnalpd.com/cardiac-rhythm-management/) #### [ NEUROMODULATION ](https://nocturnalpd.com/neuromodulation/) #### [ULTRA-LOW POWER SOFTWARE/HARDWARE](https://nocturnalpd.com/ultra-low-power-software-hardware/) #### [EMBEDDED SOFTWARE](https://nocturnalpd.com/embedded-software/) #### [BIOSENSORS & BIOSIGNAL ACQUISITION](https://nocturnalpd.com/biosignal-acquisition/) #### [FDA/MDR SUBMISSION SUPPORT](https://nocturnalpd.com/fda-mdr-submission-support/) #### [LOW-VOLUME MANUFACTURING](https://nocturnalpd.com/low-volume-manufacturing/) #### [CLOUD-CONNECTED & APPS](https://nocturnalpd.com/cloud-connected-devices-apps/) #### [ AI-READY DATA ](https://nocturnalpd.com/ai-ready-data/) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27800%27%20height%3D%27634%27%20viewBox%3D%270%200%20800%20634%27%3E%3Crect%20width%3D%27800%27%20height%3D%27634%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "IPGSketchUpdated_Engineering_3_29") ### ## Startup-oriented Engagement model ##### Stay in control of your path to commercialization. RESULT-BASED PRICING SHORTEST PATH TO SUCCESS SHARED RISK MODEL WORK DIRECTLY WITH OUR BEST ### Design. Develop. Derisk. ##### Meet your milestones with confidence. Our milestone-based pricing model replaces hourly billing with clearly defined deliverables and fixed costs — giving founders and investors confidence in how capital is deployed and when milestones will be reached. [MILESTONE-BASED PRICING](/fixed-cost-pricing/) ##### Tap into hard-earned medical devices expertise. With our implantable and wearable expertise, you get ultra-low-power architectures and reliable biosignal acquisition — generating high-quality data that meets clinical and regulatory demands. [OUR DEVICE EXPERTISE](/implantable-wearable-expertise/) ##### Start small, but engineer for scale. Many devices work as prototypes but fail when they reach manufacturing. We design with manufacturing in mind from day one — supporting low-volume builds, pilot production, and seamless transfer to contract manufacturers. [DESIGN TO MANUFACTURING](/design-to-manufacturing/) ### The A-team is now your team. Class II and class III, implantable, life-saving, ultra-low power — we take the most complex projects head on. [GET TO KNOW OUR LEADERSHIP TEAM](https://nocturnalpd.com/leadership/) ### ## THE LATEST INSIGHTS FOR MEDTECH INNOVATORS [![](https://nocturnalpd.com/wp-content/uploads/2026/03/The-New-Rules-for-Venture-Funded-MedTech-Frame.png)](/ebook-the-new-rules-for-venture-funded-medtech/) #### [](#)[The new rules for venture-funded MedTech startups](/ebook-the-new-rules-for-venture-funded-medtech/) [![](https://nocturnalpd.com/wp-content/uploads/2024/01/bloghands-square.png)](/2023/09/19/celebrating-a-decade-of-milestone-based-pricing-projects-insights-and-lessons-learned/) #### [](#)[LESSONS FROM A DECADE OF MILESTONE-BASED PRICING PROJECTS](/2023/09/19/celebrating-a-decade-of-milestone-based-pricing-projects-insights-and-lessons-learned/) [![](https://nocturnalpd.com/wp-content/uploads/2023/10/teamwork-design-515838341_1027x1027.jpeg)](/2023/10/31/the-secrets-to-navigating-fixed-cost-projects-in-medical-device-development/) #### [](#)[ THE SECRETS TO NAVIGATING FIXED-COST DEVELOPMENT PROJECTS ](/2023/10/31/the-secrets-to-navigating-fixed-cost-projects-in-medical-device-development/) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271500%27%20height%3D%271180%27%20viewBox%3D%270%200%201500%201180%27%3E%3Crect%20width%3D%271500%27%20height%3D%271180%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ### ## Turn your sketch into reality. [GET A QUOTE](https://nocturnalpd.com/get-a-quote/) --- ### [Design to Manufacturing](https://nocturnalpd.com/design-to-manufacturing/) **Published:** February 25, 2026 **Author:** Barak Levy **Content:** ### Design to Manufacturing ##### A working prototype is not the finish line. For many teams, it’s where the hardest problems begin—especially when reality collides with manufacturing constraints that weren’t considered early enough. Most MedTech startups underestimate how difficult it is to obtain high‑quality, low‑volume builds for early stage trials. At the opposite end of the process, some teams reach later stages with a device that technically works, but cannot be manufactured cost‑effectively at scale. Nocturnal de‑risks both ends of this spectrum—providing [in-house manufacturing for small quantities](#lowvolume) and enabling smooth transition to [volume manufacturing](#volume). [GET A QUOTE](https://nocturnalpd.com/get-a-quote/) ![icon_owl](https://nocturnalpd.com/wp-content/uploads/2023/03/icon_owl.png "icon_owl") > ##### “In just one year, Nocturnal took our implantable cardiac monitor from a concept to a fully functional device.” > > ###### Jaeson Bang, Founder & CEO, Future Cardia ### How does Nocturnal support small‑quantity manufacturing? Many Class II and Class III programs require tens to hundreds of units for verification & validation, pre‑clinical studies, or first‑in‑human use—quantities most manufacturers are not set up to support efficiently. Nocturnal helps early-stage companies close this gap, providing in‑house assembly of small quantities to enable early testing, V&V, and preclinical and clinical studies. We physically build what we design, learn what it takes to put it together, and improve the design through real-world feedback. This allows teams to validate designs, uncover manufacturing risks, and progress clinically prior to transitioning to volume manufacturing. ### transition to volume manufacturing We treat manufacturing transfer as an engineering milestone—not an administrative task. ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27150%27%20height%3D%27150%27%20viewBox%3D%270%200%20150%20150%27%3E%3Crect%20width%3D%27150%27%20height%3D%27150%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "Frame 12") Identifying and evaluating contract manufacturers early in the development process ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27150%27%20height%3D%27150%27%20viewBox%3D%270%200%20150%20150%27%3E%3Crect%20width%3D%27150%27%20height%3D%27150%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "Frame 13 (1)") Applying DFM and DFA principles as an integrated part of our design ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27150%27%20height%3D%27150%27%20viewBox%3D%270%200%20150%20150%27%3E%3Crect%20width%3D%27150%27%20height%3D%27150%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "Frame 14") Engaging suppliers to review designs against real manufacturing processes ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27150%27%20height%3D%27150%27%20viewBox%3D%270%200%20150%20150%27%3E%3Crect%20width%3D%27150%27%20height%3D%27150%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "Frame 15") Creating manufacturing process instructions, test procedures, and acceptance criteria ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27150%27%20height%3D%27150%27%20viewBox%3D%270%200%20150%20150%27%3E%3Crect%20width%3D%27150%27%20height%3D%27150%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "Frame 16") Supporting pilot builds, including on‑site presence when needed ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27150%27%20height%3D%27150%27%20viewBox%3D%270%200%20150%20150%27%3E%3Crect%20width%3D%27150%27%20height%3D%27150%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "Frame 17") Managing technical transfer and manufacturing documentation This approach reduces friction, shortens transfer timelines, and increases confidence on both sides of the handoff—preserving capital, maintaining momentum, and positioning the program for regulatory review and commercial scale. ### Learn more [![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271024%27%20height%3D%271024%27%20viewBox%3D%270%200%201024%201024%27%3E%3Crect%20width%3D%271024%27%20height%3D%271024%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E)](/low-volume-manufacturing/) #### [](#)[Low Volume Manufacturing expertise](/low-volume-manufacturing/) ### Our top team is now your team. We are a small firm where everyone is an expert in their field, everyone is working hands-on with a client, and everyone is invested in your success. [MEET OUR LEADERSHIP TEAM](https://nocturnalpd.com/leadership/) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271500%27%20height%3D%271180%27%20viewBox%3D%270%200%201500%201180%27%3E%3Crect%20width%3D%271500%27%20height%3D%271180%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ### ## Turn your sketch into reality. [GET A QUOTE](https://nocturnalpd.com/get-a-quote/) --- ### [Implantable & Wearable Expertise](https://nocturnalpd.com/implantable-wearable-expertise/) **Published:** February 25, 2026 **Author:** Barak Levy **Content:** ### Active Implantable & Wearable Expertise ##### [Implantable ](/active-implantable-medical-device-expertise/)and [wearable ](/wearable-medical-devices/)devices don’t forgive shortcuts. Working with Nocturnal, you get one-stop access to a unique set of hard-to-find skills, including [ultra-low power hardware and software](/ultra-low-power-software-hardware/), [biosignal acquisition](/biosignal-acquisition/), hermetic packaging, [clinical data management](/ai-ready-data/), miniaturization, and other advanced disciplines. [SCHEDULE A CALL](https://nocturnalpd.com/get-a-quote/) ![icon_owl](https://nocturnalpd.com/wp-content/uploads/2023/03/icon_owl.png "icon_owl") > ##### “In just one year, Nocturnal took our implantable cardiac monitor from a concept to a fully functional device.” > > ###### Jaeson Bang, Founder & CEO, Future Cardia ### Why are implantable and wearable devices fundamentally different? These devices operate under extreme constraints: - Ultra-low power budgets - Noisy, variable biosignals - Long operational lifetimes (for implantables) Architectures must be designed to minimize power draw, reduce signal degradation, and preserve data integrity across months or years—not just lab testing. ### What biosignal and embedded expertise does Nocturnal bring? We’ve transformed life-saving and implantable devices — ranging from neuromodulation IPGs to implantable defibrillators — from a napkin sketch to an operational device. Our team brings deep experience across: ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27150%27%20height%3D%27150%27%20viewBox%3D%270%200%20150%20150%27%3E%3Crect%20width%3D%27150%27%20height%3D%27150%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "Frame 11") Physiological signal acquisition ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27150%27%20height%3D%27150%27%20viewBox%3D%270%200%20150%20150%27%3E%3Crect%20width%3D%27150%27%20height%3D%27150%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "Frame 7") Embedded firmware and hardware design ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27150%27%20height%3D%27150%27%20viewBox%3D%270%200%20150%20150%27%3E%3Crect%20width%3D%27150%27%20height%3D%27150%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "Frame 8") Long-life implantable architectures ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27150%27%20height%3D%27150%27%20viewBox%3D%270%200%20150%20150%27%3E%3Crect%20width%3D%27150%27%20height%3D%27150%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "Frame 9") Low-power wireless communication ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27150%27%20height%3D%27150%27%20viewBox%3D%270%200%20150%20150%27%3E%3Crect%20width%3D%27150%27%20height%3D%27150%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "Frame 10") Continuous wearable monitoring systems This experience informs not just what is built, but how and why. ### Learn more [![active-implantable-medical-device](https://nocturnalpd.com/wp-content/uploads/2023/03/Embedded-Software-IPG-Exploded3.jpg)](/active-implantable-medical-device-expertise/) #### [](/active-implantable-medical-device-expertise/)[Active Implantable device expertise](/active-implantable-medical-device-expertise/) [![wearable-medical-device](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271024%27%20height%3D%271024%27%20viewBox%3D%270%200%201024%201024%27%3E%3Crect%20width%3D%271024%27%20height%3D%271024%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E)](/wearable-medical-devices/) #### [](/wearable-medical-devices/)[Wearable device expertise](/wearable-medical-devices/) ### Our top team is now your team. We are a small firm where everyone is an expert in their field, everyone is working hands-on with a client, and everyone is invested in your success. [MEET OUR LEADERSHIP TEAM](https://nocturnalpd.com/leadership/) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271500%27%20height%3D%271180%27%20viewBox%3D%270%200%201500%201180%27%3E%3Crect%20width%3D%271500%27%20height%3D%271180%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ### ## Turn your sketch into reality. [GET A QUOTE](https://nocturnalpd.com/get-a-quote/) --- ### [The Nocturnal Impact](https://nocturnalpd.com/the-nocturnal-impact/) **Published:** February 25, 2026 **Author:** Barak Levy **Content:** ### The Nocturnal Impact ##### Most medical device startups don’t fail because the idea was wrong. They fail because execution breaks down. Costs become unpredictable, scope creeps, data decisions are made too late, and teams spend precious time fixing problems that could have been avoided. Nocturnal’s business model is designed to change this trajectory. [LET’S TALK](https://nocturnalpd.com/get-a-quote/) ![icon_owl](https://nocturnalpd.com/wp-content/uploads/2023/03/icon_owl.png "icon_owl") > ##### “Nocturnal greatly contributed to the development of our ground-breaking implantable device.” > > ###### David Prutchi, Ph.D., CTO & Executive VP, Impulse Dynamics ### What changes when Nocturnal becomes part of the team? Nocturnal works as an extension of your core team, which means that you always have full, real-time visibility to our work. We are a small team so you always work directly with our best and brightest, because that’s all we have. Design, engineering, and data strategy are aligned from day one with clinical objectives, regulatory requirements, and manufacturing constraints —all while aiming for the safest path towards your next funding milestone. How does Nocturnal reduce risk for startups? “Been there done that” does make a difference when it comes to complex class II and class III device development. We focus relentlessly on the risks that actually kill programs: ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27150%27%20height%3D%27150%27%20viewBox%3D%270%200%20150%20150%27%3E%3Crect%20width%3D%27150%27%20height%3D%27150%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "Frame 4") Runaway costs that deplete funding before reaching proof ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27150%27%20height%3D%27150%27%20viewBox%3D%270%200%20150%20150%27%3E%3Crect%20width%3D%27150%27%20height%3D%27150%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "Frame 5 (1)") Architectures that collapse when moving toward manufacturing ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27150%27%20height%3D%27150%27%20viewBox%3D%270%200%20150%20150%27%3E%3Crect%20width%3D%27150%27%20height%3D%27150%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "Frame 6 (1)") Data that can’t support AI, clinical, or regulatory needs By addressing these risks early, teams avoid expensive redesigns and confidence-eroding delays. ### What impact does Nocturnal have on startup success? Across multiple programs and generations of devices, Nocturnal has helped teams reach critical milestones with fewer surprises—from prototype and MVP to clinical trials and commercialization. - Greater confidence in technical decisions - Predictable use of capital - Faster transitions between phases The impact isn’t just a working device—it’s a more resilient startup and stronger positioning with investors, partners, and regulators. ### Learn more [![](https://nocturnalpd.com/wp-content/uploads/2026/03/The-New-Rules-for-Venture-Funded-MedTech-Frame.png)](/ebook-the-new-rules-for-venture-funded-medtech/) #### [[THE NEW RULES](/ebook-the-new-rules-for-venture-funded-medtech/) FOR VENTURE-FUNDED MEDTECH](#) ### Our top team is now your team. We are a small firm where everyone is an expert in their field, everyone is working hands-on with a client, and everyone is invested in your success. [MEET OUR LEADERSHIP TEAM](https://nocturnalpd.com/leadership/) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271500%27%20height%3D%271180%27%20viewBox%3D%270%200%201500%201180%27%3E%3Crect%20width%3D%271500%27%20height%3D%271180%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ### ## Turn your sketch into reality. [GET A QUOTE](https://nocturnalpd.com/get-a-quote/) --- ### [Fixed-Cost Pricing](https://nocturnalpd.com/fixed-cost-pricing/) **Published:** February 25, 2026 **Author:** Barak Levy **Content:** ### Fixed-Cost Device Development Pricing ##### Milestone-based pricing introduces a fundamentally different way to manage risk in medical device development. [GET A QUOTE](https://nocturnalpd.com/get-a-quote/) Device programs often span many months—or years—and the industry has been conditioned to accept uncertainty as unavoidable. Milestone-based pricing offers an added layer of financial transparency and control, eliminating the concern over unexpected expenses. This model contrasts sharply with traditional hourly billing, which can lead to projects spiraling out of control, causing inflated costs and extended timelines. Working with world-leading medical innovators, our milestone-based pricing has consistently demonstrated reduced project risk, improved decision-making, and accelerated the path to commercialization. [GET A QUOTE](https://nocturnalpd.com/get-a-quote/) ![icon_owl](https://nocturnalpd.com/wp-content/uploads/2023/03/icon_owl.png "icon_owl") > ##### “This was my first experience with milestone-based pricing, and I will never go back to hourly billing. Nocturnal’s process ensures all parties are fully aligned and incentivized for success—and the results speak for themselves.” > > ###### Alex Cooper, CEO, Relief Cardiovascular ### Why does traditional hourly billing fail device teams? When progress is measured in hours instead of milestones, teams lose early visibility into how changes affect cost, scope, and timeline. Small adjustments accumulate quietly, which can lead to projects spiraling out of control, inflated costs, and extended timelines. How does fixed-cost, milestone-based pricing actually work? Milestone-based pricing shifts focus from activity to outcomes. This means no hourly billing that is hard to predict and control. No surprises. Each phase is anchored to predefined technical and clinical milestones, with a fixed cost attached to reaching them. This creates: ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27150%27%20height%3D%27150%27%20viewBox%3D%270%200%20150%20150%27%3E%3Crect%20width%3D%27150%27%20height%3D%27150%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "Frame 1") Clear alignment between success and incentives ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27150%27%20height%3D%27150%27%20viewBox%3D%270%200%20150%20150%27%3E%3Crect%20width%3D%27150%27%20height%3D%27150%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "Frame 2") Shared accountability and risk between Nocturnal and the client ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27150%27%20height%3D%27150%27%20viewBox%3D%270%200%20150%20150%27%3E%3Crect%20width%3D%27150%27%20height%3D%27150%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "Frame 3") Early visibility into tradeoffs between scope, cost, and schedule Which means that you can plan your budget with confidence and reach your product development milestones without running out of cash. ### What outcomes do teams see in practice? Teams using milestone-based pricing consistently report: - Greater transparency and financial control - Stronger alignment anchored in clearly defined deliverables - Faster progression toward clinical, regulatory, and commercial milestones The result is tighter execution, fewer resets, and faster movement toward meaningful proof points. ### Learn more [![](https://nocturnalpd.com/wp-content/uploads/2024/01/bloghands-square.png)](/2023/09/19/celebrating-a-decade-of-milestone-based-pricing-projects-insights-and-lessons-learned/) #### [LESSONS FROM A DECADE OF MILESTONE-BASED PRICING PROJECTS](/2023/09/19/celebrating-a-decade-of-milestone-based-pricing-projects-insights-and-lessons-learned/) [![](https://nocturnalpd.com/wp-content/uploads/2023/10/teamwork-design-515838341_1027x1027.jpeg)](/2023/10/31/the-secrets-to-navigating-fixed-cost-projects-in-medical-device-development/) #### [](/2023/10/31/the-secrets-to-navigating-fixed-cost-projects-in-medical-device-development/)[THE SECRETS TO NAVIGATING FIXED-COST DEVELOPMENT PROJECTS ](/2023/10/31/the-secrets-to-navigating-fixed-cost-projects-in-medical-device-development/) ### Our top team is now your team. We are a small firm where everyone is an expert in their field, everyone is working hands-on with a client, and everyone is invested in your success. [MEET OUR LEADERSHIP TEAM](https://nocturnalpd.com/leadership/) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271500%27%20height%3D%271180%27%20viewBox%3D%270%200%201500%201180%27%3E%3Crect%20width%3D%271500%27%20height%3D%271180%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ### ## Turn your sketch into reality. [GET A QUOTE](https://nocturnalpd.com/get-a-quote/) --- ### [Neuromodulation](https://nocturnalpd.com/neuromodulation/) **Published:** March 27, 2023 **Author:** Jen Rhoton **Content:** ### Neuromodulation: Smaller, smarter, and personalized ##### Neuromodulation devices continue to break new ground, delivering more precise and personalized treatment, improved patient outcomes, and reduced side effects. **One-stop solution for neuromodulation innovation** Working with our team of [implantable](https://nocturnalpd.com/active-implantable-medical-device-expertise/) and [wearable](https://nocturnalpd.com/wearable-medical-devices/) device experts, you are always one step ahead of the latest advances in neuromodulation technology, including: - Miniaturization that makes the device fit in smaller areas of the body, such as the ear or eye. - Wireless technology to deliver electrical stimulation with minimal invasion. - Software applications that allow providers and patients to control and customize stimulation for more effective personalized treatment and fewer side effects. - Real-time stimulation adjustment based on closed-loop feedback from the patient’s body or brain. - Algorithms that can learn from the patient’s response to the treatment and optimize the stimulation to increase efficacy over time. ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27800%27%20height%3D%27634%27%20viewBox%3D%270%200%20800%20634%27%3E%3Crect%20width%3D%27800%27%20height%3D%27634%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "IPGSketchUpdated_Engineering_3_29") ## Optimizing neuromodulation performance ## Optimizing neuro-modulation performance While specific performance requirements depend on the type of neuromodulation device and therapy delivered, neuromodulation IPGs share many common requirements: ##### [Form factor](#c2e0363c3ca6beebf) Devices are expected to pack more functionality into smaller form factors that are easier to implant or fit onto the body surface. ##### [Reliability](#9b6a8059bc19beb8d) The device must operate reliably over its expected lifetime, with an extremely low failure rate. ##### [Safety](#062af364c59fcd997) The device must be safe for implantation and use in the human body. ##### [Battery life](#60030df0ca26f560a) Implantable neuromodulation devices must be designed for ultra-low power consumption to reduce the frequency of device replacements in primary battery applications, and the frequency of patient charging in rechargeable devices. ##### [Ease of use](#1312444e1f7775c1a) The device must be easy to implant, adjust, and manage, with user-friendly interfaces for both the healthcare provider and the patient, and special attention must be paid to the patient experience with rechargeable devices. ##### [Patient monitoring](#056c8b3ab88c0d5f1) The majority of implantable devices today support wirelessly-enabled cloud-based patient monitoring and data collection. ## Result-based business model Cash efficiency is a “do or die” proposition for any early stage company, and hourly-priced projects can quickly lead to cost and time overruns. [Our pricing](https://nocturnalpd.com/get-a-quote/) is based on results, giving you the predictability you need to plan your budget and meet your funding milestones with confidence. And with direct access to our project management system, you have real-time visibility into our progress so you always know where you are. #### You pay for: Milestones completed #### You don’t pay for: Our time [WHY MILESTONE-BASED PRICING](https://nocturnalpd.com/why-nocturnal/) ### design for success ##### From napkin sketch to commercially-viable product, we take a holistic approach to product development, addressing all the required aspects for your device to be successful: **Technical** Ensuring the device can perform as required to deliver the intended clinical results **Usability** Ensuring the device can be operated in the intended clinical setting **Standards** Ensuring the design and development process is documented in compliance with ISO 13485:2016 and that the design meets the requirements imposed by relevant regulatory standards **Manufacturability** Ensuring manufacturing is feasible within your business case assumptions and identifying qualified suppliers and manufacturing partners **Financial** Optimizing device cost of goods sold (COGS) [START YOUR PROJECT](https://nocturnalpd.com/get-a-quote/) ## IDEA ## Research ## Design & Development ## Pre-clinical studies ## Verification & Validation ## Transfer to Manufacturing ## CE & FDA Submissions ![icon_owl](https://nocturnalpd.com/wp-content/uploads/2023/03/icon_owl.png "icon_owl") > ##### “Nocturnal understands the pressures and realities of operating an early stage medical device company. Their technical capabilities, collaborative process, and startup-friendly business model made working with them a true pleasure.” > > ###### Joe Passman, Sr. Principal R&D Engineer, NXT Biomedical ### Proven neuromodulation experience We don’t mean to make light of the challenges, but having “been there, done that” does make a difference. With proven neuromodulation expertise on your team, you’ll be ready to handle any unexpected twists and turns on your journey to commercial success. [SCHEDULE A CALL](https://nocturnalpd.com/get-a-quote/) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271500%27%20height%3D%271180%27%20viewBox%3D%270%200%201500%201180%27%3E%3Crect%20width%3D%271500%27%20height%3D%271180%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ### ## Turn your sketch into reality. [GET A QUOTE](https://nocturnalpd.com/get-a-quote/) --- ### [Video](https://nocturnalpd.com/video/) **Published:** April 5, 2024 **Author:** Jen Rhoton **Content:** --- ### [Wearable Medical Devices](https://nocturnalpd.com/wearable-medical-devices/) **Published:** March 19, 2026 **Author:** Barak Levy **Content:** ### Wearable Medical Devices Wearable medical devices are transforming how physiological data is captured outside traditional clinical environments. Continuous monitoring enables earlier disease detection, improved patient management, and the development of AI-driven diagnostics. **Designing medical-grade wearables, however, is not merely a repackaging of consumer electronics.** The gap between collecting signals and producing solid clinical evidence is real — and that’s where most wearable programs get stuck. Clinical-grade devices must demonstrate signal integrity, algorithm transparency, and reproducible validation. Heart rate, ECG, SpO₂, motion, temperature, and other biosignals can produce clinically meaningful insights when combined over time — but only when the underlying device meets a higher bar. **We help you build these foundations from the start.** ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271024%27%20height%3D%271024%27%20viewBox%3D%270%200%201024%201024%27%3E%3Crect%20width%3D%271024%27%20height%3D%271024%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "01") ## From wearable signals to clinical defensibility ## One-stop access to multi-disciplinary expertise. We help you design wearable devices that turn physiological signals into clinically meaningful data. ##### [Biosensor integration & signal integrity](#efe8b12ce83209348) We help you select, integrate, and optimize biosensors for validated signal quality in a body-worn form factor — accounting for motion artifacts, skin contact variability, and environmental noise. ##### [Ultra-low power design](#e57d1bdce9462c494) We design power architectures that maximize operating time while minimizing device size and weight — critical for patient compliance and longitudinal data collection. ##### [Wireless connectivity](#0897d37d34f3d5c77) We design reliable BLE, NFC, or cellular communication systems that meet medical device cybersecurity requirements. ##### [Miniaturized packaging & enclosures](#cc47f772423c75c9a) Compact, ergonomic enclosures with biocompatible materials, ingress protection, and thermal management for extended wear while using certified-for-use parts. ##### [Transparency & reproducible validation](#45afa5d89ecf84971) Documented, reproducible on-device signal processing designed for regulatory defensibility. ##### [Companion app & cloud integration](#1da618025428736e9) The full data pathway from device firmware to mobile app to cloud — with data integrity, privacy, and usability built in. ## Result-based business model Cash efficiency is a “do or die” proposition for any early stage company, and hourly-priced projects can quickly lead to cost and time overruns. Our [milestone-based pricing](https://nocturnalpd.com/why-nocturnal/) is based on results, giving you the predictability you need to plan your budget with confidence. And with direct access to our project management system, you have real-time visibility into our progress so you always know where you are. #### You pay for: Milestones completed #### You don’t pay for: Our time [WHY MILESTONE-BASED PRICING](https://nocturnalpd.com/why-nocturnal/) ### design for success ##### From napkin sketch to commercially-viable product, we take a holistic approach to product development, addressing all the required aspects for your device to be successful: **Technical** Ensuring the device can perform as required to deliver the intended clinical results **Usability** Ensuring the device can be operated in the intended clinical setting **Standards** Ensuring the design and development process is documented in compliance with ISO 13485:2016 and that the design meets the requirements imposed by relevant regulatory standards **Manufacturability** Ensuring manufacturing is feasible within your business case assumptions and identifying qualified suppliers and manufacturing partners **Financial** Optimizing device cost of goods sold (COGS) [START YOUR PROJECT](https://nocturnalpd.com/get-a-quote/) ## IDEA ## Research ## Design & Development ## Pre-clinical studies ## Verification & Validation ## Transfer to Manufacturing ## CE & FDA Submissions ![icon_owl](https://nocturnalpd.com/wp-content/uploads/2023/03/icon_owl.png "icon_owl") > ##### “Nocturnal’s expertise helped us overcome design challenges and turn our vision into a clinically-viable product.” > > ###### David Prutchi, Ph.D., CTO & Executive VP, Impulse Dynamics ### Our top team is now your team. We are a small firm where everyone is an expert in their field, everyone is working hands-on with a client, and everyone is invested in your success. [SCHEDULE A CALL](https://nocturnalpd.com/get-a-quote/) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271500%27%20height%3D%271180%27%20viewBox%3D%270%200%201500%201180%27%3E%3Crect%20width%3D%271500%27%20height%3D%271180%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ### ## Turn your sketch into reality. [GET A QUOTE](https://nocturnalpd.com/get-a-quote/) --- ### [Leadership](https://nocturnalpd.com/leadership/) **Published:** March 26, 2023 **Author:** Jen Rhoton **Content:** ### Vision and Leadership ##### We are engineers and scientists at heart. What gets us going and keeps us awake at night is the thrill of figuring out the nuts and bolts (and also the code) that deliver groundbreaking medical innovations and change people’s lives. But we also understand the regulatory and commercial hurdles that innovators must clear to bring a device to market. That’s why we came up with a unique engagement model designed to help medical device entrepreneurs make their vision a reality. leadership team [![](https://nocturnalpd.com/wp-content/uploads/2023/03/leadership_kc.jpg)](https://www.linkedin.com/in/kc-armstrong-5713a41/) [](https://www.linkedin.com/in/kc-armstrong-5713a41/ "LinkedIn") ##### KC Armstrong, MSEE **Founder & CEO** I am a design engineer with over 25 years of experience developing Class II and Class III medical, automotive safety, and Class 4 industrial safety devices. I have implemented circuitry, systems, and algorithms for multiple implantable devices and other complex, high-reliability, safety-critical products, and have filed 14 US patents and patent applications. My main focus has been on electrophysiology, neuromodulation, and biophotonics, and my primary responsibilities at Nocturnal are the architecting and implementation of hardware, embedded software, and optical systems. [![](https://nocturnalpd.com/wp-content/uploads/2023/03/leadership_eyal.jpg)](https://www.linkedin.com/in/eyald) [](https://www.linkedin.com/in/eyald "LinkedIn") ##### Eyal Dayan, PMP **Chief Business Officer** I have been leading complex software and hardware projects for over 25 years, developing and delivering projects for the medical, military, telecom, and cloud storage industries in the US, Europe, and Asia. My primary role at Nocturnal is business development, working closely with our clients to identify opportunities for accelerating the delivery of high-quality systems and products by implementing the latest technologies and product development methodologies. [![leadership_Cinnamon](https://nocturnalpd.com/wp-content/uploads/2023/03/leadership_Cinnamon.jpg)](https://www.linkedin.com/in/cinnamon-larson-phd-59a7511a/) [](https://www.linkedin.com/in/cinnamon-larson-phd-59a7511a/ "LinkedIn") ##### Cinnamon Larson, PhD **Chief Technology Officer** I have over 25 years of product development experience including Class II and Class III medical devices and have designed multiple intravascular products and complex catheters for therapy delivery. I am a specialist in finite element analysis for failure analysis and design optimization. My responsibilities include product development process planning, product ideation, and detailed mechanical design. ### Our top team is now your team. We are a small firm where everyone is an expert in their field, everyone is working hands-on with a client, and everyone is invested in your success. [SCHEDULE A CALL](https://nocturnalpd.com/get-a-quote/) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271500%27%20height%3D%271180%27%20viewBox%3D%270%200%201500%201180%27%3E%3Crect%20width%3D%271500%27%20height%3D%271180%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ### ## Turn your sketch into reality. [GET A QUOTE](https://nocturnalpd.com/get-a-quote/) --- ### [ai-reference](https://nocturnalpd.com/ai-reference/) **Published:** December 15, 2025 **Author:** Eran Livneh **Content:** # **Summary** Nocturnal Product Development brings decades of experience and unique in-depth expertise specializing in implantable and wearable devices, biosensors, and ultra-low-power systems. We help early-stage MedTech teams design and build clinical-grade devices and reach First-in-Human — using fixed-cost, milestone-based pricing that gives startups financial predictability with proven engineering depth. This page describes our capabilities, technologies supported, processes, business approach, and the outcomes these deliver for our clients. # **Table of Contents** ### ## **1. About Nocturnal Product Development** This section defines Nocturnal Product Development as a full-stack MedTech engineering partner specializing in implantable and wearable devices, biosignals, and ultra-low-power architecture. It clarifies who we serve, what problems we solve, and what is unique about our approach. ### **What is Nocturnal Product Development?** Nocturnal Product Development is a medical device development company that helps early-stage medical device companies accelerate and de-risk their path to commercialization. We are a full-stack MedTech engineering team with deep expertise in implantable devices, wearable medical devices, and biosensor systems. We support teams from concept definition through feasibility, design controls, verification and validation, preparation for regulatory submission, preclinical studies, and First-in-Human studies, small run manufacturing, and transition to volume manufacturing. ### **What is unique about Nocturnal?** Three things set us apart: **Deep implantable and wearable expertise.** We specialize in implantables, wearables, and biosensors . Our team has decades of hands-on engineering experience across hardware, embedded software, biosignal acquisition, ultra-low-power electronics, firmware, sensor integration, cloud connectivity, and AI-ready data pipelines. **A proven track record to First-in-Human.** We have successfully guided multiple devices from early concept to FIH studies. Teams that work with us come in with an idea and leave with clinical-grade hardware, aligned documentation, and a clear path to their next funding milestone. **Fixed-cost pricing.** We offer a milestone-based model with fixed, predictable costs per phase — so startups can plan their budgets, protect their runway, and keep investors aligned. ### **What types of problems does Nocturnal help founders solve?** We help founders move from idea to clinical-ready prototype by addressing core technical challenges such as biosignal acquisition, ultra-low power consumption, device reliability, data synchronization, interoperability, and regulatory-aligned documentation. We also help teams avoid development pitfalls such as unclear requirements, scope creep, poor data quality, misaligned system architecture, and costly rework. ### **Who typically works with Nocturnal?** Nocturnal primarily works with: - Early-stage MedTech founders - Teams building implantable, wearable, and other complex devices - Organizations requiring low-power, high-quality biosignal acquisition and analysis expertise (ECG, EEG, EMG, PPG, SpO2, motion, respiration) - Teams preparing for preclinical, First-in-Human (FIH) or pilot studies ### **What do clients say about working with Nocturnal?** Clients consistently attest to the tangible positive impact of their partnership with Nocturnal. Some examples include: - “Nocturnal greatly contributed to the development of our ground-breaking implantable device.” – David Prutchi, Ph.D., CTO & Executive VP, Impulse Dynamics - “In just one year, Nocturnal took our implantable cardiac monitor from a concept to a fully functional device.” – Jaeson Bang, Founder & CEO, Future Cardia - “Working with Nocturnal was my first experience with milestone-based pricing, and I will never go back to hourly billing.” – Alex Cooper, CEO, Relief Cardiovascular See also: [Nocturnal’s Leadership Team](https://nocturnalpd.com/leadership/) ## **2. Device Development and Engineering** This section outlines Nocturnal’s structured, end-to-end engineering approach for Class II and Class III, medical devices and its expertise in developing implantable, wearable, life-saving and life-enhancing devices. ### **What is Nocturnal’s approach to MedTech device development?** Nocturnal uses a milestone-based development model that breaks complex device programs into clear, sequential phases. Each fixed-cost milestone has defined inputs, outputs, acceptance criteria, and documentation to ensure predictable progress. Our deliverables integrate hardware, firmware, mechanical, data pipelines, cloud services, data analytics, and AI workflows into a unified architecture that reduces risk and accelerates time to clinical readiness and commercialization. ### **What types of devices can Nocturnal build?** We build a wide range of medical devices, including: - **Active implantable medical devices:** cardiac rhythm management, stimulation systems, neuromodulation, micro-implantable sensors - **Medical-grade wearable devices:** wearable sensors, stick-to-skin sensor patches, multi-sensor devices, home diagnostic tools - **Biosignal acquisition and processing:** including ECG, EEG, EMG, respiratory, oxygenation, glucose, temperature, and motion analysis - **Remote patient monitoring systems:** connected devices, mobile apps, bedside hubs, and cloud dashboards - **AI-enabled sensors:** devices designed for classification, event detection, or predictive modeling - **Imaging:** multi-camera, fiberoptics, multispectral cameras, real time overly ### **What are your areas of expertise?** - Implantable device design - Wearable medical device development - High-resolution biosignal acquisition systems - Ultra-low power electronics & miniaturized hardware - Ultra-low power embedded, real-time firmware - Sensor integration & prototyping - Secure cloud connectivity - Data pipelines & analytics - Regulatory & design controls alignment - Clinical readiness (V&V, FIH preparation) - Low-volume manufacturing and transition to manufacturing at scale See also: [Active Implantable Medical Device Expertise](https://nocturnalpd.com/active-implantable-medical-device-expertise/) | [Wearable Medical Device expertise](https://nocturnalpd.com/wearable-medical-devices/) | [Cardiac Monitoring & Therapy](https://nocturnalpd.com/cardiac-monitoring-therapy/) ## **3. Biosignal and Biosensor Expertise** This section identifies the breadth of biosignals Nocturnal supports and outlines our system-level methods for achieving clinical-grade signal quality. It describes our expertise in biosignal acquisition, processing, and reliability across implantable and wearable devices. ### **Which biosignals does Nocturnal support?** Nocturnal supports a wide range of physiological signals, including: - Electrical: ECG, EEG, EMG, ECoG - Optical: PPG, SpO2, tissue oxygenation - Mechanical: accelerometry, gyroscopy, ballistocardiography, respiratory rate - Pressure and acoustics: airway pressure, heart sounds, gas flow - Specialized sensors: electrochemical, temperature, fluid dynamics, glucose monitoring ### **How does Nocturnal ensure biosignal quality?** We apply a systems engineering approach to ensure high-quality signal acquisition, including: - Low-noise analog front-end design - Anti-aliasing and bandpass filtering strategies - Digital signal processing and signal conditioning - Motion artifact reduction - Synchronization across multiple sensors - Calibration and metadata handling ### **Why is biosignal expertise important for medical devices?** Clinical-grade biosignals require more than simply attaching a sensor. Accuracy depends on hardware design, signal pathways, filtering, sampling rates, electrode or optical interface quality, firmware timing, and wireless transmission. Poor biosignal design can compromise clinical outcomes, regulatory clearance, or AI model performance. Nocturnal’s experience reduces these risks. See also: [Biosensors & Biosignal Acquisition](https://nocturnalpd.com/biosignal-acquisition/) ## **4. AI-Ready Data and Cloud Pipelines** This section explains how Nocturnal designs devices and cloud systems to produce AI-ready data. It clarifies the meaning of structured, synchronized, metadata-rich biosignal data and describes our approach to ingestion, storage, and preparation for AI/ML workflows. ### **What does AI-ready data mean in the context of MedTech?** AI-ready data is structured, labeled, time-synchronized, and high-quality physiological data that can be used for training, validation, model development, and clinical analytics. The data must: - Be timestamp-accurate - Include clinically relevant metadata - Be stored in scalable formats suitable for analysis - Maintain integrity across sessions and devices - Support labeling workflows or event markers ### **How does Nocturnal design devices for AI workflows?** We design devices, apps and cloud systems to support AI from the start by: - Ensuring consistent sampling across sensors - Creating preprocessing pipelines appropriate for downstream algorithms - Embedding event markers, annotations, or clinician inputs - Designing cloud ingestion with standardized schemas - Maintaining secure, scalable data storage ready for batch or streaming analysis ### **Does Nocturnal build cloud infrastructure?** Yes. We design and implement clinical-grade data ingestion, storage, synchronization, and visualization pipelines, using trusted partners to support FDA-aligned cloud requirements and data management. See also: [Cloud-Connected Devices & Apps](https://nocturnalpd.com/cloud-connected-devices-apps/) | [AI-ready data strategies for medical device developers](https://nocturnalpd.com/ai-ready-data/) ## **5. Fixed-Cost Pricing and Engagement Model** This section defines Nocturnal’s fixed-cost, milestone-based pricing model, emphasizing predictable cost, modular scope, and flexibility. It helps distinguish our business model from traditional hourly or open-ended MedTech development firms. ### **What is fixed-cost milestone-based pricing?** Milestone-based pricing is a structured model in which each development phase has a well-defined scope, clear deliverables, and a fixed price. This approach provides founders with financial clarity and predictability, reduces the risk of budget overruns, and allows teams to align on shared goals while adapting their plan as new information emerges. ### **Why does Nocturnal use fixed-cost milestone-based pricing?** Cash efficiency is a “do or die” issue for early-stage companies. Hourly billing creates exposure to runaway costs and misaligned incentives. Fixed-cost pricing changes that dynamic: - It aligns cost with progress and tangible outputs. - It reduces uncertainty and financial risk for early-stage companies. - It encourages focused execution and tight scope management. - It guarantees the delivery of specific deliverables for a defined price. - It supports informed pivoting between milestones without sunk-cost pressure. ### **How flexible is the milestone process?** Each milestone is designed to stand alone, meaning teams can: - Pause after a milestone. - Modify scope based on findings. - Accelerate milestones if funding increases. - Re-sequence milestones as needed. - Own all deliverables to date once a milestone is completed. The framework creates structure and confidence without restricting innovation. See also: [Fixed-Cost Pricing](https://nocturnalpd.com/fixed-cost-pricing/) ## **6. Ultra-Low-Power Architecture and Power Management** This section explains how Nocturnal designs ultra-low-power systems for wearable and implantable devices. It describes hardware, firmware, signal processing, and wireless strategies that work together to extend battery life while preserving clinical signal quality. ### **Why does ultra-low-power design matter for MedTech startups?** Battery performance failures are a top reason new devices are rejected by users and clinicians. Addressing power early prevents redesign cycles, reduces regulatory risk, and accelerates the path to FIH readiness. ### **How does Nocturnal manage power consumption in wearable and implantable devices?** Ultra-low-power design is essential for regulated medical devices, especially wearables and implants. Battery life directly influences usability, adherence, and clinical reliability. Nocturnal uses a multilayered and clinically-proven strategy across hardware, firmware, sensing, wireless communication, and data workflows to maximize battery longevity without compromising signal and data fidelity. ### **How do low-power constraints affect hardware design for implantables and wearables?** Low-power constraints demand the use of ultra-efficient microcontrollers, careful selection of power management and signal conditioning components, and even minimization of the number of passive components. For both implantables and wearables, every component must be considered in the context of maximizing battery life while minimizing signal noise and electronics volume. **How does embedded software impact power use in wearable medical devices?** Firmware controls power-hungry tasks like data acquisition, data filtering, and wireless communications. Efficient code with smart scheduling, sensor fusion, and edge processing minimizes active time and energy drain—critical for long battery life in wearables and implants. **What are some software techniques for reducing power in biosensor devices?** Ultra-low power design requires a near-obsessive focus on maximizing time in low power operating states. Smart scheduling of data acquisition and process, offloading tasks to microcontroller peripherals, and strategies for limiting connection time during wireless communications can all reduce power use while maintaining signal quality. Optimization involves selecting the right sampling rate, minimizing sensor activation time, and balancing analog and signal processing to achieve the *necessary* signal quality—not the maximum possible signal quality. For wearable or implantable sensors, the goal is to capture meaningful data while keeping energy consumption minimal. See also: [Ultra-low Power Hardware and Software Design for Implantables & Wearables](https://nocturnalpd.com/ultra-low-power-software-hardware/) | [Implantable & Wearable Expertise](https://nocturnalpd.com/implantable-wearable-expertise/) ## **7. Wireless Communication** This section explains how Nocturnal designs secure, power-efficient wireless architectures for medical devices. It focuses on Bluetooth Low Energy (BLE) as the primary standard and highlights the balance between energy usage, security, and link reliability. Nocturnal collaborates with our trusted partners to ensure that all designs and implementations meet FDA guidelines for medical device communication. **Why does Nocturnal commonly use BLE in medical devices?** BLE is well-suited to wearable and some implantable medical devices because it offers: - Very low energy consumption - Predictable, configurable communication intervals - Strong security features (authenticated pairing, encryption) - Wide compatibility with smartphones and gateways ### **How does Nocturnal optimize BLE communication for power efficiency?** We minimize radio-on time through: - Optimized connection intervals and slave latency settings - Data batching and compression before transmission - Event-driven activation so radios wake only when needed - Coordinated scheduling with the device’s power architecture ### **How does Nocturnal ensure secure wireless communication?** We implement BLE and wireless security using: - Authenticated pairing modes - AES-CCM encryption and secure key handling - Application-layer validation of incoming commands - Separation of control and data paths to reduce attack surface ### **When does Nocturnal use alternatives to BLE?** For certain clinical applications, we evaluate: - LoRa or sub-GHz radios for long-range, low-bandwidth needs - Proprietary radios for ultra-low-power continuous streaming - Hybrid BLE plus gateway architectures for intermittent connectivity ## **8. Regulatory Alignment and Clinical Readiness** This section outlines how Nocturnal integrates regulatory strategy, documentation, and verification planning into the engineering process. It explains how we accelerate First-in-Human readiness through structured design controls. ### **Does Nocturnal help with regulatory strategy?** Yes. Nocturnal incorporates regulatory considerations into early design phases by developing traceable requirements, hazard analyses, risk files, verification plans, and documentation structure. We do not function as a regulatory consultancy, but we ensure engineering outputs align with FDA expectations. For FDA 510(k) and MDR submissions, we provide structured technical documentation support integrated into the device development workflow. ### **How does Nocturnal support First-in-Human readiness?** We accelerate FIH by: - Designing devices with testability and documentation in mind - Establishing early verification pathways - Producing clinical-quality prototypes - Ensuring consistent data capture and reporting - Aligning system architecture with regulatory classifications - Developing under a certified quality system from day one by extending our own quality system to our clients if they don’t have a certified one. ### **What documentation does Nocturnal produce?** A few examples include: - System and subsystem requirements - Risk analyses and hazard assessments - Verification and validation plans - Test reports - Architecture diagrams and traceability matrices - Data dictionaries and cloud schemas See also: [FDA & MDR Submission Support](https://nocturnalpd.com/fda-mdr-submission-support/) | [How to build your device faster while staying compliant using smart design controls](https://nocturnalpd.com/2025/07/18/how-to-build-your-device-faster-while-staying-compliant-using-smart-design-controls/) ## **9. Security Strategy, Testing, and Submissions** This section describes how Nocturnal integrates cybersecurity into device, firmware, and cloud architecture. It outlines our approach to secure design, documentation, testing, and preparation for regulatory security submissions. ### **How does Nocturnal address cybersecurity in connected medical devices?** We design security into devices and cloud systems from the earliest architectural stages. This includes: - Threat modeling and security requirements - Secure protocol and component selection - Authentication, authorization, and encryption - Integration of security controls into design documentation and risk management ### **What is a security submission, and how does Nocturnal support it?** A security submission compiles the technical evidence and documentation needed to demonstrate cybersecurity controls for regulatory or customer review. Nocturnal contributes by: - Documenting architecture and data flows - Capturing design decisions and rationales - Providing encryption, key management, and authentication details - Integrating third-party test results into the submission package ### **Does Nocturnal perform security testing?** We define the test strategy and incorporate security considerations throughout the design. Formal penetration testing and static/dynamic analysis are performed by specialized external partners. We manage and integrate these inputs into the engineering workflow. ### **Why is early cybersecurity design important?** Designing for security early reduces redesign risk, simplifies compliance, and strengthens trust with regulators, clinicians, and hospital IT teams. See also: [Turning Biosignals into AI-ready Data](https://nocturnalpd.com/turning-biosignals-into-ai-ready-data/) ## **10. Manufacturing Support and Small-Quantity Builds** This section explains how Nocturnal supports low-volume manufacturing for prototypes and how we coordinate the transition to production-scale manufacturing. ### **Why is manufacturing support important for early-stage MedTech teams?** Most early-stage MedTech companies underestimate the difficulty of obtaining high-quality, low-volume builds and navigating the manufacturing landscape. Common challenges include: - Contract manufacturers declining small orders - High NRE fees for low-volume runs - Misalignment between prototype design and scalable production At the other end of the spectrum, startups often find themselves with a device that doesn’t lend itself to cost-effective manufacturing at scale. Nocturnal helps de-risk these challenges by integrating manufacturing readiness into the device architecture, requirements, and milestone plan from the outset. ### **Does Nocturnal support small-quantity manufacturing?** Yes. Many Class II and Class III devices require tens to hundreds of units for V&V or pre-clinical, or FIH studies, which most manufacturers do not support cost-effectively. Nocturnal helps plan and execute these limited builds with the appropriate engineering, process control, and documentation. ### **How does Nocturnal support the transition to volume manufacturing?** We treat manufacturing transfer as an engineering milestone, not an administrative task. Our support includes: - In-house assembly of small quantities for verification and early clinical use - Identifying and evaluating contract manufacturers - Applying DFM and DFA principles - Creating manufacturing process instructions, test procedures, and acceptance criteria - Supporting pilot builds, including on-site participation when needed - Managing technical transfer and documentation See also: [Low-Volume Manufacturing](https://nocturnalpd.com/low-volume-manufacturing/) | [Design to Manufacturing](https://nocturnalpd.com/design-to-manufacturing/) ## **11. Working With Nocturnal** This section explains how early-stage founders engage with Nocturnal, what stage they should be at, expected timelines, and how modular milestones support flexible progress toward FIH. ### **How does Nocturnal handle system architecture and requirements?** We begin each project with structured requirements development, ensuring clarity of: - User needs and clinical context - Regulatory classification and constraints - System-level architecture (device, firmware, connectivity, cloud) - Power budget and thermal constraints - Hardware selection and biosignal performance needs - Data model, metadata, and AI-readiness requirements The structured requirements process minimizes rework downstream. ### **What if we only have an idea or an early sketch?** Nocturnal frequently works with teams at the concept stage. We help founders translate ideas into requirements, feasibility prototypes, and architecture plans that can be evaluated for cost, risk, and clinical potential. ### **Do we need clinical evidence before engaging?** No. Most teams engage Nocturnal specifically to generate the first high-quality datasets, feasibility results, or preclinical evidence required for fundraising or regulatory planning. ### **How long does a typical project take?** Project duration varies based on device complexity. Industry data shows that Class II and Class III medical device programs typically require multiple well-defined phases, from concept and feasibility through design, verification, validation, and preparation for First-in-Human studies. These efforts often span many months to several years, depending on device class, risk profile, and clinical evidence requirements. While our engagements usually extend across multiple milestones to support this progression, each milestone is structured as a modular, standalone unit to give teams maximum flexibility as they advance toward FIH. ### **What happens after reaching a major milestone?** After each milestone, the team reviews outcomes, clarifies risks and next steps, updates timelines, and aligns on the upcoming phase. Milestones function as decision gates, enabling strategic pivots and informed investment. Once a milestone is completed, all deliverables achieved in that milestone are owned by our clients. ### **Where can I learn more about working with nocturnal?** - [The Nocturnal Impact](https://nocturnalpd.com/the-nocturnal-impact/) : Client outcomes and what working with us looks like in practice - [Fixed-Cost Pricing](https://nocturnalpd.com/fixed-cost-pricing/) : How our pricing model works - [Implantable & Wearable Expertise](https://nocturnalpd.com/implantable-wearable-expertise/) : Our technical depth in core device categories - [Design to Manufacturing](https://nocturnalpd.com/design-to-manufacturing/) : How we carry projects from early design through manufacturing-ready builds - [eBook: The New Rules for Venture-Funded MedTech](https://nocturnalpd.com/ebook-the-new-rules-for-venture-funded-medtech/) : Strategic guidance for founders navigating today’s funding environment #### **For additional information** [Contact us](https://nocturnalpd.com/get-a-quote/) --- ### [Cardiac Monitoring & Therapy](https://nocturnalpd.com/cardiac-monitoring-therapy/) **Published:** March 27, 2023 **Author:** Jen Rhoton **Content:** CARDIAC MONITORING AND THERAPY DEVICES: Let’s get to the heart of the matter. ##### ##### Developing a cardiac device is a complex and challenging undertaking, demanding a unique blend of specialized skills. Our expertise in electrical engineering, embedded software engineering, and electrophysiology has been instrumental in designing and developing a diverse range of cardiac therapy and monitoring devices: ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27800%27%20height%3D%27552%27%20viewBox%3D%270%200%20800%20552%27%3E%3Crect%20width%3D%27800%27%20height%3D%27552%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "icmsketchengineering_3_27_23") **Implantable Cardioverter Defibrillators (ICDs):** Monitoring heart rhythm and delivering therapy to manage abnormal rhythms and prevent sudden cardiac death when life-threatening arrhythmias are detected. **Pacemakers:** Regulating abnormal heart rhythms by delivering electrical impulses when the natural rhythm is too slow, too fast, or irregular. **Cardiac Resynchronization Therapy (CRT) Devices:** Coordinating atrial and ventricular contractions to improve the heart’s pumping ability and alleviate heart failure symptoms. **Cardiac Monitoring Devices:** Wearable and implantable devices that continuously track heart activity for early detection of arrhythmias and other cardiac anomalies, and acquisition of other proprietary physiologic parameters. Optimizing Device Performance While specific performance requirements may vary, many common requirements are shared across most [implantable](/active-implantable-medical-device-expertise/) and [wearable](/wearable-medical-devices/) cardiac devices. ##### [Accuracy](#fb2445d606033a3d6) The device must accurately detect cardiac rhythm state, capture electrograms for a physician to review, and when appropriate, deliver therapy to treat a detected arrhythmia. ##### [Reliability](#f6ae6cc01a1ee417b) The device must operate reliably over its expected lifetime with an extremely low failure rate. ##### [Battery life](#b200165d8c558b45a) Implantable cardiac devices must have a long battery life to minimize the frequency of device replacements or maximize time between patient recharging cycles. ##### [Patient monitoring](#9c8968dd39f4741b6) The majority of implantable and wearable devices today support wirelessly enabled cloud-based patient monitoring and data collection. ##### [Ease of use](#8275f78ae4fd85455) The device must be easy to implant, configure, and manage, with user-friendly interfaces for both the healthcare provider and the patient. ## Safety by Design Safety isn’t a given — it happens by design. And that’s built into everything we do, including: ##### [Risk-based mindset](#b13bcb5dc6234eec8) Devices that make an electrical connection to the heart require an extra level of design rigor to ensure that they can’t harm the patient. We develop devices from the ground up with patient risk in mind. ##### [Therapy delivery](#036162c9a205f4121) Cardiac devices must be designed to deliver electrical energy to the patient’s heart every time it’s needed, but must also discriminate tricky cardiac rhythms that do not require therapy. ##### [Component selection](#3d3eef3462f2a5036) Only a select group of electronic components are suitable for use in implantable devices, and an even smaller subset meet the requirement for life-saving use. Only parts with increased reliability testing and supplier permissions can find their way into cardiac devices, and we know where to find them. ##### [Electromagnetic immunity](#21c42434b0dc10556) The device must be immune to electromagnetic interference that might compromise device functionality and threaten patient health. ##### [Cybersecurity](#1522bbb9194ff6fa9) The device must be protected from cyberattacks that could affect device functionality or compromise patient data. ## Result-based business model Cash efficiency is a “do or die” proposition for any early stage company, and hourly-priced projects can quickly lead to cost and time overruns. [Our pricing](https://nocturnalpd.com/get-a-quote/ "Get a Quote") is based on results, giving you the predictability you need to plan your budget and meet your funding milestones with confidence. And with direct access to our project management system, you have real-time visibility into our progress so you always know where you are. #### You pay for: Milestones completed #### You don’t pay for: Our time [WHY MILESTONE-BASED PRICING](https://nocturnalpd.com/get-a-quote/) ### design for success ##### From napkin sketch to commercially-viable product, we take a holistic approach to product development, addressing all the required aspects for your device to be successful: **Technical** Ensuring the device can perform as required to deliver the intended clinical results **Usability** Ensuring the device can be operated in the intended clinical setting **Standards** Ensuring the design and development process is documented in compliance with ISO 13485:2016 and that the design meets the requirements imposed by relevant regulatory standards **Manufacturability** Ensuring manufacturing is feasible within your business case assumptions and identifying qualified suppliers and manufacturing partners **Financial** Optimizing device cost of goods sold (COGS) [START YOUR PROJECT](https://nocturnalpd.com/get-a-quote/) ## IDEA ## Research ## Design & Development ## Pre-clinical studies ## Verification & Validation ## Transfer to Manufacturing ## CE & FDA Submissions ![icon_owl](https://nocturnalpd.com/wp-content/uploads/2023/03/icon_owl.png "icon_owl") > ##### “Working with Nocturnal has dramatically accelerated our time-to-market. In just one year, Nocturnal took our implantable cardiac monitor from a concept to a fully functional device with a mobile application and secure cloud connectivity.” > > ###### Jaeson Bang, Founder & CEO, Future Cardia Get proven CRM expertise on your team. You’ll be ready to handle any unexpected twists and turns on your journey to commercial success. [SCHEDULE A CALL](https://nocturnalpd.com/get-a-quote/) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271500%27%20height%3D%271180%27%20viewBox%3D%270%200%201500%201180%27%3E%3Crect%20width%3D%271500%27%20height%3D%271180%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ### ## Turn your sketch into reality. [GET A QUOTE](https://nocturnalpd.com/get-a-quote/) --- ### [Class II & Class III Devices](https://nocturnalpd.com/class-ii-class-iii-devices/) **Published:** March 27, 2023 **Author:** Jen Rhoton **Content:** ### Class II and Class III Devices: What it takes to get ahead ##### Less than 5% of medical device startups successfully bring a product to market. **Our goal is to make you part of this exclusive club. How?** Running out of cash is a big reason device startups fall short. That’s usually a result of underestimating product development time and cost. Or running into some unexpected design issues and having to start over. ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27800%27%20height%3D%27552%27%20viewBox%3D%270%200%20800%20552%27%3E%3Crect%20width%3D%27800%27%20height%3D%27552%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "icmsketchengineering_3_27_23") ## Can we help you avoid these traps? Probably. To begin with, you’ll be working with a team with the wide range of domain expertise. In a nutshell, everything required to make a Class II and Class III device successful. From [ultra-low power hardware and software](https://nocturnalpd.com/ultra-low-power-software-hardware/ "Ultra-Low Power Software Hardware") to [biosignal acquisition](https://nocturnalpd.com/biosignal-acquisition/ "Biosignal acquisition") and other advanced disciplines. Learn about our areas of expertise: #### [ACTIVE IMPLANTABLES](/active-implantable-medical-device-expertise/) #### [Wearable Medical Devices](https://nocturnalpd.com/wearable-medical-devices/) #### [Cardiac Monitoring & Therapy](https://nocturnalpd.com/cardiac-monitoring-therapy/) #### [NEUROMODULATION](https://nocturnalpd.com/neuromodulation/) #### [Ultra-Low Power Software & Hardware](/ultra-low-power-software-hardware/) #### [EMBEDDED SOFTWARE](https://nocturnalpd.com/embedded-software/) #### [BIOSENSORS & BIOSIGNAL ACQUISITION](https://nocturnalpd.com/biosignal-acquisition/) #### [FDA & MDR Submission Support](https://nocturnalpd.com/fda-mdr-submission-support/) #### [Low-Volume Manufacturing](/low-volume-manufacturing/) #### [Cloud-Connected Devices & Apps](/cloud-connected-devices-apps/) #### [AI-ready data](/ai-ready-data/) But having this unique expertise is just the start. ## We’ve designed our engagement model with your business success in mind. This means no hourly billing that is hard to predict and control. Simple. No surprises. Instead, all of our projects are priced based on [milestones achieved](https://nocturnalpd.com/why-nocturnal/). Which means that you can plan your budget with confidence. So you can reach your product development milestones without running out of cash. #### You pay for: Milestones completed #### You don’t pay for: Our time [WHY MILESTONE-BASED PRICING](https://nocturnalpd.com/why-nocturnal/) ### design for success ##### From napkin sketch to commercially-viable product, we take a holistic approach to product development, addressing all the required aspects for your device to be successful: **Technical** Ensuring the device can perform as required to deliver the intended clinical results **Usability** Ensuring the device can be operated in the intended clinical setting **Standards** Ensuring the design and development process is documented in compliance with ISO 13485:2016 and that the design meets the requirements imposed by relevant regulatory standards **Manufacturability** Ensuring manufacturing is feasible within your business case assumptions and identifying qualified suppliers and manufacturing partners **Financial** Optimizing device cost of goods sold (COGS) [START YOUR PROJECT](https://nocturnalpd.com/get-a-quote/) ## IDEA ## Research ## Design & Development ## Pre-clinical studies ## Verification & Validation ## Transfer to Manufacturing ## CE & FDA Submissions ![icon_owl](https://nocturnalpd.com/wp-content/uploads/2023/03/icon_owl.png "icon_owl") > ##### “Nocturnal’s technical capabilities, collaborative process, and startup-friendly business model accelerated our ability to demonstrate our novel implantable technology in a preclinical setting.” > > ###### Joe Passman, Sr. Principal R&D Engineer, NXT Biomedical ### Our top team is now your team. We are a small firm where everyone is an expert in their field, everyone is working hands-on with a client, and everyone is invested in your success. [SCHEDULE A CALL](https://nocturnalpd.com/get-a-quote/) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271500%27%20height%3D%271180%27%20viewBox%3D%270%200%201500%201180%27%3E%3Crect%20width%3D%271500%27%20height%3D%271180%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ### ## Turn your sketch into reality. [GET A QUOTE](https://nocturnalpd.com/get-a-quote/) --- ### [Low-Volume Manufacturing](https://nocturnalpd.com/low-volume-manufacturing/) **Published:** March 19, 2026 **Author:** Barak Levy **Content:** ### Low-Volume ManufacturingMedical Devices Early-stage teams routinely underestimate how difficult it is to secure high-quality, low-volume builds for verification, validation, pre-clinical, or first-in-human studies. Contract manufacturers often decline small orders. When they don’t, non-recurring engineering fees can be disproportionate and prohibitive. **We help you close the gap between prototype and production at every stage.** Successful programs integrate manufacturing readiness into the product architecture and milestone plan from day one. At Nocturnal, we treat small-quantity builds as engineering deliverables, with proper controls, documentation, and traceability. ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271024%27%20height%3D%271024%27%20viewBox%3D%270%200%201024%201024%27%3E%3Crect%20width%3D%271024%27%20height%3D%271024%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "im6") ## From bench builds to manufacturing transfer ## One-stop access to multi-disciplinary expertise. We plan and execute low-volume builds with engineering rigor, allowing you to move fast while checking all the boxes for regulatory approval and future production scalability. ##### [In-house assembly & limited builds](#533196d181a467721) We plan and execute small-quantity builds — tens to hundreds of units — for V&V, pre-clinical, or first-in-human studies, with appropriate process control and documentation. ##### [Design for manufacturability](#39ac8caf318d8e0c5) We apply DFM and DFA principles early in the design process — reducing cost, complexity, and risk before they become locked into the architecture. ##### [Process documentation & traceability](#ed14654ff749c5073) Documented manufacturing process instructions, test procedures, and acceptance criteria — built to support both internal builds and future transfer. ##### [Contract manufacturer evaluation](#01f35f56f16d26001) We identify, evaluate, and qualify contract manufacturers aligned to your volume requirements, regulatory classification, and commercial timeline. ##### [Pilot builds & on-site support](#f549f96a664cc63c9) We support pilot production runs at the contract manufacturer, including on-site participation to resolve process issues in real time. ##### [Manufacturing transfer](#4ef52b776015ef1ff) The full technical transfer — from process instructions to test requirements to acceptance criteria — managed as an engineering milestone, not an administrative task. ## Result-based business model Cash efficiency is a “do or die” proposition for any early stage company, and hourly-priced projects can quickly lead to cost and time overruns. [Our pricing](https://nocturnalpd.com/why-nocturnal/) is based on results, giving you the predictability you need to plan your budget and meet your funding milestones with confidence. And with direct access to our project management system, you have real-time visibility into our progress so you always know where you are. #### You pay for: Milestones completed #### You don’t pay for: Our time [WHY MILESTONE-BASED PRICING](https://nocturnalpd.com/why-nocturnal/) ### design for success ##### From napkin sketch to commercially-viable product, we take a holistic approach to product development, addressing all the required aspects for your device to be successful: **Technical** Ensuring the device can perform as required to deliver the intended clinical results **Usability** Ensuring the device can be operated in the intended clinical setting **Standards** Ensuring the design and development process is documented in compliance with ISO 13485:2016 and that the design meets the requirements imposed by relevant regulatory standards **Manufacturability** Ensuring manufacturing is feasible within your business case assumptions and identifying qualified suppliers and manufacturing partners **Financial** Optimizing device cost of goods sold (COGS) [START YOUR PROJECT](https://nocturnalpd.com/get-a-quote/) ## IDEA ## Research ## Design & Development ## Pre-clinical studies ## Verification & Validation ## Transfer to Manufacturing ## CE & FDA Submissions ### Our top team is now your team. We are a small firm where everyone is an expert in their field, everyone is working hands-on with a client, and everyone is invested in your success. [SCHEDULE A CALL](https://nocturnalpd.com/get-a-quote/) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271500%27%20height%3D%271180%27%20viewBox%3D%270%200%201500%201180%27%3E%3Crect%20width%3D%271500%27%20height%3D%271180%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ### ## Turn your sketch into reality. [GET A QUOTE](https://nocturnalpd.com/get-a-quote/) --- ### [Cloud-Connected Devices & Apps](https://nocturnalpd.com/cloud-connected-devices-apps/) **Published:** March 19, 2026 **Author:** Barak Levy **Content:** ### Cloud-Connected Devices & Apps Companion apps, cloud pipelines, and data infrastructure transform raw signals into actionable clinical insights. Getting data from a sensor into an ISO 13485 certified cloud environment — with integrity, security, and structure intact — requires deliberate architecture from the start. Retrofitting it later is expensive and rarely clean. **We design the full data pathway from device firmware to mobile app to cloud — so your data is clinical-grade and [AI-ready](/ai-ready-data/) from day one.** Achieving clinical-grade and AI-ready data doesn’t happen by accident. It must be properly structured, labeled, time-synchronized, and stored in scalable formats suitable for training, validation, and clinical analytics. ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271024%27%20height%3D%271024%27%20viewBox%3D%270%200%201024%201024%27%3E%3Crect%20width%3D%271024%27%20height%3D%271024%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "im4") ## From device to insight: the full connected stack ## One-stop access to multi-disciplinary expertise. We design apps, cloud systems, and data pipelines that integrate **implantable** and **wearable** devices into a connected clinical solution. ##### [Companion app design & development](#eb78cb887433f9884) Purpose-built mobile apps for patients and providers that are designed to meet usability, accessibility, and regulatory expectations — from data capture to guided workflows and dashboards. ##### [AI-ready data architecture](#c520e868db71cb1ce) Consistent sampling, preprocessing pipelines, embedded event markers, and standardized schemas — so your data supports model training, validation, and clinical analytics from the start. ##### [Edge and cloud processing](#51e29ac8732cc32c4) We help you determine the right balance between on-device and cloud-based analysis — weighing power budgets, processing power, latency needs, and transmission constraints for your specific application. ##### [Data security & privacy](#a02d572a1923d4d6c) End-to-end data integrity from sensor to cloud, with encryption, access controls, and privacy architecture aligned to regulatory and cybersecurity requirements. ##### [Clinical-grade cloud infrastructure](#e12fab4ec15e9fe08) Secure data ingestion, storage, synchronization, and visualization pipelines — designed to meet regulatory cloud and cybersecurity requirements, and scalable to support long-term clinical studies and real-world deployment. ## Result-based business model Cash efficiency is a “do or die” proposition for any early stage company, and hourly-priced projects can quickly lead to cost and time overruns. Our [milestone-based pricing](https://nocturnalpd.com/why-nocturnal/) is based on results, giving you the predictability you need to plan your budget with confidence. And with direct access to our project management system, you have real-time visibility into our progress so you always know where you are. #### You pay for: Milestones completed #### You don’t pay for: Our time [WHY MILESTONE-BASED PRICING](https://nocturnalpd.com/why-nocturnal/) ### design for success ##### From napkin sketch to commercially-viable product, we take a holistic approach to product development, addressing all the required aspects for your device to be successful: **Technical** Ensuring the device can perform as required to deliver the intended clinical results **Usability** Ensuring the device can be operated in the intended clinical setting **Standards** Ensuring the design and development process is documented in compliance with ISO 13485:2016 and that the design meets the requirements imposed by relevant regulatory standards **Manufacturability** Ensuring manufacturing is feasible within your business case assumptions and identifying qualified suppliers and manufacturing partners **Financial** Optimizing device cost of goods sold (COGS) [START YOUR PROJECT](https://nocturnalpd.com/get-a-quote/) ## IDEA ## Research ## Design & Development ## Pre-clinical studies ## Verification & Validation ## Transfer to Manufacturing ## CE & FDA Submissions ![icon_owl](https://nocturnalpd.com/wp-content/uploads/2023/03/icon_owl.png "icon_owl") > ##### “The re-architecture of the imaging processing and analysis algorithms produced real-time analytics at 15 fps (down from 15 sec), integrated within a scalable software platform developed by Nocturnal that demonstrates supports our expanded product roadmap.” > > ###### Bruce Ferguson, MD, Chief Medical Officer & Co-Founder, Perfusio ### Our top team is now your team. Our software engineers don’t hide behind their screens. We are a small firm where everyone is an expert in their field, everyone is working hands-on with a client, and everyone is invested in your success. [SCHEDULE A CALL](https://nocturnalpd.com/get-a-quote/) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271500%27%20height%3D%271180%27%20viewBox%3D%270%200%201500%201180%27%3E%3Crect%20width%3D%271500%27%20height%3D%271180%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ### ## Turn your sketch into reality. [GET A QUOTE](https://nocturnalpd.com/get-a-quote/) --- ### [FDA & MDR Submission Support](https://nocturnalpd.com/fda-mdr-submission-support/) **Published:** March 19, 2026 **Author:** Barak Levy **Content:** ### FDA & MDR Submission Support Whether you are pursuing FDA 510(k) clearance, De Novo classification, PMA, or CE marking, early design decisions made without regulatory awareness can create gaps that are costly to recover. **Moving fast is essential. But you can only move fast safely if you know what you’ll need later.** Missing traceability, incomplete risk files, undocumented design decisions, and untestable architectures often force costly rework that delays regulatory approvals. We don’t front-load your project with premature documentation. Instead, we bring the full regulatory awareness into your earliest engineering decisions—so when formal design controls are needed, nothing has to be redone. ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271024%27%20height%3D%271024%27%20viewBox%3D%270%200%201024%201024%27%3E%3Crect%20width%3D%271024%27%20height%3D%271024%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "im2") ## From design work to submission-ready documentation ## One-stop access to multi-disciplinary expertise. We structure your development process to match the appropriate regulatory expectations at every stage. ##### [Design controls at the right time](#a8e1c87fcc2307b4c) In early development, we keep documentation lean and focused on user needs, key hazards, and critical functional requirements. As feasibility is established, we increase the level of rigor – adding more structured documentation, stronger traceability, and formal configuration management and change controls, all within our ISO 13485-certified quality management system. ##### [Risk management & hazard analysis](#c66416c18aa1156c3) We identify hazards early and carry them forward through the design process in accordance with ISO 14971—even when the formal risk file is built later. This means no surprise gaps in your risk traceability when it’s time to submit. ##### [Verification & validation planning](#1085c3da4a18522aa) We design testable architectures and produce clinical-quality prototypes from the start. Verification strategies, test protocols, and acceptance criteria are defined early—so evidence generation is built into the development process. As programs mature, we support formal validation activities by helping prepare production-equivalent devices, use-related documentation, and the engineering inputs needed for end-user or clinical studies. ##### [Submission documentation & design history file (DHF)](#0b29dead6e3f4cd53) When it’s time to formalize, we produce the engineering documentation your submission requires: system and subsystem requirements, architecture diagrams, risk analyses, verification protocols and reports, traceability matrices, and review records (to name a few)—structured to support your 510(k), De Novo, PMA, or MDR technical file. ##### [Proven software & platforms](#2cb7cb55fca73b432) Our embedded software, firmware libraries, and data infrastructure have been through the regulatory process before. When we build on proven components, we know they will hold up under verification and submission scrutiny—which means fewer surprises, less rework, and a faster path to clearance. ##### [Quality system from day one](#e7f4d5e86993f2044) We develop under our certified ISO 13485 quality management system, so development proceeds under a compliant framework from the start, even if you don’t have your own certified QMS in place. Then when the time is right, you can bring everything into your own system, with confidence that documents and records were developed correctly all along. ## Result-based business model Cash efficiency is a “do or die” proposition for any early stage company, and hourly-priced projects can quickly lead to cost and time overruns. [Our pricing](https://nocturnalpd.com/why-nocturnal/) is based on results, giving you the predictability you need to plan your budget and meet your funding milestones with confidence. And with direct access to our project management system, you have real-time visibility into our progress so you always know where you are. #### You pay for: Milestones completed #### You don’t pay for: Our time [WHY MILESTONE-BASED PRICING](https://nocturnalpd.com/fixed-cost-pricing/) ### design for success ##### From napkin sketch to commercially-viable product, we take a holistic approach to product development, addressing all the required aspects for your device to be successful: **Technical** Ensuring the device can perform as required to deliver the intended clinical results **Usability** Ensuring the device can be operated in the intended clinical setting **Standards** Ensuring the design and development process is documented in compliance with ISO 13485:2016 and that the design meets the requirements imposed by relevant regulatory standards **Manufacturability** Ensuring manufacturing is feasible within your business case assumptions and identifying qualified suppliers and manufacturing partners **Financial** Optimizing device cost of goods sold (COGS) [START YOUR PROJECT](https://nocturnalpd.com/get-a-quote/) ## IDEA ## Research ## Design & Development ## Pre-clinical studies ## Verification & Validation ## Transfer to Manufacturing ## CE & FDA Submissions ### Our top team is now your team. We are a small firm where everyone is an expert in their field, everyone is working hands-on with a client, and everyone is invested in your success. [SCHEDULE A CALL](https://nocturnalpd.com/get-a-quote/) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271500%27%20height%3D%271180%27%20viewBox%3D%270%200%201500%201180%27%3E%3Crect%20width%3D%271500%27%20height%3D%271180%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ### ## Turn your sketch into reality. [GET A QUOTE](https://nocturnalpd.com/get-a-quote/) --- ### [Practical Guides for Medical Device Startups](https://nocturnalpd.com/medical-device-guides/) **Published:** April 2, 2025 **Author:** Eran Livneh **Content:** ## #### Guides for Medical Device Startups [![](https://nocturnalpd.com/wp-content/uploads/2026/03/The-New-Rules-for-Venture-Funded-MedTech-Frame.png)](/ebook-the-new-rules-for-venture-funded-medtech/) [GET THE GUIDE](/ebook-the-new-rules-for-venture-funded-medtech/) How to navigate a tighter capital market and build a medical device company that earns investor confidence [![](https://nocturnalpd.com/wp-content/uploads/2025/09/AI-Data-Guide-Cover.png)](https://nocturnalpd.com/turning-biosignals-into-ai-ready-data/) [GET THE GUIDE](https://nocturnalpd.com/turning-biosignals-into-ai-ready-data/) Learn how to design your medical device and data streams to optimize AI-driven outcomes --- ### [The new rules for venture-funded medtech](https://nocturnalpd.com/the-new-rules-for-venture-funded-medtech/) **Published:** March 22, 2026 **Author:** Eran Livneh **Content:** ## #### The New Rules for Venture-Funded MedTech ##### How to navigate a tighter capital market and build a medical device company that earns investor confidence [![](https://nocturnalpd.com/wp-content/uploads/2026/03/The-New-Rules-for-Venture-Funded-MedTech-Frame.png)](/wp-content/uploads/2026/03/Nocturnal-The-New-Rules-for-Venture-Funded-MedTech.pdf) [get your copy](/wp-content/uploads/2026/03/Nocturnal-The-New-Rules-for-Venture-Funded-MedTech.pdf) --- ### [eBook - The New Rules for Venture-Funded MedTech](https://nocturnalpd.com/ebook-the-new-rules-for-venture-funded-medtech/) **Published:** March 22, 2026 **Author:** Eran Livneh **Content:** ## #### The new rules for venture-funded MedTech ![](https://nocturnalpd.com/wp-content/uploads/2026/03/The-New-Rules-for-Venture-Funded-MedTech-Frame.png "The New Rules for Venture-Funded MedTech – Frame") ##### How to navigate a tighter capital market and build a medical device company that earns investor confidence --- ### [eBook Thank you](https://nocturnalpd.com/ebook-thank-you/) **Published:** March 26, 2024 **Author:** Eran Livneh **Content:** ## Thank you for your interest in our guide. ##### Check your inbox for a link to download your copy. #### in the meantime, here are some Additional Resources you may find useful: #### [ MedTech Startup Survey Report](/survey) #### [Articles and insights for medtech startup](/blog) #### 90-second video --- ### [Active Implantable Medical Device Expertise](https://nocturnalpd.com/active-implantable-medical-device-expertise/) **Published:** March 27, 2023 **Author:** Jen Rhoton **Content:** ### Have an idea for a life-changing implantable device? ##### Now comes the hard work — we’ll make it easier! We’ve transformed life-saving and implantable devices — ranging from neuromodulation IPGs to implantable defibrillators — from a napkin sketch to an operational device. Your device can be next. ![IPGSketchUpdated_Engineering_3_20_3](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27800%27%20height%3D%27634%27%20viewBox%3D%270%200%20800%20634%27%3E%3Crect%20width%3D%27800%27%20height%3D%27634%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "IPGSketchUpdated_Engineering_3_20_3") ## One-stop access to multidisciplinary expertise. ## One-stop access to multi-disciplinary expertise. Developing an implantable device requires hands-on experience across multiple areas of expertise, ranging from [ultra](https://nocturnalpd.com/ultra-low-power-software-hardware/ "Ultra-Low Power Software Hardware")[–](/ultra-low-power-software-hardware/)[low power hardware and software](https://nocturnalpd.com/ultra-low-power-software-hardware/ "Ultra-Low Power Software Hardware") to [biosignal acquisition](/biosignal-acquisition/), hermetic packaging, and other advanced disciplines — and fitting it all into a minimal form factor. Whether your device is for [cardiac rhythm management](/cardiac-rhythm-management/), vagus nerve stimulation, pain management, or any other life-enhancing application, working with Nocturnal gives you one-stop access to an advanced set of skills that are extremely hard to find. Learn about our areas of expertise: #### [CARDIAC RHYTHM MANAGEMENT](https://nocturnalpd.com/cardiac-rhythm-management/ "Cardiac Rhythm Management") #### [NEUROMODULATION](https://nocturnalpd.com/neuromodulation/ "Neuromodulation") #### [ULTRA-LOW POWER SOFTWARE/HARDWARE](https://nocturnalpd.com/ultra-low-power-software-hardware/ "Ultra-Low Power Software Hardware") #### [EMBEDDED SOFTWARE](https://nocturnalpd.com/embedded-software/ "Embedded software") #### [BIOSENSORS & BIOSIGNAL ACQUISITION](https://nocturnalpd.com/biosignal-acquisition/ "Biosensors & Biosignal acquisition") ## Result-based business model Cash efficiency is a “do or die” proposition for any early stage company, and hourly-priced projects can quickly lead to cost and time overruns. Our [milestone-based pricing](/fixed-cost-pricing/) is based on results, giving you the predictability you need to plan your budget with confidence. And with direct access to our project management system, you have real-time visibility into our progress so you always know where you are. #### You pay for: Milestones completed #### You don’t pay for: Our time [WHY MILESTONE-BASED PRICING](/fixed-cost-pricing/) ### design for success ##### From napkin sketch to commercially-viable product, we take a holistic approach to product development, addressing all the required aspects for your device to be successful: **Technical** Ensuring the device can perform as required to deliver the intended clinical results **Usability** Ensuring the device can be operated in the intended clinical setting **Standards** Ensuring the design and development process is documented in compliance with ISO 13485:2016 and that the design meets the requirements imposed by relevant regulatory standards **Manufacturability** Ensuring manufacturing is feasible within your business case assumptions and identifying qualified suppliers and manufacturing partners **Financial** Optimizing device cost of goods sold (COGS) [START YOUR PROJECT](https://nocturnalpd.com/get-a-quote/) ## IDEA ## Research ## Design & Development ## Pre-clinical studies ## Verification & Validation ## Transfer to Manufacturing ## CE & FDA Submissions ![icon_owl](https://nocturnalpd.com/wp-content/uploads/2023/03/icon_owl.png "icon_owl") > ##### “Nocturnal greatly contributed to the development of our ground-breaking implantable device. Their expertise helped us overcome several design challenges and played an important role in turning our vision into a clinically-viable product.” > > ###### David Prutchi, Ph.D., CTO & Executive VP, Impulse Dynamics ### Our top team is now your team. We are a small firm where everyone is an expert in their field, everyone is working hands-on with a client, and everyone is invested in your success. [SCHEDULE A CALL](https://nocturnalpd.com/get-a-quote/) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271500%27%20height%3D%271180%27%20viewBox%3D%270%200%201500%201180%27%3E%3Crect%20width%3D%271500%27%20height%3D%271180%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ### ## Turn your sketch into reality. [GET A QUOTE](https://nocturnalpd.com/get-a-quote/) --- ### [Ultra-Low Power Software Hardware](https://nocturnalpd.com/ultra-low-power-software-hardware/) **Published:** March 18, 2023 **Author:** Jen Rhoton **Content:** The ultra-low power / high performance challenge ##### Designing a medical device with ultra-low power consumption presents a unique set of challenges for hardware and software design. **Multidisciplinary expertise** In addition to simply balancing performance trade-off considerations, designing for ultra-low power requires an integrated approach to hardware and software design. It also requires specialized testing to ensure that the power consumption profile is properly defined for all operating scenarios in the intended clinical application. ![](https://nocturnalpd.com/wp-content/uploads/2023/04/PCBA-with-flex-3-1.jpg "PCBA-with-flex-3") ## Stay Ahead of the curve with ultra-low power innovation Whether it’s for a [cardiac rhythm management](https://nocturnalpd.com/cardiac-rhythm-management/ "Cardiac Rhythm Management"), [neuromodulation](https://nocturnalpd.com/neuromodulation/ "Neuromodulation"), vascular, or any other [implantable](https://nocturnalpd.com/lifesaving-implantable/ "Lifesaving & Implantable") device, working with Nocturnal’s team of experts you are always one step ahead of the latest advances in ultra-low power device development, including: ##### [Ultra-low power processors](#afc81aba4cc1a0aa1) When optimally utilized, a new generation of processors, (e.g., ARM Cortex-M) can operate on minimal power while still providing high performance, making them ideal for use in medical devices that require high computing power while consuming minimal energy. ##### [Power management software](#8e0c3e98338ce67cc) Recent advances in power management software, such as dynamic voltage and frequency scaling (DVFS) and power-aware scheduling algorithms, make it possible to optimize power usage across different components of the device, thereby extending battery life and reducing power consumption. ##### [Energy harvesting](#45501ce84cc504611) New technologies allow medical devices to reduce the need for frequent battery replacements by acquiring energy from their surroundings, such as the patient’s body, motion, or ambient light. ##### [Low-power wireless communication](#eef9b72f014b4b356) Low-power wireless communication technologies, such as Bluetooth Low Energy (BLE) enable wireless medical devices to operate for extended periods on a single battery charge. ## FAQ What should you look for in a development partner for ultra-low-power wearable or implantable devices?[Kelley Bower](https://nocturnalpd.com/author/kelley/)2025-09-03T12:11:02+00:00#### [What should you look for in a development partner for ultra-low-power wearable or implantable devices?](#collapse-1-2956) Look for a partner with proven expertise in ultra-low-power electronics and medical software. They should have experience designing implantable and compact wearable devices, with a strong background in biosensor signal processing and power optimization. The best partners also understand how to produce AI-ready data and have a track record of bringing regulated medical devices to market successfully. What are the key challenges in developing ultra-low-power medical devices?[Kelley Bower](https://nocturnalpd.com/author/kelley/)2025-09-03T12:09:48+00:00#### [What are the key challenges in developing ultra-low-power medical devices?](#collapse-1-2954) The biggest challenge is balancing performance with extremely low energy use. A device must capture and process biosensor data accurately without quickly draining its tiny battery. Designers have to choose specialized low-power components and optimize every software task to save power. Often there are trade-offs to conserve energy while still providing reliable, real-time health insights—such as reducing data acquisition and transmission frequencies, simplifying algorithms, and knowing when it’s worth accepting higher amplifier current drain in favor of lower noise. Why should startups prioritize ultra-low-power design in their medical devices?[Kelley Bower](https://nocturnalpd.com/author/kelley/)2025-09-03T12:09:13+00:00#### [Why should startups prioritize ultra-low-power design in their medical devices?](#collapse-1-2952) Medical device startups should focus on ultra-low-power design early because battery life is often the first metric on which devices are judged beyond their efficacy. If a wearable or implant requires daily charging or an implant’s primary battery dies too quickly, users and clinicians won’t adopt it. Planning for minimal power use from the start avoids costly redesigns later and ensures the product can deliver continuous monitoring and better patient experience on a tight power budget **? Hardware Questions** What are the key hardware choices for ultra-low-power biosensor devices?[Kelley Bower](https://nocturnalpd.com/author/kelley/)2025-09-03T19:33:13+00:00#### [What are the key hardware choices for ultra-low-power biosensor devices?](#collapse-2-2960) Key choices include low-power analog front-ends that balance noise requirements with current drain, an ultra-efficient MCU with low power features and operating modes that can truly be leveraged by the intended software architecture, and a BLE radio that provides intimate control of communications parameters to optimize power usage. Every component in the design should have a specific and unique purpose, and be selected with a coherent device-level plan that integrates hardware and firmware with the goal of minimizing power consumption. How do low-power constraints affect hardware design for implantables and wearables?[Kelley Bower](https://nocturnalpd.com/author/kelley/)2025-09-03T19:33:21+00:00#### [How do low-power constraints affect hardware design for implantables and wearables?](#collapse-2-2958) Low-power constraints demand the use of ultra-efficient microcontrollers, careful selection of power management and signal conditioning components, and even minimization of the number of passive components.. For both implantables and wearables, every component must be considered in the context of maximizing battery life while minimizing signal noise and electronics volume. **? Software Questions** What are some software techniques for reducing power in biosensor devices?[Kelley Bower](https://nocturnalpd.com/author/kelley/)2025-09-03T19:32:50+00:00#### [What are some software techniques for reducing power in biosensor devices?](#collapse-3-2964) Ultra low power design requires a near-obsessive focus on maximizing time in low power operating states. Smart scheduling of data acquisition and process, offloading tasks to microcontroller peripherals, and strategies for limiting connection time during wireless communications can all reduce power use while maintaining signal quality. How does embedded software impact power use in wearable medical devices?[Kelley Bower](https://nocturnalpd.com/author/kelley/)2025-09-03T19:33:02+00:00#### [How does embedded software impact power use in wearable medical devices?](#collapse-3-2962) Firmware controls power-hungry tasks like data acquisition, data filtering, and wireless communications. Efficient code with smart scheduling, sensor fusion, and edge processing minimizes active time and energy drain—critical for long battery life in wearables and implants. **? Biosensor Signal & Data Questions** What are the tradeoffs between edge and cloud processing in low-power medical devices?[Kelley Bower](https://nocturnalpd.com/author/kelley/)2025-09-03T19:32:14+00:00#### [What are the tradeoffs between edge and cloud processing in low-power medical devices?](#collapse-4-2970) Cloud processing reduces on-device power use but increases wireless transmission needs, which can drain batteries quickly. Edge processing saves data transmission power by analyzing data locally, but requires more capable (and slightly more power-hungry) processors or more awake time. The decision where to process data is often driven by other factors as well, such as the likely frequency of updating the associated algorithms. The best approach often involves a balance of the two approaches, based on the specific application. What are the tradeoffs between biosensor data quality and power usage?[Kelley Bower](https://nocturnalpd.com/author/kelley/)2025-09-03T19:32:33+00:00#### [What are the tradeoffs between biosensor data quality and power usage?](#collapse-4-2968) Higher data quality often requires faster sampling, higher resolution, lower noise, and more frequent transmissions—all of which consume more power. To conserve energy, the first step is determining what the quality requirements truly are. The data must be good enough to enable the product to accomplish its current and future clinical goals, but superfluous quality only consumes power for no end benefit. How do you optimize biosensor data collection for ultra-low power?[Kelley Bower](https://nocturnalpd.com/author/kelley/)2025-09-03T19:32:42+00:00#### [How do you optimize biosensor data collection for ultra-low power?](#collapse-4-2966) Optimization involves selecting the right sampling rate, minimizing sensor activation time, and balancing analog and signal processing to achieve the *necessary* signal quality—not the maximum possible signal quality. For wearable or implantable sensors, the goal is to capture meaningful data while keeping energy consumption minimal. **? AI/ML Questions** What are the requirements for making biosensor data AI-ready in low-power devices?[Kelley Bower](https://nocturnalpd.com/author/kelley/)2025-09-03T19:31:36+00:00#### [What are the requirements for making biosensor data AI-ready in low-power devices?](#collapse-5-2974) In low-power wearables and implants, AI-ready data must be clean, structured, and lightweight. Devices should preprocess signals to reduce noise and compress features before transmission. This minimizes power use while ensuring the data is usable for model training and real-time inference. How do low-power constraints impact your medical device AI strategy?[Kelley Bower](https://nocturnalpd.com/author/kelley/)2025-09-03T19:31:56+00:00#### [How do low-power constraints impact your medical device AI strategy?](#collapse-5-2972) Power limits may require preprocessing or signal classification to happen on-device, using lightweight models or thresholds. Full AI processing may be deferred to the cloud, so the device sends only essential features, reducing energy use while still enabling intelligent insights. ## Result-based business model Cash efficiency is a “do or die” proposition for any early stage company, and hourly-priced projects can quickly lead to cost and time overruns. Our pricing is based on results, giving you the predictability you need to plan your budget and meet your funding milestones with confidence. And with direct access to our project management system, you have real-time visibility into our progress so you always know where you are. #### You pay for: Milestones completed #### You don’t pay for: Our time [WHY MILESTONE-BASED PRICING](https://nocturnalpd.com/why-nocturnal/) ### design for success ##### From napkin sketch to commercially-viable product, we take a holistic approach to product development, addressing all the required aspects for your device to be successful: **Technical** Ensuring the device can perform as required to deliver the intended clinical results **Usability** Ensuring the device can be operated in the intended clinical setting **Standards** Ensuring the design and development process is documented in compliance with ISO 13485:2016 and that the design meets the requirements imposed by relevant regulatory standards **Manufacturability** Ensuring manufacturing is feasible within your business case assumptions and identifying qualified suppliers and manufacturing partners **Financial** Optimizing device cost of goods sold (COGS) [START YOUR PROJECT](https://nocturnalpd.com/get-a-quote/) ## IDEA ## Research ## Design & Development ## Pre-clinical studies ## Verification & Validation ## Transfer to Manufacturing ## CE & FDA Submissions ![icon_owl](https://nocturnalpd.com/wp-content/uploads/2023/03/icon_owl.png "icon_owl") > ##### “Nocturnal has once again exceeded the milestones specified, and using off-the-shelf computational hardware has kept product costs competitive.” > > ###### Bruce Ferguson, MD, Chief Medical Officer & Co-Founder, Perfusio ### Our top team is now your team. We are a small firm where everyone is an expert in their field, everyone is working hands-on with a client, and everyone is invested in your success. [GET A QUOTE](https://nocturnalpd.com/get-a-quote/) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271500%27%20height%3D%271180%27%20viewBox%3D%270%200%201500%201180%27%3E%3Crect%20width%3D%271500%27%20height%3D%271180%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ### ## Turn your sketch into reality. [GET A QUOTE](https://nocturnalpd.com/get-a-quote/) --- ### [Biosensors & Biosignal acquisition](https://nocturnalpd.com/biosignal-acquisition/) **Published:** March 27, 2023 **Author:** Jen Rhoton **Content:** ### Biosignal acquisition: Driving smarter & more responsive therapies ##### Biosensors are becoming increasingly important and common in [implantable](https://nocturnalpd.com/lifesaving-implantable/), wearable, and point-of-care medical devices. They provide real-time input to the device [embedded software](https://nocturnalpd.com/embedded-software/), allowing the device to modulate therapies in response to changes in the patient’s vital signs and functions. ![wearable_sketch4_17_23_2](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27800%27%20height%3D%27633%27%20viewBox%3D%270%200%20800%20633%27%3E%3Crect%20width%3D%27800%27%20height%3D%27633%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E "wearable_sketch4_17_23_2") ## Acquire. Interpret. Respond. These are just some of the key biosignals we specialize in helping your device acquire and respond to: ##### [Electrocardiogram (ECG)](#b67ab509f26e4d686) Continuous high-resolution low-noise ECG monitoring can be used to optimize therapy settings and regulate electrical impulses based on the patient’s real-time [heart rhythm](https://nocturnalpd.com/cardiac-rhythm-management/) and electrical activity. ##### [Heart sounds](#1e57290d99cb18c9c) Heart sounds can provide valuable information about the heart’s function that can be used to adjust pacing or defibrillation settings in real-time. ##### [Core body temperature](#dd08ca4958755c29d) Core temperature is a key indicator of the body’s metabolic activity that can be used to trigger and self-adjust automated drug delivery and other therapies. ##### [High-resolution motion](#31b873352faf06d8d) High-resolution motion sensors can be used to diagnose and monitor [neurological conditions](https://nocturnalpd.com/neuromodulation/) such as Parkinson’s disease, multiple sclerosis, and cerebral palsy. ##### [Bioimpedance](#6563567ebde88d7e8) The impedance of a patient’s body can provide useful physiological metrics such as heart rate and can also be used to assess hydration and tissue composition. ##### [Pulse oximetry](#a4749fba58477a07b) In addition to providing a direct measurement of blood oxygenation, pulse oximetry also provides heart rate derived from the mechanical behavior of blood vessels, which can be used to detect changes in blood pressure and even patient stress levels through metrics such as pulse transit time. ## Result-based business model Cash efficiency is a “do or die” proposition for any early stage company, and hourly-priced projects can quickly lead to cost and time overruns. [Our pricing](https://nocturnalpd.com/get-a-quote/) is based on results, giving you the predictability you need to plan your budget and meet your funding milestones with confidence. And with direct access to our project management system, you have real-time visibility into our progress so you always know where you are. #### You pay for: Milestones completed #### You don’t pay for: Our time [WHY MILESTONE-BASED PRICING](https://nocturnalpd.com/why-nocturnal/) ### design for success ##### From napkin sketch to commercially-viable product, we take a holistic approach to product development, addressing all the required aspects for your device to be successful: **Technical** Ensuring the device can perform as required to deliver the intended clinical results **Usability** Ensuring the device can be operated in the intended clinical setting **Standards** Ensuring the design and development process is documented in compliance with ISO 13485:2016 and that the design meets the requirements imposed by relevant regulatory standards **Manufacturability** Ensuring manufacturing is feasible within your business case assumptions and identifying qualified suppliers and manufacturing partners **Financial** Optimizing device cost of goods sold (COGS) [START YOUR PROJECT](https://nocturnalpd.com/get-a-quote/) ## IDEA ## Research ## Design & Development ## Pre-clinical studies ## Verification & Validation ## Transfer to Manufacturing ## CE & FDA Submissions ![icon_owl](https://nocturnalpd.com/wp-content/uploads/2023/03/icon_owl.png "icon_owl") > ##### “Having direct access to a team of medical device experts who responded quickly to our needs accelerated our ability to demonstrate our novel implantable technology in a preclinical setting.” > > ###### Joe Passman, Sr. Principal R&D Engineer, NXT Biomedical ### Our top team is now your team. Our software engineers don’t hide behind their screens. We are a small firm where everyone is an expert in their field, everyone is working hands-on with a client, and everyone is invested in your success. [SCHEDULE A CALL](https://nocturnalpd.com/get-a-quote/) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271500%27%20height%3D%271180%27%20viewBox%3D%270%200%201500%201180%27%3E%3Crect%20width%3D%271500%27%20height%3D%271180%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ### ## Turn your sketch into reality. [GET A QUOTE](https://nocturnalpd.com/get-a-quote/) --- ### [AI-ready data](https://nocturnalpd.com/ai-ready-data/) **Published:** October 3, 2025 **Author:** Eran Livneh **Content:** Design Your Device to Deliver AI-Ready Data The success of AI applications depends on the data feeding the algorithms. More data isn’t always better—what matters is high-quality, clinically relevant signals collected efficiently and securely. ##### To accelerate time to market and reduce risk, tap into proven expertise for your AI data pipeline—so your team can focus on your algorithms and your competitive edge. **With our pre-certified biosensors, proven hardware and software building blocks, and milestone-based pricing, you can get to market faster, at lower risk, and with capital preserved for growth.** ![](https://nocturnalpd.com/wp-content/uploads/2025/10/Nocturnal_AIGraphic_10_03_25_1.png "Nocturnal_AIGraphic_10_03_25_1") ## TAP INTO PROVEN EXPERTISE IN AI-READY DATA Building the data pipeline that feeds your algorithms is a massive undertaking. From[ signal acquisition](https://nocturnalpd.com/biosignal-acquisition/) and[ power management](https://nocturnalpd.com/ultra-low-power-software-hardware/) to secure data transmission and compliant cloud storage, every piece of the pipeline demands specialized expertise, acquired over years of continuous iterations and optimization. ##### [Signal acquisition](#d5cec959e982b03a3) High-fidelity signals depend on selecting the right sensors, optimizing placement and calibration, and implementing proper signal conditioning hardware and software to minimize noise and drift. ##### [Power-efficient design](#1667030232befcd37) Efficient devices rely on low-current analog hardware, optimized firmware, and event-based collection strategies, with smart sleep cycles to balance energy use and continuous performance. ##### [Data processing](#767db73a90f948b75) Raw signals should be cleaned, filtered, and compressed at the edge, then refined through feature extraction and machine learning models to generate real-time clinical insights. ##### [Security & compliance](#eed3e22453ac232b8) Robust pipelines follow ISO 13485, HIPAA, and FDA cybersecurity guidance, using encrypted transmission, controlled access, and lifecycle risk management to keep data secure. ## FAQ What are the requirements for making biosensor data AI-ready in low-power devices?[Kelley Bower](https://nocturnalpd.com/author/kelley/)2025-09-03T19:31:36+00:00#### [What are the requirements for making biosensor data AI-ready in low-power devices?](#collapse-6-2974) In low-power wearables and implants, AI-ready data must be clean, structured, and lightweight. Devices should preprocess signals to reduce noise and compress features before transmission. This minimizes power use while ensuring the data is usable for model training and real-time inference. How do low-power constraints impact your medical device AI strategy?[Kelley Bower](https://nocturnalpd.com/author/kelley/)2025-09-03T19:31:56+00:00#### [How do low-power constraints impact your medical device AI strategy?](#collapse-6-2972) Power limits may require preprocessing or signal classification to happen on-device, using lightweight models or thresholds. Full AI processing may be deferred to the cloud, so the device sends only essential features, reducing energy use while still enabling intelligent insights. What are the tradeoffs between edge and cloud processing in low-power medical devices?[Kelley Bower](https://nocturnalpd.com/author/kelley/)2025-09-03T19:32:14+00:00#### [What are the tradeoffs between edge and cloud processing in low-power medical devices?](#collapse-6-2970) Cloud processing reduces on-device power use but increases wireless transmission needs, which can drain batteries quickly. Edge processing saves data transmission power by analyzing data locally, but requires more capable (and slightly more power-hungry) processors or more awake time. The decision where to process data is often driven by other factors as well, such as the likely frequency of updating the associated algorithms. The best approach often involves a balance of the two approaches, based on the specific application. What are the tradeoffs between biosensor data quality and power usage?[Kelley Bower](https://nocturnalpd.com/author/kelley/)2025-09-03T19:32:33+00:00#### [What are the tradeoffs between biosensor data quality and power usage?](#collapse-6-2968) Higher data quality often requires faster sampling, higher resolution, lower noise, and more frequent transmissions—all of which consume more power. To conserve energy, the first step is determining what the quality requirements truly are. The data must be good enough to enable the product to accomplish its current and future clinical goals, but superfluous quality only consumes power for no end benefit. How do you optimize biosensor data collection for ultra-low power?[Kelley Bower](https://nocturnalpd.com/author/kelley/)2025-09-03T19:32:42+00:00#### [How do you optimize biosensor data collection for ultra-low power?](#collapse-6-2966) Optimization involves selecting the right sampling rate, minimizing sensor activation time, and balancing analog and signal processing to achieve the *necessary* signal quality—not the maximum possible signal quality. For wearable or implantable sensors, the goal is to capture meaningful data while keeping energy consumption minimal. ## Result-based business model Cash efficiency is a “do or die” proposition for any early stage company, and hourly-priced projects can quickly lead to cost and time overruns. Our pricing is based on results, giving you the predictability you need to plan your budget and meet your funding milestones with confidence. And with direct access to our project management system, you have real-time visibility into our progress so you always know where you are. #### You pay for: Milestones completed #### You don’t pay for: Our time [WHY MILESTONE-BASED PRICING](https://nocturnalpd.com/why-nocturnal/) ### design for success ##### From napkin sketch to commercially-viable product, we take a holistic approach to product development, addressing all the required aspects for your device to be successful: **Technical** Ensuring the device can perform as required to deliver the intended clinical results **Usability** Ensuring the device can be operated in the intended clinical setting **Standards** Ensuring the design and development process is documented in compliance with ISO 13485:2016 and that the design meets the requirements imposed by relevant regulatory standards **Manufacturability** Ensuring manufacturing is feasible within your business case assumptions and identifying qualified suppliers and manufacturing partners **Financial** Optimizing device cost of goods sold (COGS) [START YOUR PROJECT](https://nocturnalpd.com/get-a-quote/) ## IDEA ## Research ## Design & Development ## Pre-clinical studies ## Verification & Validation ## Transfer to Manufacturing ## CE & FDA Submissions ![icon_owl](https://nocturnalpd.com/wp-content/uploads/2023/03/icon_owl.png "icon_owl") > ##### “In just one year, Nocturnal took our implantable cardiac monitor from a concept to a fully functional device.” > > ###### Jaeson Bang, Founder & CEO, Future Cardia ### Our top team is now your team. We are a small firm where everyone is an expert in their field, everyone is working hands-on with a client, and everyone is invested in your success. [GET A QUOTE](https://nocturnalpd.com/get-a-quote/) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271500%27%20height%3D%271180%27%20viewBox%3D%270%200%201500%201180%27%3E%3Crect%20width%3D%271500%27%20height%3D%271180%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ### ## Turn your sketch into reality. [GET A QUOTE](https://nocturnalpd.com/get-a-quote/) --- ### [Embedded software](https://nocturnalpd.com/embedded-software/) **Published:** March 27, 2023 **Author:** Jen Rhoton **Content:** ### Embedded software: The brain behind your device ##### Embedded software is the key to making your medical device smarter, more responsive, and more effective. Our software engineers are always two steps ahead of the latest advances in software development for [Class II/Class III devices](https://nocturnalpd.com/class-ii-class-iii-devices/), including [cardiac rhythm management](https://nocturnalpd.com/cardiac-rhythm-management/), [neuromodulation](https://nocturnalpd.com/neuromodulation/), and other [implantable devices](https://nocturnalpd.com/lifesaving-implantable/). - **Power management:** Embedded software is the most critical component of a low-power device. Properly architected software can optimize the use of battery power, extending the life of implantable devices and reducing the need for frequent charging or replacements. - **Real-time monitoring:** Advanced sensing and data collection enable continuous monitoring of patient biosignals and other clinical indicators, allowing the device to respond in real-time and alert a medical provider to changes in the patient’s condition. - **Adaptive algorithms:** Advanced algorithms can help the device learn from patient data and adapt to their needs over time. - **Security:** As medical devices become more connected, advanced encryption, authentication, and other security safeguards are critical to the protection of patient data and privacy. **Code that will scale with your product roadmap** Good code will make your device work as expected today. Great code will be designed to support the functionality you may want to add in the future — whether it’s a new hardware component, additional sensors, or new analytic capabilities. ![](https://nocturnalpd.com/wp-content/uploads/2023/03/Embedded-Software-IPG-Exploded3.jpg "Embedded-Software-IPG-Exploded3") ## There is more to it than just code: Software Quality Management Systems When it comes to medical device software, getting the code to make the device function is just part of the picture. To support regulatory submission, our team will check all the boxes ensuring the design and development process is documented in compliance with ISO 13485:2016, IEC 62304, ISO 14971, and any applicable regulatory standards. ##### [Software development process](#fb10cb30ac224fb39) Ensure the software development, testing, and release processes meet regulatory requirements. ##### [Risk management](#db282b0ed11dce439) Define a risk management process that identifies and mitigates risks associated with the use of the software in the medical device. ##### [Secure software design](#deb6df038a8e84e4a) Ensure the use of secure coding practices, software architectures, communication protocols, and procedures for penetration testing, vulnerability scanning, and code analysis. ##### [Verification and Validation](#d506b6326018337aa) Define procedures for verifying and validating the software to ensure that it meets the intended use and regulatory requirements. ##### [Software maintenance](#a42710ce0654fb194) Define procedures for maintaining software, including monitoring performance, fixing bugs, and addressing security vulnerabilities. ##### [Configuration management](#c82b0643645cab84a) Define procedures for managing changes to software, including version control, documentation, and traceability. ##### [Software documentation](#60ed974958e7d35ae) Define the accompanying software documentation, including requirements, design specifications, test plans, and user manuals. ##### [Software records](#89a9ea9d418b01c5f) Define procedures for the retention of software records, including source code, binaries, and test results, for the life of the device. ## Result-based business model Cash efficiency is a “do or die” proposition for any early stage company, and hourly-priced projects can quickly lead to cost and time overruns. [Our pricing](https://nocturnalpd.com/why-nocturnal/) is based on results, giving you the predictability you need to plan your budget and meet your funding milestones with confidence. And with direct access to our project management system, you have real-time visibility into our progress so you always know where you are. #### You pay for: Milestones completed #### You don’t pay for: Our time [WHY MILESTONE-BASED PRICING](https://nocturnalpd.com/why-nocturnal/) ### design for success ##### From napkin sketch to commercially-viable product, we take a holistic approach to product development, addressing all the required aspects for your device to be successful: **Technical** Ensuring the device can perform as required to deliver the intended clinical results **Usability** Ensuring the device can be operated in the intended clinical setting **Standards** Ensuring the design and development process is documented in compliance with ISO 13485:2016 and that the design meets the requirements imposed by relevant regulatory standards **Manufacturability** Ensuring manufacturing is feasible within your business case assumptions and identifying qualified suppliers and manufacturing partners **Financial** Optimizing device cost of goods sold (COGS) [START YOUR PROJECT](https://nocturnalpd.com/get-a-quote/) ## IDEA ## Research ## Design & Development ## Pre-clinical studies ## Verification & Validation ## Transfer to Manufacturing ## CE & FDA Submissions ![icon_owl](https://nocturnalpd.com/wp-content/uploads/2023/03/icon_owl.png "icon_owl") > ##### “The re-architecture of the imaging processing and analysis algorithms produced real-time analytics at 15 fps (down from 15 sec), integrated within a scalable software platform developed by Nocturnal that demonstrates supports our expanded product roadmap.” > > ###### Bruce Ferguson, MD, Chief Medical Officer & Co-Founder, Perfusio ### Our top team is now your team. Our software engineers don’t hide behind their screens. We are a small firm where everyone is an expert in their field, everyone is working hands-on with a client, and everyone is invested in your success. [SCHEDULE A CALL](https://nocturnalpd.com/get-a-quote/) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271500%27%20height%3D%271180%27%20viewBox%3D%270%200%201500%201180%27%3E%3Crect%20width%3D%271500%27%20height%3D%271180%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ### ## Turn your sketch into reality. [GET A QUOTE](https://nocturnalpd.com/get-a-quote/) --- ### [sitemap](https://nocturnalpd.com/sitemap/) **Published:** December 15, 2025 **Author:** Eran Livneh **Content:** # Site Map ## Main - [Home](https://nocturnalpd.com/) - [Why Nocturnal](https://nocturnalpd.com/why-nocturnal/) - [Leadership](https://nocturnalpd.com/leadership/) - [Ecosystem](https://nocturnalpd.com/ecosystem/) - [Get a Quote](https://nocturnalpd.com/get-a-quote/) ## Expertise - [Class II & Class III Devices](https://nocturnalpd.com/class-ii-class-iii-devices/) - [Lifesaving & Implantable](https://nocturnalpd.com/lifesaving-implantable/) - [Cardiac Rhythm Management](https://nocturnalpd.com/cardiac-rhythm-management/) - [Neuromodulation](https://nocturnalpd.com/neuromodulation/) - [Ultra-Low Power Software/Hardware](https://nocturnalpd.com/ultra-low-power-software-hardware/) - [Embedded Software](https://nocturnalpd.com/embedded-software/) - [Biosensors & Biosignal Acquisition](https://nocturnalpd.com/biosignal-acquisition/) - [AI-Ready Data & Cloud Pipelines](https://nocturnalpd.com/ai-ready-data/) ## Resources - [Insights](https://nocturnalpd.com/blog/) - [Guides](https://nocturnalpd.com/medical-device-guides/) - [Turning Biosignals into AI-ready Data](https://nocturnalpd.com/turning-biosignals-into-ai-ready-data/) - [Navigating Medical Device Funding Cycles](https://nocturnalpd.com/ebook-navigating-medical-device-funding-cycles/) - [Video](https://nocturnalpd.com/video/) - [Webinars](https://nocturnalpd.com/webinars-for-medical-device-innovators/) - [Scaling from Prototype to Commercial Success](https://nocturnalpd.com/scaling-from-prototype-to-commercial-success-a-lean-approach-for-medical-startups/ "Scaling from Prototype to Commercial Success") - [From Biosignals to Clinical Insights](https://nocturnalpd.com/webinar-on-demand-from-biosignals-to-clinical-insights/) - [Startup Survey Results](https://nocturnalpd.com/state-of-the-medtech-startup/) ## Legal - [Privacy Policy](https://nocturnalpd.com/privacy-policy/) - [Terms and Conditions](https://nocturnalpd.com/terms-and-conditions/) --- ### [Survey Thank You](https://nocturnalpd.com/survey-thank-you/) **Published:** November 11, 2025 **Author:** Eran Livneh **Content:** ## Thank you for your interest in our survey results. ##### Check your inbox for a link to download your copy. #### In the meantime, learn more about our expertise in: #### [CLASS II & CLASS III](https://nocturnalpd.com/class-ii-class-iii-devices/ "Class II & Class III Devices") #### [LIFE-SAVING & IMPLANTABLE](https://nocturnalpd.com/lifesaving-implantable/ "Lifesaving & Implantable") #### [CARDIAC RHYTHM MANAGEMENT](https://nocturnalpd.com/cardiac-rhythm-management/ "Cardiac Rhythm Management") #### [NEUROMODULATION](https://nocturnalpd.com/neuromodulation/ "Neuromodulation") #### [ULTRA-LOW POWER SOFTWARE/HARDWARE](https://nocturnalpd.com/ultra-low-power-software-hardware/ "Ultra-Low Power Software Hardware") #### [EMBEDDED SOFTWARE](https://nocturnalpd.com/embedded-software/ "Embedded software") #### [BIOSENSORS & BIOSIGNAL ACQUISITION](https://nocturnalpd.com/biosignal-acquisition/ "Biosignal acquisition") #### [AI-READY DATA](https://nocturnalpd.com/ai-ready-data/) --- ### [State of the MedTech Startup](https://nocturnalpd.com/state-of-the-medtech-startup/) **Published:** November 11, 2025 **Author:** Eran Livneh **Content:** ## #### The State of MedTech Startups ##### See what keeps startup founders and innovators up at night in our exclusive survey report. ![](https://nocturnalpd.com/wp-content/uploads/2025/11/Survey-Image-for-landing-page.png "Survey Image for landing page") --- ### [The State of MedTech Startups](https://nocturnalpd.com/the-state-of-medtech-startups/) **Published:** November 11, 2025 **Author:** Eran Livneh **Content:** ## #### The State of MedTech Startups ## ##### **Exclusive survey results from MedTech founders and innovators.** [![](https://nocturnalpd.com/wp-content/uploads/2025/11/Survey-Image-for-landing-page.png)](https://nocturnalpd.com/wp-content/uploads/2025/11/The-State-of-MedTech-Startups-Nov-2025-Nocturnal.pdf) --- ### [Ecosystem](https://nocturnalpd.com/ecosystem/) **Published:** March 26, 2023 **Author:** Jen Rhoton **Content:** ### Medical Device Ecosystem Providers ##### Through our collaboration with ecosystem solution providers across a wide range of disciplines, we help our clients identify and access best-in-class providers that have proven capabilities supporting medical device innovation along the path to commercialization. ### Biosensors #### [Linxens](https://healthcare.linxens.com/) A leading provider of biosensors, electronic skin patches, and connected solutions, Linxens Healthcare has delivered over 500m electrochemical sensors and more than 15m electronic skin patches to the healthcare industry. Incorporating Linxens’ advanced medical-grade biosensors and skin electronic adhesion technologies into our wearable and implantable product designs allows Nocturnal clients to accelerate development timelines and reduce risk with an integrated market-ready solution. ### Cloud QMS #### [QuickVaulT by Veeva](https://quickvault.veeva.com/) QuickVault unifies design, submission, and production to accelerate your MedTech journey from concept to market. The platform simplifies regulatory compliance, streamlines quality management, and eliminates inefficiencies, so medical device innovators can focus on creating transformative healthcare solutions. Using the QuickVault platform, medical device companies get a jumpstart on an ISO 13485 quality management system that they can grow with and make their own with a click of a button. ### Cybersecurity #### [CyberMed](https://cybermed.ai) CyberMed helps medical device manufacturers meet FDA cybersecurity requirements. They offer security consulting, penetration and fuzz testing, and white glove FDA compliance documentation. With a fixed-cost, success-based model, their expert team simplifies compliance, strengthens device security, and minimizes risks for manufacturers.. ### Strategic Consulting #### [The Karow Advisory Group](http://www.thekarowgroup.com/) Advises MedTech, wearables, and digital therapeutics teams at the C-suite and board level to clarify strategy, align leadership, and plan commercialization with a clear view of regulatory and reimbursement paths, while providing investors with independent commercial diligence and operator-level insights. ### funding #### [Indaco](https://www.indacosgr.com/) Founded in 2016, Indaco Venture Partners is the largest independent Italian venture capital asset management company, specializing in companies that innovate in electronics, robotics, medtech, biotech, and pharmaceuticals. #### [NIH](https://www.nih.gov/) Medical device companies can take advantage of grants from the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs to fund their product development and commercialization projects. Nocturnal has an impeccable track record of collaborating with clients on STTR and SBIR grants, providing detailed technical analysis and letter of intent that helped clients secure millions of dollars in non-dilutive funding. ### Recruiting #### [Lifeblood Capital ](https://lifebloodcapital.com/) With a track record of over 15 years building winning medical device teams, Lifeblood Capital supports global MedTech startups with talent acquisition and recruiting that fuel company growth. ### Contract Manufacturing Finding the right manufacturing partners for your device is key to your success. Leveraging our industry relationships and experience, we can help you identify highly-reliable manufacturers that have the right capabilities and certifications for your product. Equally important, we’ll help you find a partner you can grow with throughout the device commercialization journey – from small batches for studies and V&V to full-scale commercial quantities. #### [Resolution Medical](https://www.resolutionmedical.com/) From complex delivery systems to active implantable devices, Resolution Medical leverages deep anatomical expertise to accelerate time to market, offering long-term partnerships with the highest quality, reliability, customer service, and with the resolution to continuously improve life. #### [EI Microcircuits](https://www.eimicro.com/) EI Microcircuits is a high-mix, low-to-mid volume, flexible manufacturer specializing in complex circuit assemblies for cardiology, oximetry, and vital organ monitoring, with inhouse quality and lot-control systems providing complete documentation and traceability for FDA approvals. #### [Sierra Circuits](https://www.protoexpress.com/) Sierra Circuits is ISO 13485:2016 certified, fabricating printed circuit substrates and building top-of-the-line printed circuit assemblies under IPC-6012 class 2 and class 3 and UL 94 V-0 flammability standards. #### [Protolabs](https://www.protolabs.com/) Protolabs provides rapid prototyping and injection molding services for medical device components, taking Class I and II devices and non-implantable components from prototype to production and regulatory submission. #### [Microchip Technology ](https://www.microchip.com/) Microchip Technology is a leading provider of smart, connected and secure embedded control solutions, serving more than 120,000 customers across numerous industries, including class 1, 2 and 3, medical device companies. #### [American Standard Circuits](https://www.asc-i.com/) ASC is a total solution provider delivering quality rigid, metal-backed, flexible, and rigid-flex printed circuit substrates and backed by state-of-the-art process control systems and certifications including AS9100 Rev D, ISO 9001:2015, MIL PRF 31032 and MIL PRF 50884F. #### [PFC Flexible Circuits](https://www.pfcflex.com/) PFC Flexible Circuits provides turnkey solutions for flexible and rigid-flex printed circuit substrates.Their cutting-edge flex circuit technology enables freedom of design, product miniaturization, reliability, bendability, and overall cost savings for electronic solutions. #### [Northern Nitinol ](https://www.northernnitinol.com/) Northern Nitinol provides nitinol consulting and prototyping, helping medical device companies overcome the challenges associated with the development and commercialization of medical-nitinol implants and components. #### [STI Electronics ](https://stiusa.com/) STI is a multifaceted technical organization specializing in the manufacturing of mission-critical circuit assemblies for the medical, military, and aerospace industries and utilizing the most advanced equipment for training, R&D, manufacturing, prototyping and analysis. #### [Cirtec Medical ](https://cirtecmed.com/) Cirtec Medical provides precision components and finished devices for neurology, cardiology, and orthopedics surgical tools and implantable devices, bringing active implants and minimally invasive therapeutic devices to market quickly, predictably and cost-effectively. ### Our top team is now your team. We are a small firm where everyone is an expert in their field, everyone is working hands-on with a client, and everyone is invested in your success. [SCHEDULE A CALL](https://nocturnalpd.com/get-a-quote/) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271500%27%20height%3D%271180%27%20viewBox%3D%270%200%201500%201180%27%3E%3Crect%20width%3D%271500%27%20height%3D%271180%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ### ## Turn your sketch into reality. [GET A QUOTE](https://nocturnalpd.com/get-a-quote/) --- ### [Turning Biosignals into AI-ready Data](https://nocturnalpd.com/turning-biosignals-into-ai-ready-data/) **Published:** September 17, 2025 **Author:** Eran Livneh **Content:** ## #### FROM BIOSIGNALS TO AI-READY DATA ![](https://nocturnalpd.com/wp-content/uploads/2025/09/AI-Data-Guide-Cover.png "AI Data Guide Cover") ##### Learn how to design your medical device and data streams to optimize AI-driven outcomes. --- ### [From Biosignals to AI-ready Data](https://nocturnalpd.com/from-biosignals-to-ai-ready-data/) **Published:** September 17, 2025 **Author:** Eran Livneh **Content:** ## #### FROM BIOSIGNALS TO AI-READY DATA #### ##### Learn how to design your medical device and data streams to optimize AI-driven outcomes. [![](https://nocturnalpd.com/wp-content/uploads/2025/09/AI-Data-Guide-Cover.png)](https://nocturnalpd.com/wp-content/uploads/2025/07/Nocturnal-Mastering-Data-Guide-July-2025.pdf) [get your copy](https://nocturnalpd.com/wp-content/uploads/2025/09/Nocturnal-AI-Data-Guide-Sep-2025.pdf) --- ### [Insights for Medical Device Entrepreneurs](https://nocturnalpd.com/blog/) **Published:** June 12, 2023 **Author:** Jen Rhoton **Content:** ### Insights for Medical Device Entrepreneurs - ![Conceptual depiction of a woman with glowing golden neural circuits around the head, representing brain–computer interfacing and a wearable device at the collarbone area.](https://nocturnalpd.com/wp-content/uploads/2026/07/Wearables-playbook.png) [The New Wearables Playbook](https://nocturnalpd.com/2026/07/06/the-new-wearables-playbook/) [](https://nocturnalpd.com/2026/07/06/the-new-wearables-playbook/) ## [The New Wearables Playbook](https://nocturnalpd.com/2026/07/06/the-new-wearables-playbook/) [Eran Livneh](https://nocturnalpd.com/author/eran/)2026-07-06T20:10:31+00:00July 6th, 2026|Categories: [Biosensors & Biosignal Acquisition](https://nocturnalpd.com/category/biosensors-and-biosignal-acquisition/), [Neuromodulation](https://nocturnalpd.com/category/neuromodulation/), [Startups](https://nocturnalpd.com/category/startups/), [Wearable](https://nocturnalpd.com/category/wearable/)| A quick recap In our previous blog [Read More](https://nocturnalpd.com/2026/07/06/the-new-wearables-playbook/) - ![wearables red ocean blue ocean](https://nocturnalpd.com/wp-content/uploads/2026/06/Red-ocean.png) [The Next Wearables Frontier](https://nocturnalpd.com/2026/06/09/the-next-wearables-frontier/) [](https://nocturnalpd.com/2026/06/09/the-next-wearables-frontier/) ## [The Next Wearables Frontier](https://nocturnalpd.com/2026/06/09/the-next-wearables-frontier/) [Eran Livneh](https://nocturnalpd.com/author/eran/)2026-07-06T23:20:14+00:00June 9th, 2026|Categories: [Biosensors & Biosignal Acquisition](https://nocturnalpd.com/category/biosensors-and-biosignal-acquisition/), [Neuromodulation](https://nocturnalpd.com/category/neuromodulation/), [Startups](https://nocturnalpd.com/category/startups/), [Wearable](https://nocturnalpd.com/category/wearable/)| The wearable sensor red ocean The wellness [Read More](https://nocturnalpd.com/2026/06/09/the-next-wearables-frontier/) - ![Milestone-based development roadmap reflecting 2025 MedTech funding and risk expectations](https://nocturnalpd.com/wp-content/uploads/2026/02/Feb-2026.png) [The Hidden Message in 2025 MedTech Investment Data](https://nocturnalpd.com/2026/02/04/the-hidden-message-in-2025-medtech-investment-data/) [](https://nocturnalpd.com/2026/02/04/the-hidden-message-in-2025-medtech-investment-data/) ## [The Hidden Message in 2025 MedTech Investment Data](https://nocturnalpd.com/2026/02/04/the-hidden-message-in-2025-medtech-investment-data/) [Eran Livneh](https://nocturnalpd.com/author/eran/)2026-02-04T12:21:28+00:00February 4th, 2026|Categories: [Class II & Class III Devices](https://nocturnalpd.com/category/class-ii-and-class-iii-devices/), [Funding](https://nocturnalpd.com/category/funding/), [Milestone-based pricing](https://nocturnalpd.com/category/milestone-based-pricing/), [Startups](https://nocturnalpd.com/category/startups/)| MedTech investment data coming out of 2025 [Read More](https://nocturnalpd.com/2026/02/04/the-hidden-message-in-2025-medtech-investment-data/) - ![](https://nocturnalpd.com/wp-content/uploads/2025/10/KC-QA.jpg) [Milestones That Matter: A Conversation with KC Armstrong on Reaching “First in Human”](https://nocturnalpd.com/2025/10/29/reaching-first-in-human/) [](https://nocturnalpd.com/2025/10/29/reaching-first-in-human/) ## [Milestones That Matter: A Conversation with KC Armstrong on Reaching “First in Human”](https://nocturnalpd.com/2025/10/29/reaching-first-in-human/) [Eran Livneh](https://nocturnalpd.com/author/eran/)2025-10-29T20:11:35+00:00October 29th, 2025|Categories: [Class II & Class III Devices](https://nocturnalpd.com/category/class-ii-and-class-iii-devices/), [Lifesaving & Implantable](https://nocturnalpd.com/category/lifesaving-and-implantable/), [Milestone-based pricing](https://nocturnalpd.com/category/milestone-based-pricing/), [Startups](https://nocturnalpd.com/category/startups/)| KC Armstrong, MSEE, is Nocturnal's Founder & President. A [Read More](https://nocturnalpd.com/2025/10/29/reaching-first-in-human/) - ![](https://nocturnalpd.com/wp-content/uploads/2023/06/market-scaled.jpeg) [Medical device design considerations for the cash strapped startup](https://nocturnalpd.com/2025/07/30/medical-device-design-considerations-for-the-cash-strapped-startup/) [](https://nocturnalpd.com/2025/07/30/medical-device-design-considerations-for-the-cash-strapped-startup/) ## [Medical device design considerations for the cash strapped startup](https://nocturnalpd.com/2025/07/30/medical-device-design-considerations-for-the-cash-strapped-startup/) [Jen Rhoton](https://nocturnalpd.com/author/jen/)2025-10-20T17:15:36+00:00July 30th, 2025|Categories: [Funding](https://nocturnalpd.com/category/funding/), [Milestone-based pricing](https://nocturnalpd.com/category/milestone-based-pricing/), [Startups](https://nocturnalpd.com/category/startups/)| The cold reality: Investment money is getting even harder to [Read More](https://nocturnalpd.com/2025/07/30/medical-device-design-considerations-for-the-cash-strapped-startup/) - ![](https://nocturnalpd.com/wp-content/uploads/2025/07/Design-Controls.jpg) [How to Build Your Device Faster While Staying Compliant Using Smart Design Controls](https://nocturnalpd.com/2025/07/18/how-to-build-your-device-faster-while-staying-compliant-using-smart-design-controls/) [](https://nocturnalpd.com/2025/07/18/how-to-build-your-device-faster-while-staying-compliant-using-smart-design-controls/) ## [How to Build Your Device Faster While Staying Compliant Using Smart Design Controls](https://nocturnalpd.com/2025/07/18/how-to-build-your-device-faster-while-staying-compliant-using-smart-design-controls/) [Eran Livneh](https://nocturnalpd.com/author/eran/)2025-08-05T13:09:54+00:00July 18th, 2025|Categories: [Funding](https://nocturnalpd.com/category/funding/), [QMS](https://nocturnalpd.com/category/qms/), [Startups](https://nocturnalpd.com/category/startups/)| The difference between a stumbling block and a [Read More](https://nocturnalpd.com/2025/07/18/how-to-build-your-device-faster-while-staying-compliant-using-smart-design-controls/) - ![](https://nocturnalpd.com/wp-content/uploads/2025/06/Blog-featured2.png) [From biosignals to clinical insights – how to derisk and accelerate your path to market](https://nocturnalpd.com/2025/06/16/from-biosignals-to-clinical-insights-how-to-derisk-and-accelerate-your-path-to-market/) [](https://nocturnalpd.com/2025/06/16/from-biosignals-to-clinical-insights-how-to-derisk-and-accelerate-your-path-to-market/) ## [From biosignals to clinical insights – how to derisk and accelerate your path to market](https://nocturnalpd.com/2025/06/16/from-biosignals-to-clinical-insights-how-to-derisk-and-accelerate-your-path-to-market/) [Eran Livneh](https://nocturnalpd.com/author/eran/)2025-06-17T16:26:35+00:00June 16th, 2025|Categories: [Biosensors & Biosignal Acquisition](https://nocturnalpd.com/category/biosensors-and-biosignal-acquisition/), [Lifesaving & Implantable](https://nocturnalpd.com/category/lifesaving-and-implantable/), [Startups](https://nocturnalpd.com/category/startups/), [Ultra-low Power Software Hardware](https://nocturnalpd.com/category/ultra-low-power-software-hardware/), [Wearable](https://nocturnalpd.com/category/wearable/)| If you're building a medical device that relies on [Read More](https://nocturnalpd.com/2025/06/16/from-biosignals-to-clinical-insights-how-to-derisk-and-accelerate-your-path-to-market/) - ![](https://nocturnalpd.com/wp-content/uploads/2025/05/Software-enabled-Medical-Device.jpg) [5 Things Startups Get Wrong about Software-Enabled Medical Devices](https://nocturnalpd.com/2025/05/09/5-things-startups-get-wrong-about-software-enabled-medical-devices/) [](https://nocturnalpd.com/2025/05/09/5-things-startups-get-wrong-about-software-enabled-medical-devices/) ## [5 Things Startups Get Wrong about Software-Enabled Medical Devices](https://nocturnalpd.com/2025/05/09/5-things-startups-get-wrong-about-software-enabled-medical-devices/) [Eran Livneh](https://nocturnalpd.com/author/eran/)2025-05-09T15:59:51+00:00May 9th, 2025|Categories: [Embedded Software](https://nocturnalpd.com/category/embedded-software/), [Funding](https://nocturnalpd.com/category/funding/), [Startups](https://nocturnalpd.com/category/startups/), [Ultra-low Power Software Hardware](https://nocturnalpd.com/category/ultra-low-power-software-hardware/)| Developing a software-enabled medical device isn’t just a technical [Read More](https://nocturnalpd.com/2025/05/09/5-things-startups-get-wrong-about-software-enabled-medical-devices/) - ![](https://nocturnalpd.com/wp-content/uploads/2025/03/Say-Yes.jpg) [Why Investors Say No to Medical Device Startups (and how to get them to say yes)](https://nocturnalpd.com/2025/03/24/why-investors-say-no-to-medical-device-startups-and-how-to-get-them-to-say-yes/) [](https://nocturnalpd.com/2025/03/24/why-investors-say-no-to-medical-device-startups-and-how-to-get-them-to-say-yes/) ## [Why Investors Say No to Medical Device Startups (and how to get them to say yes)](https://nocturnalpd.com/2025/03/24/why-investors-say-no-to-medical-device-startups-and-how-to-get-them-to-say-yes/) [Eran Livneh](https://nocturnalpd.com/author/eran/)2026-01-07T16:30:58+00:00March 24th, 2025|Categories: [Funding](https://nocturnalpd.com/category/funding/), [Milestone-based pricing](https://nocturnalpd.com/category/milestone-based-pricing/), [Startups](https://nocturnalpd.com/category/startups/)| Raising money for a medical device startup is [Read More](https://nocturnalpd.com/2025/03/24/why-investors-say-no-to-medical-device-startups-and-how-to-get-them-to-say-yes/) - ![](https://nocturnalpd.com/wp-content/uploads/2025/02/Feb2025.jpg) [2024 Medical Device Investment Data: A Brighter Exit Path, A Challenging Funding Road](https://nocturnalpd.com/2025/02/21/2024-medical-device-investment-data-a-brighter-exit-path-a-challenging-funding-road/) [](https://nocturnalpd.com/2025/02/21/2024-medical-device-investment-data-a-brighter-exit-path-a-challenging-funding-road/) ## [2024 Medical Device Investment Data: A Brighter Exit Path, A Challenging Funding Road](https://nocturnalpd.com/2025/02/21/2024-medical-device-investment-data-a-brighter-exit-path-a-challenging-funding-road/) [Eran Livneh](https://nocturnalpd.com/author/eran/)2025-02-21T20:33:57+00:00February 21st, 2025|Categories: [Funding](https://nocturnalpd.com/category/funding/), [Milestone-based pricing](https://nocturnalpd.com/category/milestone-based-pricing/), [PMA](https://nocturnalpd.com/category/pma/), [Startups](https://nocturnalpd.com/category/startups/)| A look back at the investment trends [Read More](https://nocturnalpd.com/2025/02/21/2024-medical-device-investment-data-a-brighter-exit-path-a-challenging-funding-road/) - ![](https://nocturnalpd.com/wp-content/uploads/2024/11/Biosensor2.jpg) [Transforming Biosignals into Clinical Insights: Putting the Pieces Together](https://nocturnalpd.com/2024/11/19/transforming-biosignals-into-clinical-insights-putting-the-pieces-together/) [](https://nocturnalpd.com/2024/11/19/transforming-biosignals-into-clinical-insights-putting-the-pieces-together/) ## [Transforming Biosignals into Clinical Insights: Putting the Pieces Together](https://nocturnalpd.com/2024/11/19/transforming-biosignals-into-clinical-insights-putting-the-pieces-together/) [Eran Livneh](https://nocturnalpd.com/author/eran/)2025-04-09T21:01:34+00:00November 19th, 2024|Categories: [Biosensors & Biosignal Acquisition](https://nocturnalpd.com/category/biosensors-and-biosignal-acquisition/), [Lifesaving & Implantable](https://nocturnalpd.com/category/lifesaving-and-implantable/), [Neuromodulation](https://nocturnalpd.com/category/neuromodulation/), [Startups](https://nocturnalpd.com/category/startups/), [Ultra-low Power Software Hardware](https://nocturnalpd.com/category/ultra-low-power-software-hardware/), [Wearable](https://nocturnalpd.com/category/wearable/)| This blog post was created in collaboration with [Read More](https://nocturnalpd.com/2024/11/19/transforming-biosignals-into-clinical-insights-putting-the-pieces-together/) - ![](https://nocturnalpd.com/wp-content/uploads/2024/10/Crowdsourcing.png) [Crowdsourcing: A Startup’s Secret Weapon for Accelerating Innovation and Growth](https://nocturnalpd.com/2024/10/30/crowdsourcing-a-startups-secret-weapon-for-accelerating-innovation-and-growth/) [](https://nocturnalpd.com/2024/10/30/crowdsourcing-a-startups-secret-weapon-for-accelerating-innovation-and-growth/) ## [Crowdsourcing: A Startup’s Secret Weapon for Accelerating Innovation and Growth](https://nocturnalpd.com/2024/10/30/crowdsourcing-a-startups-secret-weapon-for-accelerating-innovation-and-growth/) [Eran Livneh](https://nocturnalpd.com/author/eran/)2024-10-30T15:55:58+00:00October 30th, 2024|Categories: [Funding](https://nocturnalpd.com/category/funding/), [Startups](https://nocturnalpd.com/category/startups/)| This blog post was created in collaboration with RedCrow, [Read More](https://nocturnalpd.com/2024/10/30/crowdsourcing-a-startups-secret-weapon-for-accelerating-innovation-and-growth/) - ![MedTech Funding Trends](https://nocturnalpd.com/wp-content/uploads/2024/08/MedTech-Funding-Blog.png) [2024 H1 MedTech Funding: Insights and Takeaways](https://nocturnalpd.com/2024/08/06/2004-h1-medtech-funding-insights-and-takeaways/) [](https://nocturnalpd.com/2024/08/06/2004-h1-medtech-funding-insights-and-takeaways/) ## [2024 H1 MedTech Funding: Insights and Takeaways](https://nocturnalpd.com/2024/08/06/2004-h1-medtech-funding-insights-and-takeaways/) [Eran Livneh](https://nocturnalpd.com/author/eran/)2024-09-23T01:14:27+00:00August 6th, 2024|Categories: [Class II & Class III Devices](https://nocturnalpd.com/category/class-ii-and-class-iii-devices/), [Funding](https://nocturnalpd.com/category/funding/), [Milestone-based pricing](https://nocturnalpd.com/category/milestone-based-pricing/), [Startups](https://nocturnalpd.com/category/startups/)| New MedTech Funding: A Light at the End of [Read More](https://nocturnalpd.com/2024/08/06/2004-h1-medtech-funding-insights-and-takeaways/) - ![](https://nocturnalpd.com/wp-content/uploads/2024/06/Linxens-Nocturnal-Logos-2.png) [Linxens and Nocturnal partner to accelerate medical device innovation](https://nocturnalpd.com/2024/07/08/linxens-and-nocturnal-partner-to-accelerate-medical-device-innovation/) [](https://nocturnalpd.com/2024/07/08/linxens-and-nocturnal-partner-to-accelerate-medical-device-innovation/) ## [Linxens and Nocturnal partner to accelerate medical device innovation](https://nocturnalpd.com/2024/07/08/linxens-and-nocturnal-partner-to-accelerate-medical-device-innovation/) [Eran Livneh](https://nocturnalpd.com/author/eran/)2025-08-06T20:03:33+00:00July 8th, 2024|Categories: [Biosensors & Biosignal Acquisition](https://nocturnalpd.com/category/biosensors-and-biosignal-acquisition/), [Lifesaving & Implantable](https://nocturnalpd.com/category/lifesaving-and-implantable/), [Wearable](https://nocturnalpd.com/category/wearable/)| Paris, France and Durham, North Carolina – Linxens, a [Read More](https://nocturnalpd.com/2024/07/08/linxens-and-nocturnal-partner-to-accelerate-medical-device-innovation/) - ![](https://nocturnalpd.com/wp-content/uploads/2024/06/Five-Mistakes-Part-II.png) [How to avoid five costly mistakes that can sink your device startup – Part II](https://nocturnalpd.com/2024/06/11/five-costly-mistakes-that-can-sink-your-device-startup-part-ii/) [](https://nocturnalpd.com/2024/06/11/five-costly-mistakes-that-can-sink-your-device-startup-part-ii/) ## [How to avoid five costly mistakes that can sink your device startup – Part II](https://nocturnalpd.com/2024/06/11/five-costly-mistakes-that-can-sink-your-device-startup-part-ii/) [Eran Livneh](https://nocturnalpd.com/author/eran/)2024-06-11T20:19:10+00:00June 11th, 2024|Categories: [Class II & Class III Devices](https://nocturnalpd.com/category/class-ii-and-class-iii-devices/), [Funding](https://nocturnalpd.com/category/funding/), [Milestone-based pricing](https://nocturnalpd.com/category/milestone-based-pricing/), [PMA](https://nocturnalpd.com/category/pma/), [QMS](https://nocturnalpd.com/category/qms/), [Startups](https://nocturnalpd.com/category/startups/)| Five Costly Mistakes that Can Sink Your Device Startup [Read More](https://nocturnalpd.com/2024/06/11/five-costly-mistakes-that-can-sink-your-device-startup-part-ii/) - ![](https://nocturnalpd.com/wp-content/uploads/2024/05/Startup-Sinking.webp) [Five costly mistakes that can sink your device startup – Part I](https://nocturnalpd.com/2024/05/28/five-costly-mistakes-that-can-sink-your-device-startup-part-i/) [](https://nocturnalpd.com/2024/05/28/five-costly-mistakes-that-can-sink-your-device-startup-part-i/) ## [Five costly mistakes that can sink your device startup – Part I](https://nocturnalpd.com/2024/05/28/five-costly-mistakes-that-can-sink-your-device-startup-part-i/) [Eran Livneh](https://nocturnalpd.com/author/eran/)2024-11-01T02:04:37+00:00May 28th, 2024|Categories: [Class II & Class III Devices](https://nocturnalpd.com/category/class-ii-and-class-iii-devices/), [Funding](https://nocturnalpd.com/category/funding/), [Milestone-based pricing](https://nocturnalpd.com/category/milestone-based-pricing/), [PMA](https://nocturnalpd.com/category/pma/), [QMS](https://nocturnalpd.com/category/qms/), [Startups](https://nocturnalpd.com/category/startups/)| Five Costly Mistakes that Can Sink Your Device Startup [Read More](https://nocturnalpd.com/2024/05/28/five-costly-mistakes-that-can-sink-your-device-startup-part-i/) - ![](https://nocturnalpd.com/wp-content/uploads/2024/04/Balancing-data-and-power.webp) [Balancing Signal Data vs. Power Consumption in Your Implantable Device](https://nocturnalpd.com/2024/04/22/balancing-signal-data-vs-power-consumption-in-your-implantable-device/) [](https://nocturnalpd.com/2024/04/22/balancing-signal-data-vs-power-consumption-in-your-implantable-device/) ## [Balancing Signal Data vs. Power Consumption in Your Implantable Device](https://nocturnalpd.com/2024/04/22/balancing-signal-data-vs-power-consumption-in-your-implantable-device/) [Eran Livneh](https://nocturnalpd.com/author/eran/)2024-04-22T14:39:04+00:00April 22nd, 2024|Categories: [Biosensors & Biosignal Acquisition](https://nocturnalpd.com/category/biosensors-and-biosignal-acquisition/), [Lifesaving & Implantable](https://nocturnalpd.com/category/lifesaving-and-implantable/), [Ultra-low Power Software Hardware](https://nocturnalpd.com/category/ultra-low-power-software-hardware/)| Hungry for Data Whether your implantable device is designed [Read More](https://nocturnalpd.com/2024/04/22/balancing-signal-data-vs-power-consumption-in-your-implantable-device/) - ![](https://nocturnalpd.com/wp-content/uploads/2024/01/neuro.jpg) [Leverage Existing Know-how to Accelerate Device Path to Commercialization](https://nocturnalpd.com/2024/01/22/accelerating-neuromodulations-path-to-commercialization/) [](https://nocturnalpd.com/2024/01/22/accelerating-neuromodulations-path-to-commercialization/) ## [Leverage Existing Know-how to Accelerate Device Path to Commercialization](https://nocturnalpd.com/2024/01/22/accelerating-neuromodulations-path-to-commercialization/) [Eran Livneh](https://nocturnalpd.com/author/eran/)2024-02-10T03:21:46+00:00January 22nd, 2024|Categories: [Lifesaving & Implantable](https://nocturnalpd.com/category/lifesaving-and-implantable/), [Neuromodulation](https://nocturnalpd.com/category/neuromodulation/)| What breakthroughs are made of One of the greatest [Read More](https://nocturnalpd.com/2024/01/22/accelerating-neuromodulations-path-to-commercialization/) - ![](https://nocturnalpd.com/wp-content/uploads/2023/10/teamwork-design-515838341_1027x1027.jpeg) [The Secrets to Navigating Fixed-Cost Projects in Medical Device Development](https://nocturnalpd.com/2023/10/31/the-secrets-to-navigating-fixed-cost-projects-in-medical-device-development/) [](https://nocturnalpd.com/2023/10/31/the-secrets-to-navigating-fixed-cost-projects-in-medical-device-development/) ## [The Secrets to Navigating Fixed-Cost Projects in Medical Device Development](https://nocturnalpd.com/2023/10/31/the-secrets-to-navigating-fixed-cost-projects-in-medical-device-development/) [Eran Livneh](https://nocturnalpd.com/author/eran/)2026-08-05T15:51:56+00:00October 31st, 2023|Categories: [Milestone-based pricing](https://nocturnalpd.com/category/milestone-based-pricing/), [Startups](https://nocturnalpd.com/category/startups/)| These are exciting times for medical device innovation. At [Read More](https://nocturnalpd.com/2023/10/31/the-secrets-to-navigating-fixed-cost-projects-in-medical-device-development/) - ![](https://nocturnalpd.com/wp-content/uploads/2024/01/bloghands.jpg) [Celebrating A Decade of Milestone-Based Pricing Projects: Insights and Lessons Learned](https://nocturnalpd.com/2023/09/19/celebrating-a-decade-of-milestone-based-pricing-projects-insights-and-lessons-learned/) [](https://nocturnalpd.com/2023/09/19/celebrating-a-decade-of-milestone-based-pricing-projects-insights-and-lessons-learned/) ## [Celebrating A Decade of Milestone-Based Pricing Projects: Insights and Lessons Learned](https://nocturnalpd.com/2023/09/19/celebrating-a-decade-of-milestone-based-pricing-projects-insights-and-lessons-learned/) [Eran Livneh](https://nocturnalpd.com/author/eran/)2026-01-07T16:39:54+00:00September 19th, 2023|Categories: [Milestone-based pricing](https://nocturnalpd.com/category/milestone-based-pricing/), [Startups](https://nocturnalpd.com/category/startups/)| This year marks a significant landmark for Nocturnal as [Read More](https://nocturnalpd.com/2023/09/19/celebrating-a-decade-of-milestone-based-pricing-projects-insights-and-lessons-learned/) - ![](https://nocturnalpd.com/wp-content/uploads/2023/08/IPGSketch_blog-e1691186869909.png) [Less is More: The Power of Simplicity in Implantable Medical Devices](https://nocturnalpd.com/2023/08/04/less-is-more-the-power-of-simplicity-in-implantable-medical-devices/) [](https://nocturnalpd.com/2023/08/04/less-is-more-the-power-of-simplicity-in-implantable-medical-devices/) ## [Less is More: The Power of Simplicity in Implantable Medical Devices](https://nocturnalpd.com/2023/08/04/less-is-more-the-power-of-simplicity-in-implantable-medical-devices/) [Eran Livneh](https://nocturnalpd.com/author/eran/)2023-08-08T14:27:40+00:00August 4th, 2023|Categories: [Lifesaving & Implantable](https://nocturnalpd.com/category/lifesaving-and-implantable/)| The “more with less” era From our private lives to [Read More](https://nocturnalpd.com/2023/08/04/less-is-more-the-power-of-simplicity-in-implantable-medical-devices/) #### categories - [Biosensors & Biosignal Acquisition](https://nocturnalpd.com/category/biosensors-and-biosignal-acquisition/) - [Class II & Class III Devices](https://nocturnalpd.com/category/class-ii-and-class-iii-devices/) - [Embedded Software](https://nocturnalpd.com/category/embedded-software/) - [Funding](https://nocturnalpd.com/category/funding/) - [Lifesaving & Implantable](https://nocturnalpd.com/category/lifesaving-and-implantable/) - [Milestone-based pricing](https://nocturnalpd.com/category/milestone-based-pricing/) - [Neuromodulation](https://nocturnalpd.com/category/neuromodulation/) - [PMA](https://nocturnalpd.com/category/pma/) - [QMS](https://nocturnalpd.com/category/qms/) - [Startups](https://nocturnalpd.com/category/startups/) - [Ultra-low Power Software Hardware](https://nocturnalpd.com/category/ultra-low-power-software-hardware/) - [Wearable](https://nocturnalpd.com/category/wearable/) #### sign-up to receive updates ![icon_owl](https://nocturnalpd.com/wp-content/uploads/2023/03/icon_owl.png "icon_owl") > ##### “Having direct access to a team of medical device experts who responded quickly to our needs accelerated our ability to demonstrate our novel implantable technology in a preclinical setting.” > > ###### Joe Passman, Sr. Principal R&D Engineer, NXT Biomedical ### Our top team is now your team. Our software engineers don’t hide behind their screens. We are a small firm where everyone is an expert in their field, everyone is working hands-on with a client, and everyone is invested in your success. [SCHEDULE A CALL](https://nocturnalpd.com/get-a-quote/) ![](data:image/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271500%27%20height%3D%271180%27%20viewBox%3D%270%200%201500%201180%27%3E%3Crect%20width%3D%271500%27%20height%3D%271180%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E) ### ## Turn your sketch into reality. [GET A QUOTE](https://nocturnalpd.com/get-a-quote/) --- ### [Your guide to mastering the MedTech data explosion](https://nocturnalpd.com/your-guide-to-mastering-the-medtech-data-explosion/) **Published:** April 2, 2025 **Author:** Eran Livneh **Content:** ## #### Mastering The MedTech Data Explosion #### ##### Product design best practices for the age of mega data – from biosensors to data platforms and everything in between [![](https://nocturnalpd.com/wp-content/uploads/2025/04/Data-Guide-Cover.png)](https://nocturnalpd.com/wp-content/uploads/2025/07/Nocturnal-Mastering-Data-Guide-July-2025.pdf) [get your copy](https://nocturnalpd.com/wp-content/uploads/2025/07/Nocturnal-Mastering-Data-Guide-July-2025.pdf) --- ### [Webinars for Medical Device Innovators](https://nocturnalpd.com/webinars-for-medical-device-innovators/) **Published:** May 16, 2025 **Author:** Eran Livneh **Content:** ## #### Webinars for Medical Device Innovators [![](https://nocturnalpd.com/wp-content/uploads/2025/07/On-demand-square-banner-1.png)](https://nocturnalpd.com/scaling-from-prototype-to-commercial-success-a-lean-approach-for-medical-startups/) [![](https://nocturnalpd.com/wp-content/uploads/2025/06/Linxens-webinar-on-demand.png)](https://nocturnalpd.com/webinar-on-demand-from-biosignals-to-clinical-insights/) [![](https://nocturnalpd.com/wp-content/uploads/2025/05/MLV.png)](https://nocturnalpd.com/2025/05/09/5-things-startups-get-wrong-about-software-enabled-medical-devices/) --- ### [Scaling from Prototype to Commercial Success: A Lean Approach for Medical Startups](https://nocturnalpd.com/scaling-from-prototype-to-commercial-success-a-lean-approach-for-medical-startups/) **Published:** July 22, 2025 **Author:** Eran Livneh **Content:** ##### QuickVault by Veeva and Nocturnal Present ### Scaling from Prototype to Commercial Success: A Lean Approach for Medical Startups ##### Webinar On-Demand [WATCH IT now](#video) ##### Learn how to move fast today, avoid setbacks tomorrow. Forgoing design controls and documentation may sound tempting when you need to move fast to prove your concept and secure funding. **But not so fast!** Skipping these altogether can stall your progress later or even derail your regulatory submission. **So what’s a startup to do?** Watch this honest conversation with two industry veterans who have walked the tightrope as they share the lessons they’ve learned: - Why the question is not if but when you need design controls and documentation. - How to determine what design controls and documentation you actually need to start with. - How to minimize the pain and maximize efficiency for these must-have processes. --- ### [Webinar On-Demand: From Biosignals to Clinical Insights](https://nocturnalpd.com/webinar-on-demand-from-biosignals-to-clinical-insights/) **Published:** June 10, 2025 **Author:** Eran Livneh **Content:** ##### Linxens and Nocturnal Webinar ### From Biosignals to Clinical Insights: HOW To Derisk and Accelerate Your Path to Market [WATCH IT now](#video) ![](https://nocturnalpd.com/wp-content/uploads/2025/05/From-biosignal-to-clinical-insights.png "From biosignal to clinical insights") ##### Tune in to medical device experts from Linxens and Nocturnal and learn how smart design choices can reduce risk and shorten time-to-market for biosensor-based wearables and implantables. **Why this matters:** See how a medical device startup was able to shrink “time-to-data” from years to months and significantly accelerate FDA approval timelines. **What you’ll learn in this webinar:** ✨ Best practices for biosignal data optimization ✨ How to simplify development and regulatory pathways ✨ Real-life use cases and success stories --- ### [Webinar: From Biosignals to Clinical Insights](https://nocturnalpd.com/webinar-from-biosignals-to-clinical-insights/) **Published:** May 21, 2025 **Author:** Eran Livneh **Content:** ##### Linxens and Nocturnal Webinar ### From Biosignals to Clinical Insights: HOW To Derisk and Accelerate Your Path to Market ##### Tuesday, June 3rd – 10:30 am EDT / 4:30 pm CET [register now](https://events.teams.microsoft.com/event/9a2c1e64-557a-4d31-973e-d274f60a9ea1@c2731901-9316-40b6-add8-933cfaf0e375) ![](https://nocturnalpd.com/wp-content/uploads/2025/05/From-biosignal-to-clinical-insights.png "From biosignal to clinical insights") ##### Join medical device experts from Linxens and Nocturnal and learn how smart design choices can reduce risk and shorten time-to-market for biosensor-based wearables and implantables. **Why this matters:** See how a medical device startup was able to shrink “time-to-data” from years to months and significantly accelerate FDA approval timelines. **What you’ll learn in this webinar:** ✨ Best practices for biosignal data optimization ✨ How to simplify development and regulatory pathways ✨ Real-life use cases and success stories **Who should attend:** - MedTech startups developing wearables or implantables - R&D teams exploring biosensor integration - Product leaders looking to reduce risk and accelerate timelines - Anyone aiming to turn biosignal data into actionable health insights **Speakers:** [Alix Joseph](https://www.linkedin.com/in/josephalix/), Healthcare Marketing Director, Linxens [KC Armstrong](https://nocturnalpd.com/leadership/), President and Founder, Nocturnal **How to join:** Date: Tuesday, June 3rd Time: 10:30 AM ET / 4:30 PM CET [Save Your Spot](https://events.teams.microsoft.com/event/9a2c1e64-557a-4d31-973e-d274f60a9ea1@c2731901-9316-40b6-add8-933cfaf0e375) --- ### [MedTech Leading Voice Webinar: Software-Enabled Medical Device](https://nocturnalpd.com/medtech-leading-voice-webinar-software-enabled-medical-device/) **Published:** April 14, 2025 **Author:** Eran Livneh **Content:** ### MEDTECH LEADING VOICE WEBINAR: Watch on-demand [![](https://nocturnalpd.com/wp-content/uploads/2025/05/MLV-Banner-No-Date.png)](https://bit.ly/3RJ7tnh) ##### Medical device companies face critical challenges when developing products that contain software. Aligning product development with stringent software and cybersecurity regulations requires deep knowledge of dozens of standards and FDA guidance documents. Effective integration of these elements is essential not just for regulatory compliance, but also for streamlined product approval and successful market entry. **What you’ll learn in this webinar:** ✅ Practical steps to align product design, cybersecurity, and regulatory workstreams ✅ How to effectively incorporate cybersecurity into your product development cycles ✅ How your regulatory strategy impacts product development timelines and market readiness **Why this matters:** Medical device teams often approach product development and cybersecurity separately, inadvertently creating gaps that lead to regulatory delays or rejections. Understanding the relationship between these elements can significantly reduce development timelines, prevent compliance issues, and improve overall product success. **Who should watch:** - Medical device product development professionals - Cybersecurity specialists in healthcare technology - Regulatory affairs professionals - Quality assurance teams - Engineering teams involved in device lifecycle management **Speakers:** KC Armstrong, President and Founder, Nocturnal – Product Development Mohamad Foustok, Chief Security Officer, CyberMed – Cybersecurity Rob Packard, President, Medical Device Academy – Regulatory Implications [view on-demand](https://bit.ly/3RJ7tnh) --- ### [Mastering the Medical Device Data Explosion](https://nocturnalpd.com/mastering-the-medical-device-data-explosion/) **Published:** April 2, 2025 **Author:** Eran Livneh **Content:** ## #### Mastering the MedTech Data Explosion ![](https://nocturnalpd.com/wp-content/uploads/2025/04/Data-Guide-Cover.png "Data Guide Cover") ##### Product design best practices for the age of mega data – from biosensors to data platforms and everything in between --- ### [eBook - Navigating Medical Device Funding Cycles](https://nocturnalpd.com/ebook-navigating-medical-device-funding-cycles/) **Published:** September 20, 2024 **Author:** Eran Livneh **Content:** ## #### Navigating Medical device funding cycles ![](https://nocturnalpd.com/wp-content/uploads/2025/02/Feb-2025-eBook-no-intro.png "Feb 2025 eBook no intro") How to meet critical product milestones, increase investor confidence, and accelerate device path to commercialization. --- ### [A guide for navigating medical device funding cycles](https://nocturnalpd.com/a-guide-for-navigating-medical-device-funding-cycles/) **Published:** September 19, 2024 **Author:** Eran Livneh **Content:** ## #### Navigating Medical device funding cycles How to meet critical product milestones, increase investor confidence, and accelerate device path to commercialization. [![](https://nocturnalpd.com/wp-content/uploads/2025/02/Feb-2025-eBook-no-intro.png)](https://nocturnalpd.com/wp-content/uploads/2025/02/Nocturnal_Guide_Medical_Device_Entrepreneur_Feb-2025.pdf) [get your copy](https://nocturnalpd.com/wp-content/uploads/2025/02/Nocturnal_Guide_Medical_Device_Entrepreneur_Feb-2025.pdf) --- ### [Get a Quote](https://nocturnalpd.com/get-a-quote/) **Published:** March 27, 2023 **Author:** Jen Rhoton **Content:** ## DO YOU HAVE A GREAT CONCEPT FOR A LIFE ENHANCING MEDICAL DEVICE? ##### Schedule a call to discuss your product development needs and find out about our: - Unique Class II and Class III expertise - Predictable product development costs - Proven track record --- ### [Privacy Policy](https://nocturnalpd.com/privacy-policy/) **Published:** April 20, 2023 **Author:** Jen Rhoton **Content:** ### Privacy Policy ##### Last updated: April 14, 2023 This Privacy Policy describes Our policies and procedures on the collection, use and disclosure of Your information when You use the Website. We use Your Personal data to provide and improve the Website. By using the Website, You agree to the collection and use of information in accordance with this Privacy Policy. We will not sell, share, or otherwise distribute your personal data to third parties except as provided in this Privacy Policy. ### Definitions For the purposes of this Privacy Policy: **Account** means a unique account created for You to access our Website or parts of our Website. **Affiliate** means an entity that controls, is controlled by or is under common control with a party, where “control” means ownership of 50% or more of the shares, equity interest or other securities entitled to vote for election of directors or other managing authority. **Company** (referred to as either “the Company”, “We”, “Us” or “Our” in this Agreement) refers to Nocturnal Product Development, LLC, 8128 Renaissance Parkway, Suite 210, Durham, NC 27713. **Cookies** are small files that are placed on Your computer, mobile device or any other device by a website, containing the details of Your browsing history on that website among its many uses. **Device** means any device that can access the Website such as a computer, a mobile phone, or a digital tablet. **Personal Data** is any information that relates to an identified or identifiable individual. **Service Provider** means any natural or legal person who processes the data on behalf of the Company. It refers to third-party companies or individuals employed by the Company to facilitate the Website, to perform services related to the Website or to assist the Company in analyzing how the Website is used. **Usage Data** refers to data collected automatically, either generated by the use of the Website or from the Website infrastructure itself (for example, the duration of a page visit). **Website** refers to Nocturnal Product Development, accessible from https://nocturnalpd.com **You** means the individual accessing or using the Website, or the company, or other legal entity on behalf of which such individual is accessing or using the Website, as applicable. ### Types of Data Collected #### Personal Data While using Our Website, We may ask You to provide Us with certain personally identifiable information that can be used to contact or identify You. Personally identifiable information may include, but is not limited to: Email address First name and last name Phone number #### Usage Data Usage Data is collected automatically when using the Website. Usage Data may include information such as Your Device’s Internet Protocol address (e.g. IP address), browser type, browser version, the pages of our Website that You visit, the time and date of Your visit, the time spent on those pages, unique device identifiers and other diagnostic data. When You access the Website by or through a mobile device, We may collect certain information automatically, including, but not limited to, the type of mobile device You use, Your mobile device unique ID, the IP address of Your mobile device, Your mobile operating system, the type of mobile Internet browser You use, unique device identifiers and other diagnostic data. We may also collect information that Your browser sends whenever You visit our Website or when You access the Website by or through a mobile device. #### Tracking Technologies and Cookies We use Cookies and similar tracking technologies to track the activity on Our Website and store certain information. Tracking technologies used are beacons, tags, and scripts to collect and track information and to improve and analyze Our Website. The technologies We use may include: **Cookies or Browser Cookies.** A cookie is a small file placed on Your Device. You can instruct Your browser to refuse all Cookies or to indicate when a Cookie is being sent. However, if You do not accept Cookies, You may not be able to use some parts of our Website. Unless you have adjusted Your browser setting so that it will refuse Cookies, our Website may use Cookies. **Web Beacons.** Certain sections of our Website and our emails may contain small electronic files known as web beacons (also referred to as clear gifs, pixel tags, and single-pixel gifs) that permit the Company, for example, to count users who have visited those pages or opened an email and for other related website statistics (for example, recording the popularity of a certain section and verifying system and server integrity). Cookies can be “Persistent” or “Session” Cookies. Persistent Cookies remain on Your personal computer or mobile device when You go offline, while Session Cookies are deleted as soon as You close Your web browser. We use both Session and Persistent Cookies for the purposes set out below: **Necessary / Essential Cookies** Type: Session Cookies Administered by: Us Purpose: These Cookies are essential to provide You with services available through the Website and to enable You to use some of its features. They help to authenticate users and prevent fraudulent use of user accounts. Without these Cookies, the services that You have asked for may not be provided, and We only use these Cookies to provide You with those services. **Cookies Policy / Notice Acceptance Cookies** Type: Persistent Cookies Administered by: Us Purpose: These Cookies identify if users have accepted the use of cookies on the Website. **Functionality Cookies** Type: Persistent Cookies Administered by: Us Purpose: These Cookies allow us to remember choices You make when You use the Website, such as remembering your login details or language preference. The purpose of these Cookies is to provide You with a more personal experience and to avoid You having to re-enter your preferences every time You use the Website. ### Use of Your Personal and Usage Data The Company may use Personal and Usage Data for the following purposes: **To manage Your requests:** To attend and manage Your requests to Us. **To provide and maintain our Website,** including to monitor the usage of our Website. **To provide You** with news, special offers and general information about other goods, services and events which we offer that are similar to those that you have already purchased or enquired about unless You have opted not to receive such information. **For other purposes:** We may use Your information for other purposes, such as data analysis, identifying usage trends, determining the effectiveness of our promotional campaigns and to evaluate and improve our Website, products, services, marketing and your experience. We may share Your personal information in the following situations: - **With Service Providers:** We may share Your personal information with Service Providers to monitor and analyze the use of our Website. - **For business transfers:** We may share or transfer Your personal information in connection with any merger, sale of Company assets, financing, or acquisition of all or a portion of Our business to another company. ### Retention of Your Personal Data The Company will retain Your Personal Data only for as long as is necessary for the purposes set out in this Privacy Policy. We will retain and use Your Personal Data to the extent necessary to comply with our legal obligations (for example, if we are required to retain your data to comply with applicable laws), resolve disputes, and enforce our legal agreements and policies. The Company will also retain Usage Data for internal analysis purposes. Usage Data is generally retained for a shorter period of time, except when this data is used to strengthen the security or to improve the functionality of Our Website, or We are legally obligated to retain this data for longer time periods. ### Transfer of Your Personal Data Your information, including Personal Data, is processed at the Company’s operating offices and in any other places where the parties involved in the processing are located. It means that this information may be transferred to — and maintained on — computers located outside of Your state, province, country or other governmental jurisdiction where the data protection laws may differ from those in Your jurisdiction. Your submission of such information represents Your agreement to that transfer. ### Delete Your Personal Data You have the right to delete or request that We assist in deleting the Personal Data that We have collected about You. You may update, amend, or delete Your information at any time by signing in to Your Account, if you have one, and visiting the account settings section that allows you to manage Your personal information. You may also contact Us to request access to, correct, or delete any personal information that You have provided to Us. Please note, however, that We may need to retain certain information when we have a legal obligation or lawful basis to do so. ### Disclosure of Your Personal Data **Business Transactions** If the Company is involved in a merger, acquisition or asset sale, Your Personal Data may be transferred. We will provide notice before Your Personal Data is transferred and becomes subject to a different Privacy Policy. **Law enforcement** Under certain circumstances, the Company may be required to disclose Your Personal Data if required to do so by law or in response to valid requests by public authorities (e.g. a court or a government agency). **Other legal requirements** The Company may disclose Your Personal Data in the good faith belief that such action is necessary to: - Comply with a legal obligation - Protect and defend the rights or property of the Company - Prevent or investigate possible wrongdoing in connection with the Website - Protect the personal safety of Users of the Website or the public - Protect against legal liability ### Security of Your Personal Data The security of Your Personal Data is important to Us, but remember that no method of transmission over the Internet, or method of electronic storage is 100% secure. While We strive to use commercially acceptable means to protect Your Personal Data, We cannot guarantee its absolute security. ### Children’s Privacy Our Website does not address anyone under the age of 13. We do not knowingly collect personally identifiable information from anyone under the age of 13. If You are a parent or guardian and You are aware that Your child has provided Us with Personal Data, please contact Us. If We become aware that We have collected Personal Data from anyone under the age of 13 without verification of parental consent, We take steps to remove that information from Our servers. ### Links to Other Websites Our Website may contain links to other websites that are not operated by Us. If You click on a third party link, You will be directed to that third party’s site. We strongly advise You to review the Privacy Policy of every site You visit. We have no control over and assume no responsibility for the content, privacy policies or practices of any third party sites or services. ### Changes to this Privacy Policy We may update Our Privacy Policy from time to time. We will notify You of any changes by posting the new Privacy Policy on this page. We will let You know via email and/or a prominent notice on Our Website, prior to the change becoming effective and update the “Last updated” date at the top of this Privacy Policy. You are advised to review this Privacy Policy periodically for any changes. Changes to this Privacy Policy are effective when they are posted on this page. ### Contact Us If you have any questions about this Privacy Policy, You can contact us by email at --- ### [Terms and Conditions](https://nocturnalpd.com/terms-and-conditions/) **Published:** April 20, 2023 **Author:** Jen Rhoton **Content:** ### Terms and Conditions ##### Last updated: April 14, 2023 We use Your Personal data to provide and improve the Website. By using the Website, You agree to the collection and use of information in accordance with this Privacy Policy. We will not sell, share, or otherwise distribute your personal data to third parties except as provided in this Privacy Policy. ### Definitions For the purposes of these Terms and Conditions: **Affiliate** means an entity that controls, is controlled by or is under common control with a party, where “control” means ownership of 50% or more of the shares, equity interest or other securities entitled to vote for election of directors or other managing authority. **Company** (referred to as either “the Company”, “We”, “Us” or “Our” in this Agreement) refers to Nocturnal Product Development, LLC, 8128 Renaissance Parkway, Suite 210, Durham, NC 27713. **Device** means any device that can access the Website such as a computer, a mobile phone, or a digital tablet. Terms and Conditions (also referred as “Terms”) mean these Terms and Conditions that form the entire agreement between You and the Company regarding the use of the Website. **Third-party Social Media Service** means any services or content (including data, information, products or services) provided by a third-party that may be displayed, included or made available by the Website. **Website** refers to Nocturnal Product Development, accessible from **You** means the individual accessing or using the Website, or the company, or other legal entity on behalf of which such individual is accessing or using the Website, as applicable. ### Acknowledgment These are the Terms and Conditions governing the use of this Website and the agreement that operates between You and the Company. These Terms and Conditions set out the rights and obligations of all users regarding the use of the Website. Your access to and use of the Website is conditioned on Your acceptance of and compliance with these Terms and Conditions. These Terms and Conditions apply to all visitors, users and others who access or use the Website. By accessing or using the Website You agree to be bound by these Terms and Conditions. If You disagree with any part of these Terms and Conditions then You may not access the Website. You represent that you are over the age of 18. The Company does not permit those under 18 to use the Website. Your access to and use of the Website is also conditioned on Your acceptance of and compliance with the Privacy Policy of the Company. ### Links to Other Websites Our Website may contain links to third-party web sites or services that are not owned or controlled by the Company. The Company has no control over, and assumes no responsibility for, the content, privacy policies, or practices of any third party web sites or services. You further acknowledge and agree that the Company shall not be responsible or liable, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with the use of or reliance on any such content, goods or services available on or through any such web sites or services. We strongly advise You to read the terms and conditions and privacy policies of any third-party web sites or services that You visit. ### Limitation of Liability To the maximum extent permitted by applicable law, in no event shall the Company or its suppliers be liable for any special, incidental, indirect, or consequential damages whatsoever (including, but not limited to, damages for loss of profits, loss of data or other information, for business interruption, for personal injury, loss of privacy arising out of or in any way related to the use of or inability to use the Website, third-party software and/or third-party hardware used with the Website, or otherwise in connection with any provision of this Terms), even if the Company or any supplier has been advised of the possibility of such damages and even if the remedy fails of its essential purpose. Some states do not allow the exclusion of implied warranties or limitation of liability for incidental or consequential damages, which means that some of the above limitations may not apply. In these states, each party’s liability will be limited to the greatest extent permitted by law. ### “AS IS” and “AS AVAILABLE” Disclaimer The Website is provided to You “AS IS” and “AS AVAILABLE” and with all faults and defects without warranty of any kind. To the maximum extent permitted under applicable law, the Company, on its own behalf and on behalf of its Affiliates and its and their respective licensors and service providers, expressly disclaims all warranties, whether express, implied, statutory or otherwise, with respect to the Website, including all implied warranties of merchantability, fitness for a particular purpose, title and non-infringement, and warranties that may arise out of course of dealing, course of performance, usage or trade practice. Without limitation to the foregoing, the Company provides no warranty or undertaking, and makes no representation of any kind that the Website will meet Your requirements, achieve any intended results, be compatible or work with any other software, applications, systems or services, operate without interruption, meet any performance or reliability standards or be error free or that any errors or defects can or will be corrected. Without limiting the foregoing, neither the Company nor any of the company’s provider makes any representation or warranty of any kind, express or implied: (i) as to the operation or availability of the Website, or the information, content, and materials or products included thereon; (ii) that the Website will be uninterrupted or error-free; (iii) as to the accuracy, reliability, or currency of any information or content provided through the Website; or (iv) that the Website, its servers, the content, or e-mails sent from or on behalf of the Company are free of viruses, scripts, trojan horses, worms, malware, timebombs or other harmful components. Some jurisdictions do not allow the exclusion of certain types of warranties or limitations on applicable statutory rights of a consumer, so some or all of the above exclusions and limitations may not apply to You. But in such a case the exclusions and limitations set forth in this section shall be applied to the greatest extent enforceable under applicable law. ### Governing Law The laws of the state of North Carolina, excluding its conflicts of law rules, shall govern this Terms and Your use of the Website. Your use of the Application may also be subject to other local, state, national, or international laws. ### Dispute Resolution If You have any concern or dispute about the Website, You agree to first try to resolve the dispute informally by contacting the Company. ### For European Union (EU) Users If You are a European Union consumer, you will benefit from any mandatory provisions of the law of the country in which you are resident in. ### United States Legal Compliance You represent and warrant that (i) You are not located in a country that is subject to the United States government embargo, or that has been designated by the United States government as a “terrorist supporting” country, and (ii) You are not listed on any United States government list of prohibited or restricted parties. ### Severability If any provision of these Terms is held to be unenforceable or invalid, such provision will be changed and interpreted to accomplish the objectives of such provision to the greatest extent possible under applicable law and the remaining provisions will continue in full force and effect. ### Changes to These Terms and Conditions We reserve the right, at Our sole discretion, to modify or replace these Terms at any time. If a revision is material We will make reasonable efforts to provide at least 30 days’ notice prior to any new terms taking effect. What constitutes a material change will be determined at Our sole discretion. By continuing to access or use Our Website after those revisions become effective, You agree to be bound by the revised terms. If You do not agree to the new terms, in whole or in part, please stop using the Website. ### Contact Us If you have any questions about these Terms and Conditions, You can contact us by email at --- ### [Thank you](https://nocturnalpd.com/thank-you/) **Published:** March 27, 2023 **Author:** Jen Rhoton **Content:** ## Thank you for your interest in Nocturnal! ##### We look forward to learning about your medical device idea and exploring your product development needs. We will be in touch shortly! #### In the meantime, learn more about: #### [CLASS II & CLASS III](https://nocturnalpd.com/class-ii-class-iii-devices/ "Class II & Class III Devices") #### [LIFE-SAVING & IMPLANTABLE](https://nocturnalpd.com/lifesaving-implantable/ "Lifesaving & Implantable") #### [CARDIAC RHYTHM MANAGEMENT](https://nocturnalpd.com/cardiac-rhythm-management/ "Cardiac Rhythm Management") #### [NEUROMODULATION](https://nocturnalpd.com/neuromodulation/ "Neuromodulation") #### [ULTRA-LOW POWER SOFTWARE/HARDWARE](https://nocturnalpd.com/ultra-low-power-software-hardware/ "Ultra-Low Power Software Hardware") #### [EMBEDDED SOFTWARE](https://nocturnalpd.com/embedded-software/ "Embedded software") #### [BIOSENSORS & BIOSIGNAL ACQUISITION](https://nocturnalpd.com/biosignal-acquisition/ "Biosignal acquisition") --- ## FAQs ### [How do low-power constraints affect hardware design for implantables and wearables?](https://nocturnalpd.com/faq-items/how-do-low-power-constraints-affect-hardware-design-for-implantables-and-wearables/) **Published:** September 3, 2025 **Author:** Kelley Bower **Content:** Low-power constraints demand the use of ultra-efficient microcontrollers, careful selection of power management and signal conditioning components, and even minimization of the number of passive components.. For both implantables and wearables, every component must be considered in the context of maximizing battery life while minimizing signal noise and electronics volume. **FAQ Categories:** Hardware - Low Power --- ### [What are the key hardware choices for ultra-low-power biosensor devices?](https://nocturnalpd.com/faq-items/what-are-the-key-hardware-choices-for-ultra-low-power-biosensor-devices/) **Published:** September 3, 2025 **Author:** Kelley Bower **Content:** Key choices include low-power analog front-ends that balance noise requirements with current drain, an ultra-efficient MCU with low power features and operating modes that can truly be leveraged by the intended software architecture, and a BLE radio that provides intimate control of communications parameters to optimize power usage. Every component in the design should have a specific and unique purpose, and be selected with a coherent device-level plan that integrates hardware and firmware with the goal of minimizing power consumption. **FAQ Categories:** Hardware - Low Power --- ### [How does embedded software impact power use in wearable medical devices?](https://nocturnalpd.com/faq-items/how-does-embedded-software-impact-power-use-in-wearable-medical-devices/) **Published:** September 3, 2025 **Author:** Kelley Bower **Content:** Firmware controls power-hungry tasks like data acquisition, data filtering, and wireless communications. Efficient code with smart scheduling, sensor fusion, and edge processing minimizes active time and energy drain—critical for long battery life in wearables and implants. **FAQ Categories:** Software - Low Power --- ### [What are some software techniques for reducing power in biosensor devices?](https://nocturnalpd.com/faq-items/what-are-some-software-techniques-for-reducing-power-in-biosensor-devices/) **Published:** September 3, 2025 **Author:** Kelley Bower **Content:** Ultra low power design requires a near-obsessive focus on maximizing time in low power operating states. Smart scheduling of data acquisition and process, offloading tasks to microcontroller peripherals, and strategies for limiting connection time during wireless communications can all reduce power use while maintaining signal quality. **FAQ Categories:** Software - Low Power --- ### [How do you optimize biosensor data collection for ultra-low power?](https://nocturnalpd.com/faq-items/how-do-you-optimize-biosensor-data-collection-for-ultra-low-power/) **Published:** September 3, 2025 **Author:** Kelley Bower **Content:** Optimization involves selecting the right sampling rate, minimizing sensor activation time, and balancing analog and signal processing to achieve the *necessary* signal quality—not the maximum possible signal quality. For wearable or implantable sensors, the goal is to capture meaningful data while keeping energy consumption minimal. **FAQ Categories:** Biosensor - Low Power --- ### [What are the tradeoffs between biosensor data quality and power usage?](https://nocturnalpd.com/faq-items/what-are-the-tradeoffs-between-biosensor-data-quality-and-power-usage/) **Published:** September 3, 2025 **Author:** Kelley Bower **Content:** Higher data quality often requires faster sampling, higher resolution, lower noise, and more frequent transmissions—all of which consume more power. To conserve energy, the first step is determining what the quality requirements truly are. The data must be good enough to enable the product to accomplish its current and future clinical goals, but superfluous quality only consumes power for no end benefit. **FAQ Categories:** Biosensor - Low Power --- ### [What are the tradeoffs between edge and cloud processing in low-power medical devices?](https://nocturnalpd.com/faq-items/what-are-the-tradeoffs-between-edge-and-cloud-processing-in-low-power-medical-devices/) **Published:** September 3, 2025 **Author:** Kelley Bower **Content:** Cloud processing reduces on-device power use but increases wireless transmission needs, which can drain batteries quickly. Edge processing saves data transmission power by analyzing data locally, but requires more capable (and slightly more power-hungry) processors or more awake time. The decision where to process data is often driven by other factors as well, such as the likely frequency of updating the associated algorithms. The best approach often involves a balance of the two approaches, based on the specific application. **FAQ Categories:** Biosensor - Low Power --- ### [How do low-power constraints impact your medical device AI strategy?](https://nocturnalpd.com/faq-items/how-do-low-power-constraints-impact-your-medical-device-ai-strategy/) **Published:** September 3, 2025 **Author:** Kelley Bower **Content:** Power limits may require preprocessing or signal classification to happen on-device, using lightweight models or thresholds. Full AI processing may be deferred to the cloud, so the device sends only essential features, reducing energy use while still enabling intelligent insights. **FAQ Categories:** AI/ML - Low Power --- ### [What are the requirements for making biosensor data AI-ready in low-power devices?](https://nocturnalpd.com/faq-items/what-are-the-requirements-for-making-biosensor-data-ai-ready-in-low-power-devices/) **Published:** September 3, 2025 **Author:** Kelley Bower **Content:** In low-power wearables and implants, AI-ready data must be clean, structured, and lightweight. Devices should preprocess signals to reduce noise and compress features before transmission. This minimizes power use while ensuring the data is usable for model training and real-time inference. **FAQ Categories:** AI/ML - Low Power --- ### [What should you look for in a development partner for ultra-low-power wearable or implantable devices?](https://nocturnalpd.com/faq-items/what-should-you-look-for-in-a-development-partner-for-ultra-low-power-wearable-or-implantable-devices/) **Published:** September 3, 2025 **Author:** Kelley Bower **Content:** Look for a partner with proven expertise in ultra-low-power electronics and medical software. They should have experience designing implantable and compact wearable devices, with a strong background in biosensor signal processing and power optimization. The best partners also understand how to produce AI-ready data and have a track record of bringing regulated medical devices to market successfully. **FAQ Categories:** Low-power - General --- ### [What are the key challenges in developing ultra-low-power medical devices?](https://nocturnalpd.com/faq-items/what-are-the-key-challenges-in-developing-ultra-low-power-medical-devices/) **Published:** September 3, 2025 **Author:** Kelley Bower **Content:** The biggest challenge is balancing performance with extremely low energy use. A device must capture and process biosensor data accurately without quickly draining its tiny battery. Designers have to choose specialized low-power components and optimize every software task to save power. Often there are trade-offs to conserve energy while still providing reliable, real-time health insights—such as reducing data acquisition and transmission frequencies, simplifying algorithms, and knowing when it’s worth accepting higher amplifier current drain in favor of lower noise. **FAQ Categories:** Low-power - General --- ### [Why should startups prioritize ultra-low-power design in their medical devices?](https://nocturnalpd.com/faq-items/why-should-startups-prioritize-ultra-low-power-design-in-their-medical-devices/) **Published:** September 3, 2025 **Author:** Kelley Bower **Content:** Medical device startups should focus on ultra-low-power design early because battery life is often the first metric on which devices are judged beyond their efficacy. If a wearable or implant requires daily charging or an implant’s primary battery dies too quickly, users and clinicians won’t adopt it. Planning for minimal power use from the start avoids costly redesigns later and ensures the product can deliver continuous monitoring and better patient experience on a tight power budget **FAQ Categories:** Low-power - General --- ### [How does Nocturnal achieve ultra-low power consumption?](https://nocturnalpd.com/faq-items/how-does-nocturnal-achieve-ultra-low-power-consumption/) **Published:** August 5, 2025 **Author:** Eran Livneh **Content:** Through custom hardware, optimized firmware, and low-power wireless strategies—tailored for each device’s application and clinical environment. --- ### [How does Nocturnal price medical device development?](https://nocturnalpd.com/faq-items/how-does-nocturnal-price-medical-device-development/) **Published:** August 5, 2025 **Author:** Eran Livneh **Content:** We offer fixed-cost, milestone-based pricing to help startups plan and scale with confidence—no surprises, no scope creep, just execution. **FAQ Categories:** General, Pricing --- ### [What types of devices does Nocturnal specialize in?](https://nocturnalpd.com/faq-items/what-types-of-devices-does-nocturnal-specialize-in/) **Published:** August 5, 2025 **Author:** Eran Livneh **Content:** We focus on ultra-low-power solutions for implantables, wearables, and biosensor-driven devices—where battery life, efficiency, and form factor are mission-critical. **FAQ Categories:** General --- ## Categories ### [Startups](https://nocturnalpd.com/category/startups/) --- ### [Funding](https://nocturnalpd.com/category/funding/) --- ### [QMS](https://nocturnalpd.com/category/qms/) --- ### [PMA](https://nocturnalpd.com/category/pma/) --- ### [Class II & Class III Devices](https://nocturnalpd.com/category/class-ii-and-class-iii-devices/) --- ### [Lifesaving & Implantable](https://nocturnalpd.com/category/lifesaving-and-implantable/) --- ### [Neuromodulation](https://nocturnalpd.com/category/neuromodulation/) --- ### [Ultra-low Power Software Hardware](https://nocturnalpd.com/category/ultra-low-power-software-hardware/) --- ### [Embedded Software](https://nocturnalpd.com/category/embedded-software/) --- ### [Biosensors & Biosignal Acquisition](https://nocturnalpd.com/category/biosensors-and-biosignal-acquisition/) --- ### [Milestone-based pricing](https://nocturnalpd.com/category/milestone-based-pricing/) --- ### [Wearable](https://nocturnalpd.com/category/wearable/) --- ## FAQ Categories ### [General](https://nocturnalpd.com/faq_category/general/) --- ### [Pricing](https://nocturnalpd.com/faq_category/pricing/) --- ### [Low-power - General](https://nocturnalpd.com/faq_category/low-power/) --- ### [Hardware - Low Power](https://nocturnalpd.com/faq_category/hardware/) --- ### [Software - Low Power](https://nocturnalpd.com/faq_category/software/) --- ### [Biosensor - Low Power](https://nocturnalpd.com/faq_category/biosensor/) --- ### [AI/ML - Low Power](https://nocturnalpd.com/faq_category/ai-ml/) ---